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Abstract: 
 In the context of cancer therapy, resistance to chemotherapy agents is a serious threat to 
patient welfare. In these circumstances, patients can either present with cancers that are naturally 
resistant to conventional therapy, referred to as innate resistance, or with cancers that become 
resistant following treatment, referred to as acquired resistance. In this thesis, we address the 
phenomenon of acquired drug resistance, involving cell lines selected for resistance to the 
anthracycline, doxorubicin. In the first study, we examined the role of the aldo-keto reductases 
AKR1C3 and AKR1B10 in doxorubicin resistance, enzymes that can hydroxylate doxorubicin to 
a less toxic form (doxorubicinol). Additionally, these enzymes can function to promote estrogen 
biosynthesis from estrone, which can have significant effects on cell growth and survival. We 
demonstrated in the first study that AKR1C3 and AKR1B10 are expressed at higher levels in 
doxorubicin resistant MCF-7 cells than their isogenic control counterparts. This change in 
expression correlated very well with increased estrogen synthesis. siRNA-mediated reduction in 
AKR1C3 and/or AKR1B10 transcript expression had no major effect on doxorubicin resistance, 
suggesting that these enzymes are not sufficient to mediate the doxorubicin resistance phenotype 
and that other mechanisms of doxorubicin resistance exist in these cells. We did, however, note 
that a pharmacological inhibitor of AKR enzymes (a bile acid termed β-cholanic acid) was 
effective in reversing doxorubicin resistance in doxorubicin-selected cell lines. This prompted a 
second study to investigate the mechanism for this reversal. We observed that β-cholanic acid 
strongly reduced doxorubicin resistance in cell lines that express the ABC transporter ABCC1, 
including doxorubicin-resistant MCF-7 breast tumour cells and H-69 lung cancer cells. Reversal 
of doxorubicin resistance was also observed in HEK293 cells transfected with ABCC1 
expression vectors. Subsequent experiments confirmed that β-cholanic acid and another bile acid 
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that does not inhibit the aldo-keto reductases was able to inhibit ABCC1-mediate doxorubicin 
efflux from tumour cells, thereby providing a mechanism for the reversal of doxorubicin 
resistance. Bile acids thus represent an important new class of compounds that could prove 
useful in improving the effectiveness of doxorubicin chemotherapy in cancer patients, 
specifically in recurrent tumours overexpressing the ABCC1 transporter.  
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Chapter 1  
Introduction 
1.1: Cancer 
Cancer is a medical condition in which cells of the body begin to proliferate abnormally in 
a highly invasive, unregulated capacity  (1, 2). These cells can be freely circulating as in 
leukemias, or can form solid tumors as in breast or lung cancers. It should be noted that cancer 
can originate from and affect every tissue type in the body. In general, cancer begins as benign 
growths which undergo transformation into malignancies. These malignancies are characterized 
by 6 known hallmarks as defined by Hanahan and Weinberg in 2000 and later revised in 2011  
(1). Briefly, these hallmarks are listed as: sustained proliferative signalling, evading growth 
suppression, resisting cell death, enabling replicative immortality, inducing angiogenesis and 
activating invasion and metastasis. Current treatments for cancer include surgery to remove 
tumorous growths, radiation and /or chemotherapy to treat non-solid cancers or, in the case of 
solid tumors, to eliminate any remaining cancerous cells  (2). 
Cancer is a condition that will occur in roughly 45% of Canadian women and 49% of 
Canadian men according to the statistics presented by the Cancer Society of Canada in 2017  (3). 
Current estimates are that 1 in 4 Canadians will succumb to this disease. Cancer is characterized 
by abnormal growth and invasion of cells into neighbouring tissues. This may also include the 
spreading of the cancerous cells away from the primary tumour site to distant tissues through the 
blood stream or lymphatic system known as metastasis. The causes of this disorder are generally 
attributed to either environmental factors or hereditary factors or some combination of the two 
(4–9). Among the identified environmental contributors to cancer incidence are exposure to: 
tobacco smoke, infections (particularly viral), radiation exposure and environmental pollutants 
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(3). Cancer is often initially detected by the appearance of local symptoms which include lumpy 
growths (tumours), hemorrhage, ulceration, and pain. Symptoms of metastasis include enlarged 
lymph nodes, enlarged liver or spleen, pain, fracture of bones that are affected, as well as 
neurological symptoms. In some cases, systemic symptoms develop distant from either the 
primary tumour or the subsequent metastases. These include weight loss, either from lack of 
appetite or cachexia, fatigue, excessive sweating, anemia, as well as other paraneoplastic 
phenomena (3). Due to the complex nature of this disease, finding successful treatments has 
proven difficult. In this light, much emphasis has been placed on cancer prevention and early 
detection or screening of tumours.  
 The most common cancers diagnosed in North America affect lung, prostate, breast and 
colorectal tissues, which account for roughly 50% of new cancer cases diagnosed every year. 
Lung cancer accounts for nearly 26% of all deaths caused by cancers in either men or women 
(3). Breast cancer accounts for 13.1% of cancer deaths in women and prostate cancer accounts 
for 9.6% of cancer deaths in men, with colorectal cancer deaths now reaching 12% in men and 
11.3% in women (3). While the rates of cancer incidence have been steadily on the rise, we can 
now boast an overall survival rate from cancer at 60%, with some cancers such as testicular or 
thyroid cancers having a survival rate as high as 96% and 98%, respectively (3). Unfortunately 
not all cancer types can share this impressive statistic. Cancers of the esophagus or pancreas tend 
to have very low survival rates, on the order of 14% and 8%, respectively (3). Survival statistics 
are highly dependent on several issues which include but are not limited to: tissue or origin, 
availability of early detection technologies, and treatment options, which are often dependent on 
tumour type, subtype and stage. 
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1.2: Breast Cancer 
 Breast cancer can be categorized into 2 broad types: invasive and non-invasive 
carcinomas (10).  
1.2.1: Non-Invasive Breast Cancer 
 
The non-invasive breast cancers generally present as one of two types: ductal carcinoma 
in situ, and lobular carcinoma in situ (11, 12). Within these types, each cancer can then be 
“staged” and “graded” based on the level of tumor growth spread and the level of differentiation 
observed in the cells, respectively. Briefly, stage 0 are low grade cancers that tend to be highly 
differentiated and highly localized with a very high rate of treatment success. As the grades and 
stages increase in number, cells become less differentiated as compared to the normal cells of the 
related tissue, and tend to become more invasive leading to an increased risk of metastasis (stage 
4 are high grade and describe a poorly differentiated metastatic cancer) (10). It should be noted 
that the definition of in situ specifically refers to a cancerous lesion which remains at its site of 
origin and is therefore non-invasive (11–13). While these in situ carcinomas can be found at all 
stages, from low to high grade tumors, many are now detected at early stages thanks to improved 
screening techniques. These screening techniques also account for overall increases in diagnosis 
of both lobular and ductal in situ carcinoma  (14, 15). Ductal in situ carcinoma has historically 
been diagnosed more frequently than lobular carcinoma in situ, accounting for nearly 70% of 
non-invasive breast carcinomas  (11). Lobular carcinoma in situ is currently regarded as a marker 
during the development of invasive lobular carcinoma  (15). Each of these in situ carcinomas has 
historically been treated in the same manner with radical surgery being preferred  (11, 12, 14–
16). As a result, little data exists on the true progression of these in situ carcinomas. Recent 
studies have attempted to derive data on the progression of these cancers to better tailor 
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treatment for patients. While preferred treatment for lobular carcinoma in situ continues to be 
radical mastectomy, it is becoming more common in modern medicine to treat with breast 
sparing surgery followed by chemo- or radiotherapy  (11, 15). Ductal carcinoma in situ is also 
treated with breast sparing methods followed by chemo- or radio therapy to prevent recurrence 
with reasonable success  (11, 14, 15). 
1.2.2: Invasive Breast Cancer 
 
Little is known about the disease progression of lobular carcinoma in situ as it is a 
relatively rare form of breast cancer, is usually detected early, and is typically treated rapidly and 
radically with good success overall  (12, 15). However, it is known that lobular carcinoma can 
become invasive. Invasive lobular carcinoma has a relatively low occurrence rate, accounting for 
approximately 10% of all breast cancers  (17). Invasive lobular carcinoma possesses a unique 
growth pattern wherein strands of single cells tend to spread away from the tumour origin  (18, 
19). Due to the unique properties of their growth, central tumours of invasive lobular cancer tend 
to not form distinct masses and can be difficult to distinguish from surrounding tissues using 
conventional means  (17, 19). Early diagnosis of invasive lobular carcinoma is very difficult as a 
result of this and thus tends to be detected later in life  (18). Various studies have been done to 
compare differences in patient outcomes between invasive lobular and invasive ductal 
carcinomas with mixed results  (17). A 1996 study showed while patterns of metastasis and 
spread were different between invasive lobular and invasive ductal carcinomas, no statistical 
difference in overall survival could be detected  (20). A contrasting study from 2005 indicated 
that following treatment by conventional chemotherapy (anthracycline and/or taxane as primary 
chemotherapy), patients with invasive lobular carcinoma were less likely to have a pathological 
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complete response than those with invasive ductal carcinoma, however they did exhibit a longer 
recurrence free survival rate than their counterparts with invasive ductal carcinoma  (21). 
The most common form of invasive breast cancer is invasive ductal carcinoma 
accounting for 80% of all invasive breast cancers  (10). As a result, invasive ductal carcinoma 
tends to define a much broader spectrum of disease than invasive lobular carcinoma. Aside from 
their obvious histological differences, invasive ductal carcinomas tend to present as malignancies 
more often, albeit not exclusively  (22–24). In addition, upon genetic/molecular analysis of each 
histologic type, significant differences can be observed  (22). While lobular and ductal cancers 
comprise the majority of breast cancers, invasive or otherwise, other specific types exist based on 
histology. Regardless of the type of breast cancer almost all are further subdivided into types 
based on various genetic markers. These include steroid and growth receptors (estrogen receptor, 
progesterone receptor, HER2 receptor)  (25), and the presence of absence of BRCA1 mutations 
as the most common markers  (25). 
1.3: Treatment of Breast Cancer 
Treatment of patients for breast cancers can take several forms depending on the type, 
grade and stage of their cancer. Surgery is historically preferred as this procedure will typically 
remove the disease-causing cells from the body before metastasis occurs  (26). While surgery is 
an adequate treatment option for certain cancers, in many (if not all) cases it is accompanied or 
followed by chemotherapy or radiation therapy, depending on the type and stage of the cancer  
(26). Ionizing radiation is used prior to surgery to shrink tumors to facilitate their subsequent 
removal. In most cases of breast cancer, radiation is typically used post-surgery to ensure 
complete destruction of the tumour, including local metastases  (26). In other cases, 
chemotherapy drugs are used in the same capacity, depending again on the specific cancer 
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presented. In the specific case of chemotherapy drugs, they can be used prior to surgery (known 
as neo-adjuvant chemotherapy)  (26), to shrink the tumours and provide better margins for 
surgical removal, or can be applied following surgery (known as adjuvant chemotherapy) to 
ensure that no cancer cells are left  (26). It should be noted at this time that preferences for 
adjuvant vs. neoadjuvant chemotherapy differ based on global regions  (27). In North America, 
for instance, while neoadjuvant chemotherapy is performed, adjuvant chemotherapy is preferred. 
Several European nations have adopted the opposite policy preferring neoadjuvant therapy. A 
study from 2005 comparing cohorts of patients who underwent adjuvant chemotherapy showed 
lower recurrence than those who underwent neoadjuvant chemotherapy  (26). Conversely, 
neoadjuvant chemotherapy has been demonstrated to reduce tumour size offering improved 
survival and in some cases to eliminate cancerous cells without the need for surgery  (27). 
Specific chemotherapy regimens for breast cancer will be discussed in Chapter 2 of this thesis in 
more detail. While chemotherapy agents have proven somewhat effective in treating cancers, 
they present several drawbacks. Chief among the weaknesses of chemotherapy drugs are their 
broad range of adverse side effects  (29). These side effects vary depending on the chemotherapy 
agent used, but typically include: nausea, vomiting, neutropenia, hepatotoxicity, renal toxicity, 
cardiotoxicity, cachexia (muscle wasting), and in some cases neurotoxicity  (28, 29).  
1.4: Anthracyclines 
 Anthracyclines are a class of chemotherapeutic drugs derived from Streptomyces 
peucetius and are among the most effective chemotherapeutic agents developed to date  (30). 
This is partly due to the wide range of cancer types that can be successfully treated with this 
class of drugs, including leukemias, lymphomas, and tumours of the breast, uterus, ovary, and 
lung  (31). The first anthracycline discovered was daunorubicin  (31). It was found that 
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daunorubicin possessed positive anti-tumour activity in murine models  (31). Clinical trials 
began in the 1960’s and proved successful in treating patients with leukemias, but had serious 
cardio toxic side-effects  (31, 32). For this reason, researchers sought to modify the structure of 
daunorubicin in the hope of finding less toxic, but equally effective, analogues of the drug. To 
this end, doxorubicin and epirubicin were developed  (31). Doxorubicin shares a common 
scaffold structure with daunorubicin, but has an additional hydroxyl group  (31). Epirubicin has a 
similar structure to doxorubicin, however the hydroxyl group on the 4’ carbon of the sugar group 
has a different stereochemistry. Both doxorubicin and epirubicin are favoured for use as 
chemotherapy drugs over daunorubicin; however, epirubicin is favored over doxorubicin for 
cancer treatment as it has lower cardiotoxicity with only a small loss in efficacy  (32, 33).  
Specific actions of anthracylcines will be discussed in detail in chapter 2.  Breifly, they 
function by intecaliting DNA, interfering with topoisomerase II, and generation of iron-mediated 
oxygen-derived free radicals  (31, 33, 34). Since tumour cells often divide more rapidly than 
most cell types within the body (except hematopoietic or intestinal crypt cells), the above 
mechanisms likely account for the anti-tumour properties of anthracyclines. Despite the success 
of these agents as chemotherapeutic drugs, their use is not without risk. Common acute side 
effects include nausea, vomiting, heart arrhythmias, neutropenia, and alopecia  (31, 34). Chronic 
side effects, as a result of high cumulative dosage, can result in chronic heart failure, dilated 
cardiomyopathy, and death  (31, 34). These side effects are most strongly associated with 
doxorubicin treatment; it is for these reasons that epirubicin is preferred as a chemotherapeutic 
agent  (31, 34, 35). While anthracyclines are used as primary chemotherapy in breast cancer, 
they are by no means an exclusive treatment method. Several other chemotherapy agents are 
briefly discussed as part of common treatment regiments in Chapter 2 of this thesis. It should be 
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noted at this time that while anthracyclines have common defined side effects, others may occur 
depending on the specific combination of chemotherapy agents used  (28, 29). 
1.5: Chemotherapy Resistance in Breast Cancer 
These toxic side effects are further complicated by the occurrence of chemotherapy 
resistance, a phenomenon which is observed in all cancer types and subtypes. The degree of 
resistance also varies depending on dis (ease type and treatment applied. Briefly, resistance to 
chemotherapy has been observed to occur via two different scenarios. First, some cancers exhibit 
innate resistance to chemotherapy and do not respond to initial treatment (often referred to as 
“primary or innate chemotherapy resistance”). These cancers are usually treated with stronger 
chemotherapy drugs, if possible, or alternate treatments may become necessary, which may 
include surgery or radiation therapy  (36). A second form of resistant cancers has also been 
described in patients that undergo a full course of chemotherapy. Patients will initially either 
respond or show partial response to the therapy. In many cases, a fraction, or the majority, of the 
tumour cell population is killed (36, 37). The remaining cells survive and continue to replicate, 
resulting in disease progression. When the patient returns for treatment, the tumour is no longer 
responsive to the previously used chemotherapy agent and is termed drug resistant. In addition, 
these tumours will frequently not respond to a wide variety of chemotherapeutic agents, resulting 
in a phenomenon known as multi-drug resistance (38, 39).  
To further complicate our understanding of chemotherapy resistance, differences in 
resistance pathways are often observed between in vitro and in vivo systems. This leads to a 
critical weakness in studying chemotherapy resistance, in that most studies conducted on 
chemotherapy resistance are performed using in vitro systems (41–43). As we will discuss in 
more detail in Chapter 2 of this thesis, we will see that in many circumstances the mechanisms of 
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resistance identified in these in vitro systems may not translate to in vivo systems. The best 
example of this is related to the drug transporter ABCB1, also known as the multidrug resistance 
protein 1 (MDR1) or P-glycoprotein (P-gp)  (41). ABCB1 has been shown to be expressed at 
high levels in a variety of in vitro cancer cell lines selected for resistance to the most commonly 
used chemotherapy agents, which include the various anthracyclines and taxanes as well as 
several other drugs  (40). This increased expression has been shown to be critical for the in vitro 
resistance to chemotherapy  (41, 42). Effective chemical inhibitors for ABCB1 exist and have 
been assessed in clinical trials, but the usage of these inhibitors is often associated with increased 
neurotoxicity as ABCB1 is a key xenobiotic defence mechanism in the blood-brain barrier and 
are therefore not very useful clinically  (42). We provide this example to show that while in vitro 
studies are important in developing insight into new approaches to treat chemotherapy-resistant 
cancers, they do not often tell the whole story and may not translate well into a clinical setting  
(42). It should also be noted that setbacks such as these are why we must pursue further studies 
into understanding clinically-relevant mechanisms of chemotherapy resistance. 
Various other mechanisms associated with chemotherapy resistance will be discussed in 
greater detail in Chapters 2 and 3 and include: increased expression of metabolic enzymes to 
detoxify chemotherapy agents, reduced expression of pro-apoptotic proteins to prevent cell death 
and enhance survival, increased expression of cell survival proteins, and changes in expression 
of chemotherapy target proteins  (41, 42). For the purpose of this study we focussed on the 
mechanisms of resistance associated with anthracycline resistance, specifically doxorubicin. 
In the following chapters we will discuss the role of 2 major resistance mechanisms with 
specific hypotheses and aims discussed in Chapters 4 and 6 of this thesis. First, we will examine 
in detail the various treatment regimens used in breast cancer treatment and the resistance 
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mechanisms associated with anthracyclines as well as a second class of drugs called taxanes. We 
will then focus on anthracycline resistance and the role of chemotherapy metabolism in this 
phenomenon, in particular on the doxorubicin-inactivating enzymes known as the aldo-keto 
reductases (AKRs). We will show that while these enzymes can play a role in chemotherapy 
resistance, ABC transporters, specifically ABCC1, play the dominant role in MCF-7 breast 
cancer cells selected for doxorubicin resistance in vitro. Interestingly, we will present data that 
shows the efficacy of using a bile acid, β-cholanic acid (normally used as an inhibitor of AKRs), 
to sensitize certain doxorubicin-resistant cell lines to doxorubicin treatment. Finally, we will 
show that this sensitization is related to the expression of the ABCC1 transporter and that cells 
which express ABCB1 are unaffected by treatment with bile acids. Our aim is to demonstrate the 
utility of a compound which is capable of inhibiting multiple mechanisms of chemotherapy 
resistance, and this could have a great impact on improving patient care in the future. 
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1.6: Hypotheses and Specific Aims 
I postulate that the increase in AKR1C3 expression will result in higher levels of 
serum estradiol. This will result in one of two possibilities: 1) An increase in estrogen 
signaling will resulting in enhanced survival and increased growth of the cells, or 2) 
increased estradiol levels that will result in a negative feedback in turn reducing the ERα 
levels and resulting in a down regulation of the growth-promoting signal. We also 
hypothesize that in addition to their role in modulating AKR1C3 function, bile acids also 
have a regulatory role in ABCC1-mediated drug transport. Based on the above hypotheses, 
the primary aims of this thesis are to: 
1) Assess AKR1C3 protein levels in wildtype and anthracycline-resistant MCF-7 breast 
tumour cells, 
2) Determine if overexpressing AKR1C3 in wildtype MCF-7 cells impart resistance to 
anthracyclines, 
3) Use siRNA approaches in MCF-7DOX2-12 cells to reduce levels of AKR1C3 and 
AKR1B10 and determine the effect on resistance to doxorubicin 
4) Assess the ability to convert estrone to estradiol in MCF-7 anthracycline-resistant 
and AKR1C3-transfected cells, 
5) Assess the estrogen receptor signaling activity in MCF-7 Anthracycline-resistant 
cells by assessing expression levels of BCL-2 and Cyclin D1 as indicators of 
genomic signaling, 
6) Assess the growth rate of MCF-7 Anthracycline resistant and AKR1C3 transfected 
cells to confirm the reduced rate of growth in anthracycline resistant cells, 
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7) Monitor chemotherapy resistance in a variety of ABCC1 expressing cell lines 
including the MCF-7DOX2-12 cells, H69AR (doxorubicin resistance small cell lung 
carcinoma) cells, and HEK293MRP1 transfected with ABCC1. 
8) Monitor intracellular accumulation of doxorubicin in the aforementioned cells by 
flow cytometry. 
9) Verify that ABCC1 is being inhibited by monitoring glutathione levels 
intracellularly. 
10) Determine if the inhibition of chemotherapy transport is specific to ABCC1 or if 
ABCB1 can also be affected by bile acid treatment. 
11) Determine the nature of β-cholanic acid-mediated ABCC1 inhibition. 
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2.2: Abstract 
 
 Taxanes and anthracyclines are widely used in chemotherapy regimens for the treatment 
of invasive breast cancer. Whether used in the neoadjuvant or adjuvant settings, numerous 
clinical trials have validated their effectiveness in improving both progression-free and overall 
survival in breast cancer patients. However, while clinical response (decrease in tumor size by 
palpation) is common, for many patients this response is short-lived, after which tumors become 
refractory to treatment. In addition, some tumors exhibit innate (intrinsic) resistance to these 
regimens at the start of treatment. Consequently, the vast majority of patients do not exhibit 
either a pathologic complete response post-treatment or a survival benefit from chemotherapy. 
Numerous in vitro studies have identified potential mechanisms of action for the anthracyclines 
and taxanes and how tumors may evade the cytotoxic properties of these agents, but their clinical 
relevance remains questionable. In vivo studies of drug resistance are less subject to such 
criticisms, but false discovery rates can be high, in particular for genomic studies of biomarkers 
of drug response or resistance. Nevertheless, studies of drug response and resistance are now 
starting to provide useful tools to distinguish between responding and non-responding tumors 
and insight on how to best treat patients with tumors that are refractory to treatment. 
Keywords: Incidence rates, Adjuvant therapy, Estrogen Receptor (ER) positive cancers, 
Taxanes, Anthracyclines, In vitro studies, Drug transporters, Aldo–keto reductase enzymes 
(AKRs), Microtubules, β-tubulin isotypes, Apoptosis, Chemotherapy resistance, Stromal cells, 
Tumor initiating cells (TICs), Chloroquine 
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2.3: Introduction 
 
 Breast cancer is the most common form of cancer among women worldwide, with 
incidence frequencies continuing to rise (1). This increasing incidence is generally attributed to 
prolonged life expectancy, urbanization and adoption of western lifestyles (1). Global statistics as 
of 2004 from the World Health Organization (WHO) estimate that breast cancer comprises 
roughly 16 % of all female cancers worldwide (1); of these, an estimated 519,000 women 
succumbed to the disease in 2004 alone. The WHO estimates that a majority of these deaths 
occurred in developing countries, roughly 69 % (1). While incidence rates vary greatly 
worldwide they have been recorded to be as high as 99.4 per 100,000 women in North America. 
Moderate incidence rates have been recorded in Eastern Europe, southern Africa, eastern Asia 
and South America, with the lowest incidence rates occurring in most African countries (1, 2). 
As is the case with incidence rates, survival rates also vary greatly worldwide, ranging from 80 
% in high income nations to less than 40 % in low income nations. These discrepancies are 
mostly attributed to availability of early detection and treatment methods (1, 2). 
 Upon detection of disease that is contained within the breast, the primary treatment for 
breast cancer is typically surgical resection of the tumor with negative margins to prevent 
recurrence (3). This is because many patients with early-stage disease respond well to this 
treatment method. If the disease is sufficiently advanced but within the axilla, many adjuvant 
treatments exist for breast cancer which include radiation therapy and a variety of chemotherapy 
regimens (3). Adjuvant therapy is generally designed to treat micro metastatic disease or breast 
cancer cells that have escaped the primary tumor but not yet established identifiable metastases. 
Specific treatments differ depending on the nature of the tumor subtype (3). Locally advanced 
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and inflammatory breast cancers, however, do not respond well to primary surgical techniques 
and are therefore deemed inoperable. Neoadjuvant chemotherapy regimens are thus used as the 
first treatment for these breast cancers and typically include the anthracyclines and taxanes. 
These regimens include but are not limited to: TAC (Taxotere (Docetaxel), Adriamycin 
(Doxorubicin), and Cyclophosphamide) (4, 5), AC T (Adriamycin and Cyclophosphamide 
followed by Taxol) in both conventional and dose-dense regimens (6, 7), FEC 100 (5-
fluorouracil, Epirubicin, Cyclophosphamide) (8), FAC (5-fluorouracil, Adriamycin, 
Cyclophosphamide) (9, 10), TC (Taxotere, Cyclophosphamide), or TCH (Taxotere, Carboplatin, 
and Trastuzumab (Herceptin) for HER2-positive tumors (11) (see Table 2-1, adapted from 
WebMD http:// emedicine.medscape.com/article/1946040-overview#aw2aab6b3). Each of these 
chemotherapy drugs serves a different function in treatment. The taxanes (paclitaxel and 
docetaxel) function as anti-microtubule agents disrupting the cell’s ability to divide during 
mitosis (4, 5). The anthracyclines (doxorubicin and epirubicin) function as DNA-damaging 
antibiotics (6, 7).  
 Cyclophosphamide is an alkylating agent, adding alkyl groups to the guanine bases of 
DNA, and Trastuzumab is a monoclonal antibody targeting and inhibiting the HER2 growth 
receptor present on some breast cancer types (9, 10). Additionally, in early-stage breast cancer, 
adjuvant chemotherapy can play a critical role in the treatment of Estrogen Receptor (ER) 
positive cancers (12). Adjuvant therapy in these cases involves the use of compounds that target 
the estrogen signaling pathway, either through interfering with estrogen synthesis (aromatase 
inhibitors (Letrozole) or through selective estrogen receptor modulators (SERMs (tamoxifen)) 
(13). 
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Table 2-1 Anthracycline and taxane containing regimens for the treatment of breast cancer 
 
  
Treatment 
Regimen 
Chemotherapy 
agents used 
Dose Frequency Cycles Reference 
TAC Taxotere 
(Docetaxel) 
Adriamycin 
(Doxorubicin) 
Cyclophosphami
de 
75 mg/m
2
 IV 
 
50 mg/m
2
 IV 
 
500 mg/m
2
 IV 
Every 21 days 6  (4,5) 
ACT Adriamycin 
Cyclophosphami
de 
 
Followed by 
 
Taxol 
(Paclitaxel) 
60 mg/m
2
 IV 
600 mg/m
2
 IV 
 
 
 
175 mg/m
2
 IV 
Every 21 days 
(14 days for 
dose dense) 
 
 
Every 21 days 
(14 days for 
dose dense) 
4 
 
 
 
 
4 
 (6,7) 
FEC 100 5-Fluorouracil 
Epirubicin 
Cyclophosphami
de 
500 mg/m² IV 
100 mg/m² IV 
500 mg/m² IV 
Every 21 days 6  (8) 
FAC 5-Fluorouracil 
Adriamycin 
Cyclophosphami
de 
600 mg/m² IV 
60 mg/m² IV 
600 mg/m² 
Every 21 days 4  (9,10) 
TC Taxotere 
Cyclophosphami
de 
75 mg/m² IV 
600 mg/m² IV 
Every 21 days 4  (11) 
TCH Taxotere 
Carboplatin 
Trastuzumab 
(Herceptin) 
75 mg/m² IV 
AUC 6, IV 
4 mg/kg 
loading dose 
IV followed by 
2 mg/kg/wk X 
18 then q3wk 
X 12 
Every 21 days 6  (11) 
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 Even with such available treatments, disease progression typically occurs in advanced 
breast cancers, likely due to the presence or development of chemotherapy-resistant tumors (14). 
Some patients possess tumors that exhibit innate resistance to chemotherapy and do not respond 
to initial treatment (often referred to as ‘‘primary chemotherapy’’). These cancers are then 
typically treated with other chemotherapy drugs, if possible, or alternate treatments may become 
necessary, including surgery or radiation therapy (15). Other patients have tumors that initially 
respond or show partial response to the therapy. In such cases, a fraction or even the majority of 
the tumor cell population is killed (15, 16). The remaining drug-resistant cells, however, survive 
and continue to replicate, resulting in disease progression. Here we will explore some of the 
mechanisms associated with resistance to taxanes and anthracyclines in the treatment of breast 
cancers as well as some of the current work being done to manage patients with drug-resistant 
tumors. 
2.4: Resistance to Anthracyclines and Anthracycline-Based Regimens In vitro 
 
 Anthracyclines are believed to be cytotoxic to tumor cells through three mechanisms. 
First, they intercalate between strands of DNA or RNA molecules and interfere with normal 
synthesis of these macromolecules in rapidly dividing cells (17). Second, they interfere with 
topoisomerase II, which is normally responsible for relaxing supercoiled DNA in order to 
facilitate DNA replication and transcription (18). Finally, anthracylines cause cellular damage by 
facilitating the creation of iron-mediated oxygen free radicals (18). 
 Many of the biochemical and cellular mechanisms of anthracycline resistance that have 
been identified to date have been obtained from in vitro studies. 
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2.4.1: Drug Transporters and Anthracyclines 
 
 The innate or acquired overexpression of drug transporters has been proposed as a 
possible mechanism of resistance to anthracyclines in breast cancer and has been observed 
primarily in cells exposed to high concentrations of these agents (19–21). The drug transporters 
are typically integral ‘‘ATP-binding cassette’’ (ABC) membrane proteins that actively transport 
anthracyclines and other chemotherapy drugs from tumor cells in an ATP-dependent manner 
(19–21). By exporting drugs from the cytoplasm into the extracellular space, tumor cells are 
protected from the damaging effects of the chemotherapy agents (19–21). As revealed in a recent 
study (15), selection of tumor cells for survival in increasing concentrations of anthracyclines 
resulted in the acquisition of anthracycline resistance at a specific threshold dose. At or above 
this threshold dose, uptake of anthracyclines was substantially reduced. Coincident with the 
acquisition of drug resistance and reduced drug uptake into tumor cells was the increased 
expression of various ABC transporters, specifically Abcb1, Abcc1, and Abcc2 (15). The 
induced ABC transporter differed depending on the cell line examined: for example, epirubicin 
resistant cells showed elevated levels of Abcb1 when the selection dose reached a 30 nM 
concentration, while doxorubicin-resistant cells only showed elevated levels of Abcc1 late during 
selection (100 nM doxorubicin) (15). While the expression of these transporters correlated well 
with the reduced cellular uptake of drugs, their expression did not correlate well with drug 
sensitivity, suggesting that multiple factors were at play in the acquisition of drug resistance (15). 
2.4.2: Alterations in Anthracycline Metabolism 
 
 An additional mechanism for anthracycline resistance appears to involve the ability of the 
liver and possibly breast tumor cells to convert chemotherapy agents into considerably less 
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cytotoxic forms (22), thus protecting tumor cells from the killing action of these agents. One 
example of this is moderated by the overexpression of the aldo–keto reductase superfamily of 
enzymes (AKRs) (16). The AKRs reduce ketones and aldehydes into secondary and primary 
alcohols (23) and their expression has been shown to be regulated by osmotic pressure, AP-1 
transcription factors, and anthracycline-generated reactive oxygen species (ROS). The AKR1C 
family of enzymes has been shown to metabolize a variety of chemotherapy agents, including 
doxorubicin (23). AKR1A1 and AKR1C2 have been shown to convert the anti-tumor agent 
doxorubicin into doxorubicinol, a significantly less toxic anthracycline (23). In a similar fashion 
to AKRs, carbonyl reductases and quinone oxidoreductase-1 (NQO1) have been shown to 
metabolize doxorubicin into doxorubicinol (24). The conversion of doxorubicin to doxorubicinol 
appears to result in altered localization of the drug to lysosomes (16), such that the drug no 
longer reaches its target in the nucleus. 
2.4.3: Other Putative Anthracycline Resistance Mechanisms In vitro 
 
 In addition to the expression of drug efflux pumps and drug metabolizing enzymes, other 
proteins have been implicated in anthracycline resistance in vitro, including the downregulation 
of topoisomerase II (25), changes in p53 function (26), and reduced drug-induced apoptosis (27). 
Gene expression profiling studies suggest that a variety of genes change expression as breast 
tumors acquire resistance to anthracyclines (27). It remains unclear how many of these genes 
play a bona fide role in clinical resistance to anthracyclines and how many are ‘‘passenger’’ 
genes that change expression with the ‘‘drivers’’ of drug resistance. 
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2.5: Mechanisms of Resistance to Taxanes In vitro 
 
 The taxanes block the growth of tumor cells by binding to microtubules and preventing 
their depolymerisation, leading to mitotic catastrophe (28), multinucleation of cells, and the 
induction of apoptosis (29). One such apoptosis-inducing agent upregulated by the taxanes is the 
cytokine TNFα (30). Like other chemotherapy drugs, the efficacy of taxane treatment is limited 
by a tumors’ inherent or acquired ability to resist their killing action. Taxane resistance can be 
the product of a variety of alterations in cell behavior (29). A number of potential mechanisms 
for taxane resistance have been identified in vitro, including elevated expression of the ABC 
family of drug transporters, alterations in microtubule structure and stability, inhibition of 
apoptosis, as well as the activation of some survival pathways. 
2.5.1: Drug Transporters and Taxanes 
 
 One of the most studied mechanisms of drug resistance is the overexpression of the ABC 
transporters (31). ABC transporters are highly expressed in some tissues such as the intestinal 
epithelium and in less differentiated cell types (32). They are associated with the membrane and 
actively transport a variety of molecules out of the cell (31). Among the ABC transporters is the 
permeability glycoprotein 1 (P-gp), also known as multi-drug resistance protein 1 (Mdr1) or 
Abcb1. It has been shown that P-gp contributes to taxane resistance in breast cancer cells in vitro, 
as its elevated expression correlates with low cytoplasmic concentration and decreased 
sensitivity to paclitaxel (33). 
Breast tumor cell lines have been shown to develop P-gp mediated cross-resistance to drugs of 
the same class and in certain cases to drugs of different classes. Interestingly, breast 
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adenocarcinoma cells selected for resistance to doxorubicin showed several thousand-fold cross-
resistance to both docetaxel and paclitaxel (34). An explanation for this may be that the 
anthracyclines first induce P-gp and that severe cross-resistance is observed because taxanes are 
a preferred substrate for P-gp compared to the anthracycline, doxorubicin (35). This observation 
may help to explain why patients were significantly less responsive to paclitaxel after late 
crossover from doxorubicin compared to treatment with doxorubicin after late crossover from 
paclitaxel (36). However, it appears unlikely that P-gp or other ABC drug efflux transporters 
play a prominent role in clinical resistance to taxanes in breast cancer patients. 
2.5.2: Alterations in Microtubule Structure and Stability 
 
 Microtubules are dynamic polymers essential to the cell that can undergo elongation and 
shrinking with the ability to interact laterally with one another (29). They are required for a 
variety of cellular processes including transportation of macromolecules and organelles, 
maintaining and changing structure of the cytoskeleton, and mitosis and cell division (37). 
Microtubules are made up of α and β-tubulin subunits, which can be in either a polymerized or 
dimer form (29). It is widely accepted that taxanes bind to β-tubulin in the polymerized form and 
increase polymer stability (29). In the case of cell division, the increased stability of β-tubulin 
leads to cell cycle arrest in mitosis (29) and eventually to cell death. The β-tubulins are 
comprised of a variety of isotypes which vary at their C-termini (38). Molecular diversity among 
isotypes is accomplished by both the expression of distinct β-tubulin genes (38) and also post-
translational modifications to β-tubulin gene products (39). Expression of certain β-tubulin 
isotypes is tissue-specific, while other isotypes are constitutively expressed (29). The functional 
specificity of different tubulin isotypes among tissues has yet to be determined (29). 
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 Regardless of the β-tubulin isotype, polymers can form and the binding site for paclitaxel 
is only present in the case of the polymerized form of β-tubulin. Hence, it is suggested that 
selection for cancer cells in which the equilibrium between dimer and polymer has shifted 
towards the dimer form, could offer a survival advantage for a tumor that is treated with a 
microtubule-stabilizing agent, such as paclitaxel (29). 
Microtubule dynamics are also controlled by the differential expression of tubulin 
isotypes, mutations within the tubulin genes, and also interactions with tubulin regulatory 
proteins. Tubulin regulatory proteins such as the microtubule-associated proteins (MAPs) or 
stathmin interact with tubulin to promote polymerization or disassembly, respectively (29). 
Increased stathmin mRNA levels have been measured in breast carcinoma tissue from patients 
with more aggressive disease (40). It is also possible that post-translational modifications to 
tubulin such as phosphorylation, polyglutamylation, polyglycylation among others, may alter the 
binding of tubulin regulatory proteins, microtubule dynamics, and thus taxane efficacy (29). 
2.5.2.1: Differential Expression of Specific β-tubulin Isotypes 
 
 As mentioned, the tubulin isotype expressed in cells has an effect on the properties of 
polymer assembly and thus affects interactions with taxanes and microtubule dynamics. For 
example, microtubules assembled from βIII-tubulin are considerably less sensitive to the 
suppressive effects of paclitaxel on their dynamics, than microtubules assembled from βII-
tubulin (41). This suggests that selective expression of certain β-tubulin isotypes may affect the 
cellular sensitivity to taxanes. 
 A number of in vitro studies suggest a relationship between βIII-tubulin isotype levels 
and taxane resistance. For example, one study examined tubulin isotypes and mutations in 
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paclitaxel-resistant cells by combined isoelectric focusing and mass spectrometry, and found that 
class III β-tubulin expression did, in fact, correlate with resistance to paclitaxel (42). Moreover, 
an association between class III β-tubulin expression and resistance to paclitaxel has been 
observed in a variety of human cancer cell lines of lung, ovarian, prostate and breast origin (43). 
However, another study showed that βI, βII, and βIII-tubulin levels were decreased and βIV-
tubulin levels increased when MDA-MB-231 cells were selected for taxane resistance (44). 
Nevertheless, there is evidence of β-III tubulin’s role in tumor resistance to taxanes in cancer 
patients (see 2.4.1), suggesting that differential expression of β-tubulin isotypes may be an 
important mechanism of taxane resistance in breast tumors. 
2.5.2.2: Point Mutations in Tubulin 
 
 The binding of taxanes to β-tubulin subunits in microtubules can also be affected by 
mutations in genes coding for either β- or α-tubulin (45). These mutations can affect the 
sensitivity of cells to taxanes by causing a change in microtubule dynamics. It has been observed 
that cells with specific βI-tubulin mutations become resistant to paclitaxel in vitro (46), and that 
some paclitaxel-resistant cell lines depend on paclitaxel for survival (29). A potential explanation 
for this is that certain tubulin mutations shift the equilibrium in favor of the dimer form, such that 
cells harboring these mutations become hypersensitive to drugs that bind the dimer form of 
tubulin such as colchicine and vinblastine (47). In some cases, the equilibrium is shifted to such 
an extent that the resulting lack of polymer stability compromises the cell’s basic functions and 
thus paclitaxel’s polymer stabilizing effects shift the polymer-dimer equilibrium in a more 
favorable direction, promoting survival (29). 
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 Another form of taxane resistance can occur from a mutation in either α- or β-tubulin that 
alters the drug-binding site on β-tubulin polymers, such that it has less affinity for taxanes. In 
vitro reports of point mutations associated with taxane resistance in breast cancer cells have been 
reported, but in other studies, including clinical studies, no association between point mutations 
in tubulin genes and taxane resistance has been observed. For example, no mutations in β-tubulin 
genes were found when β-tubulin sequence information was compared between two docetaxel-
resistant variants of the MDA-MB-231 and MCF-7 human breast adenocarcinoma cell lines and 
their drug-sensitive parental cell lines (44). A clinical study in 2003 also revealed that mutations 
in the class I β-tubulin gene did not predict response to paclitaxel in breast cancer patients (48). 
Thus, despite in vitro reports showing an association between β-tubulin mutations and taxane 
resistance, this association is not observed in breast cancer patients treated with taxanes. 
2.5.3: Inhibition of Apoptosis 
 
 The arrest in mitosis caused by taxane-binding to microtubules appears to promote the 
induction of apoptosis. The trigger for apoptosis is governed by the effects of taxanes on key 
apoptotic regulatory proteins. For example, it is believed that taxanes induce hyper 
phosphorylation of BCL-2 and BCL-XL, which subsequently blocks their ability to bind to and 
antagonize the apoptosis-inducers BAX and BAK (49, 51). BAX and BAK are then free to 
dimerize and cause pore formation within the mitochondrial membrane, thus mediating apoptosis 
by the intrinsic apoptotic pathway (49–51). Taxanes also can cause BAX upregulation to 
promote apoptosis (49–51). It has also been suggested that paclitaxel can directly bind and 
sequester BCL-2, a microtubule-independent mechanism of cell death (52). 
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 The function of BCL-2 is often regulated post-translationally by a variety of growth 
factor and cytokine signaling pathways (53). These pathways can drive BCL-2 upregulation and 
induce paclitaxel resistance (54). For example, exposure to estrogen in estrogen-responsive 
breast adenocarcinoma cells (MCF-7) is associated with an increase in BCL-2 levels and 
resistance to paclitaxel-induced apoptosis (55). Interestingly, one study found that induced 
recombinant ERα expression in ER-negative breast cancer cells caused resistance to paclitaxel by 
inhibiting apoptosis, while blocking ERα receptor activity in ER-positive breast cancer cells 
caused sensitization to paclitaxel (56). There is also clinical evidence that patients with ER-
positive breast tumors are less responsive to paclitaxel than patients with ER-negative tumors 
(57–59). 
 Breast cancer cells selected for resistance to escalating doses of docetaxel were shown to 
have alterations in TNF signaling pathways. Specifically, the TNFRI receptor, which promotes 
cellular apoptosis, became downregulated upon resistance to docetaxel (30). This downregulation 
of TNFRI lead to increased activation of the transcription factor NF-kB, which promotes 
expression of antiapoptotic survival genes such as c-FLIP (60) XIAP, and BCL-XL, which are 
known to cause chemotherapy resistance (61, 62). 
2.5.4: Activation of Survival Pathways 
 
 A cell’s tendency to live or die is determined by the net balance of opposing death and 
survival pathways. Induction of survival pathways in breast cancer cells is often associated with 
resistance to taxanes. Taxane-resistant breast adenocarcinoma cells have been observed to 
possess an amplified positive-feedback loop involving the TNFα-dependent activation of NF-kB, 
which promotes expression of pro-survival genes. This involves the expression and secretion of 
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cytokines, which complete the loop by way of autocrine or paracrine signaling (30). Increased 
nuclear staining of NF-kB in tumors (indicative of activated NF-kB) has been shown to be 
associated with resistance to chemotherapy treatment with anthracycline- or taxane-containing 
regimens in breast cancer patients (63). Nevertheless, the true clinical relevance of such 
pathways in taxane resistance in breast cancer can only be determined through repeated clinical 
investigation. 
2.6: Mechanisms of Resistance to Anthracyclines and Taxanes In Vivo 
 
 While providing significant insight into potential mechanisms of taxane or anthracycline 
resistance, the majority of the above in vitro studies fail to address important characteristics of 
human tumors that can impact on drug response and resistance. Such characteristics include their 
three-dimensional nature, the vasculature that provides nutrients and oxygen, and a complex 
tumor microenvironment comprised of surrounding stromal tissue, the extracellular matrix, and 
cells recruited by tumors (endothelial cells, fibroblasts, inflammatory cells of the immune system 
and pericytes). It is likely that some of these characteristics can account for the lack of relevance 
of some in vitro drug resistance mechanisms in clinical studies. This tumor microenvironment 
creates the potential for cells within a tumor to be deprived of oxygen and nutrients, evade drug 
exposure, and exhibit a reduced proliferation rate, all of which could present a barrier to taxane 
or anthracycline cytotoxicity. 
2.6.1: Changes in Tubulin Isoform Expression 
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 As mentioned previously, in vitro studies have shown that there may be a correlation 
between expression levels of specific tubulin isoforms and taxane resistance in breast cancer 
cells (43, 64). Clinical studies appear to support such a view, as one study showed that breast 
cancer patients with high levels of class I and class III β-tubulin transcripts are less likely to 
respond to docetaxel than patients with the following levels of tubulin transcripts: class I-
low/class III-low, class I-high/ class III low or class I-low/class III high (65). Also supporting 
this study, high tumor levels of tubulin β-I and β-III transcripts were found to correlate with 
clinical resistance to paclitaxel in advanced breast cancer (66). While these reports are 
compelling, further studies are required to assess whether tumor levels of tubulin β-I and β-III 
transcripts can serve as an effective biomarker of taxane resistance in multiple cohorts of breast 
cancer patients. 
2.6.2: Interactions with Stromal Cells 
 
 Interactions between epithelial and stromal tissue play an important role in the function of 
healthy mammary glands (67) and mediate suppression of transformation to preneoplastic 
phenotypes (68). It has been suggested that cancer could be a physiological response to an 
abnormal stromal environment in some cases (69), as reviewed by Barcellos-Hoff and Medina 
(70). In addition, stromal tissue can affect chemotherapy response through its tumor-supporting 
behavior (71). 
 Human cells communicate by secreting cytokines, chemokines, and growth factors that 
convey signals to nearby cells or travel through the bloodstream and affect more distal tissues. 
Activation of the innate immune response originates from the site of infection or inflammation, 
whereby signals are made available to components of the immune system, including monocytes, 
via the bloodstream. In breast cancer, signals originating from tumor or nearby stromal cells can 
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strongly affect the host (patient) and may affect tumor response to chemotherapy. Accumulation 
of tumor-associated macrophages has been associated with poor prognosis in breast carcinoma, 
as they are suggested to exhibit a tumor-supporting phenotype in some cases, which can include 
secretion of cytokines that promote proliferation, angiogenesis, and metastasis (71). 
 It has recently been demonstrated that stromal gene expression can be an important factor 
in the clinical outcome of breast cancer patients treated with adjuvant chemotherapy (72). In this 
study, tumor stromal samples were classified as being from a patient with good, poor or bad 
outcome after assessment of clinical status post-treatment. Stromal overexpression of a specific 
set of immune-related genes, including T cell and natural killer cell markers, typical of a TH1 type 
immune response, was correlated with a good clinical outcome in patients (72). On the other 
hand, stroma from individuals in the poor-outcome group showed markers of hypoxia and 
angiogenesis, along with a decrease in chemokines that stimulate natural killer cell migration and 
mediate pro-survival signals in T-lymphocytes (72, 73). In another clinical study, 
mesenchymal/stromal gene expression signatures were shown to be useful in predicting 
resistance to neoadjuvant chemotherapy in breast cancer (74). 
2.6.3: Nutrient Deprivation, Hypoxia, and Acidity 
 
 Tumors are generally less vascularized than healthy tissue. As cells within a tumor reside 
farther from blood vessels, the level of nutrients falls and tumor cells in these areas tend to have 
decreased proliferation rates (75). It is suggested that since most anticancer drugs including 
taxanes and anthracyclines tend to be most toxic to rapidly dividing cells, slowly proliferating 
cells tend to be more drug-resistant (76). As nutrient levels are lower at distances further from 
vessels, so are pH and levels of molecular oxygen (77). Such hypoxic regions typically have 
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increased expression of P-gp (78), which as mentioned, can cause taxane or anthracycline efflux 
from tumor cells. It has been suggested that anthracyclines may rely on superoxide formation as 
a means of cytotoxicity (79) and thus tumor cells in hypoxic regions may be less likely to suffer 
an attack of this nature (77). 
 Low pH in the tumor microenvironment is typical, as cancers often rely more heavily on 
glycolysis than normal tissues (80, 81) and slower clearance of breakdown products (82–84). 
This can influence the cytotoxicity of anticancer drugs like doxorubicin, which are weakly basic. 
Protonation of such weak bases in acid environments could then result in decrease cellular drug 
uptake (84, 85). 
2.6.4: Drug Penetration in Tumors 
 
 Both taxanes and anthracyclines are administered intravenously and must cross capillary 
vessel walls to reach cancer cells. For cells in the interior of tumors, this requires extensive 
diffusion through multiple layers of tumor cells (referred to as ‘‘packing density’’) (76). By 
visualizing the location of doxorubicin through its natural fluorescence, it has been shown that 
high concentrations of doxorubicin are found within and around blood vessels, but 
concentrations of doxorubicin are considerably lower as the distance from the nearest blood 
vessel increases (86). It is suggested that the inability of both doxorubicin and epirubicin to 
penetrate deep into tumors may be the result of its sequestration in perinuclear endosomes and 
other organelles at the tumor surface or nearby host tissue (87). 
2.6.5: Role of Tumor Initiating Cells in Anthracycline and Taxane Resistance 
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 Solid tumors are generally heterogeneous, a product of their relatively high genetic 
instability. This results in tumors containing cells with a diversity of phenotypes, including rare 
cells exhibiting stem cell characteristics (quiescence, pluripotency, increased capacity for DNA 
repair) and both ABC transporter expression or dependence on surrounding stromal cells for 
survival (32). Such ‘‘stem cells’’ within tumors are referred to as tumor initiating cells (TICs)—
due to their ability to initiate tumor formation when injected into mice. Such cells may have 
significant relevance in taxane and anthracycline resistance in patients with breast cancer. 
 TICs have been identified in a variety of cancers including multiple myelomas (88), 
leukemia (89, 90), colorectal (91), prostate (92), and hepatocellular carcinomas (93). Breast 
cancer TICs are defined by specific cell surface markers (CD44
+
/CD24
-
/ALDH1
+
). Additionally, 
in many cases, breast cancer TICs have been shown to be dependent on developmental signaling 
pathways (94), particularly the Notch, WNT and Hedgehog pathways (94). Since TICs tend to 
possess properties similar to less differentiated cells, they may possess the ability to adapt to the 
adverse conditions caused by chemotherapy treatment (94, 95). In addition, since TICs are 
relatively quiescent, they are less sensitive to chemotherapy agents that target rapidly dividing 
cells, such as the taxanes or anthracyclines. They also may overexpress ABC drug transporters, 
which are known to play a role in resistance to both taxanes and anthracyclines, as mentioned in 
previous sections (94, 95). Nevertheless, there has been controversy about the cell surface 
markers that define breast TICs and which stem cell markers are correlated with chemotherapy 
resistance (95, 96). ‘‘Basal-like’’ breast cancers are associated with poor patient prognosis and 
have many of the properties of TICs (97), but such cancers remain some of the most 
chemotherapy responsive tumors (98). Moreover, while clear subtypes of breast cancer have 
been identified through gene profiling studies (99), and while these subtypes differ in response to 
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adjuvant chemotherapy (100), there are currently no pre-treatment genetic or protein biomarkers 
that can definitively distinguish between tumors that are responsive to anthracycline or taxane-
chemotherapy regimens and those that are not (101). 
2.7: Management of Breast Cancer Patients with Drug-Resistant Tumors 
 
 Even if the appropriate biomarkers can be found to identify chemotherapy resistant 
tumors, the challenge of how to manage patients with such tumors remains. Typically upon 
failure to respond to chemotherapy with anthracyclines and taxanes, treatment moves to other 
chemotherapy drugs in the adjuvant setting or to surgery and/or radiation therapy in the 
neoadjuvant setting. Strategies used to treat drug-resistant breast cancer involve the employment 
of drugs with mechanisms of action distinct from taxanes and anthracyclines, including 
capecitabine (102), navelbine, gemcitabine (103), and carboplatin. 
 Currently there has been little success in restoring drug sensitivity to patients whose 
tumors have acquired resistance to anthracyclines and taxanes (3). With increased knowledge of 
clinically relevant drug resistance mechanisms, it may become possible to interfere with these 
mechanisms to restore chemotherapy sensitivity. An early example of attempts to re-establish 
drug sensitivity by interfering with a drug-resistance mechanism involves the employment of P-
gp inhibitors in patients with chemotherapy-resistant tumors (104). Two such inhibitors, 
Verapamil and Tariquidar, were found to restore sensitivity to doxorubicin in drug-resistant cells 
in vitro (104), but had little effect on restoring clinical response to anthracycline- or taxane-
containing chemotherapy regimens (105). 
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 Another possible mechanism to restore sensitivity to chemotherapy regimens in breast 
cancer patients may involve the use of chloroquine. Chloroquine (Resochin) was originally 
developed as a drug to prevent malarial infections in humans (106). Its use has been expanded to 
include treatment for autoimmune disorders such as rheumatoid arthritis and recently as a radio-
sensitizing or chemo-sensitizing agent in cancer and HIV chemotherapy (107–110). In the case 
of cancer treatment, chloroquine is thought to act by inhibiting autophagic survival while 
activating apoptotic pathways (109, 110). This occurs because chloroquine preferentially 
accumulates in lysosomes of the cells where the pH of the lysosomes traps the chloroquine (107). 
Additionally, chloroquine permeabilizes the lysosomes allowing for the release of lysosomal 
enzymes into the cytosol (107). Thus, chloroquine may sensitize tumor cells to radiotherapy or 
chemotherapy by interfering with autophagic survival pathways induced upon exposure to 
chemotherapy agents (107). Several clinical trials are currently under way to assess the efficacy 
of chloroquine as a possible tool to restore sensitivity to chemotherapy agents, such as the 
anthracyclines and taxanes. Research is also being performed on other autophagy inhibitors as 
sensitizing agents for chemo-resistant tumors. 
Given that patient tumors vary in response to chemotherapy agents (both prior to and after 
previous rounds of chemotherapy), an additional approach to manage breast cancer patients 
would be to accurately assess tumor response to chemotherapy early in treatment, such that 
patients with non-responding tumors could be quickly switched to other downstream regimens 
such as surgery, radiation therapy, or other chemotherapy drugs. A recent study revealed that 
locally advanced breast cancer patients exhibiting a pathologic complete response to 
epirubicin/docetaxel chemotherapy post-treatment exhibited significant reductions in RNA 
integrity during chemotherapy (111). This ‘‘response biomarker’’ may be of particular value in 
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patient management, if tumor response can be determined after one or two cycles of 
chemotherapy. The true value of this biomarker will only be determined through additional 
studies involving the assessment of multiple cohorts of breast cancer patients at various cycles 
during chemotherapy treatment. 
2.8: Concluding Remarks 
 
 Anthracyclines and taxanes are powerful chemotherapy drugs used in the treatment of 
breast cancer, in particular for those patients that achieve a pathologic complete response to 
treatment with these agents. However, the majority of patients exhibit innate or acquired 
resistance to anthracycline- or taxane-containing regimens. While much has been learned from in 
vitro and in vivo studies on resistance to anthracyclines and taxanes in breast tumor cells, it 
appears likely that breast tumors evade the action of these agents through multiple mechanisms. 
Moreover, these mechanisms likely vary among patients and among the cell population within a 
given tumor. This makes it difficult to predict chemotherapy response and to identify a single 
small molecule that will block innate or acquired drug resistance. Nevertheless, significant 
advancements have been made in understanding the molecular diversity of breast cancers and 
their differential sensitivity to anthracyclines and taxanes. These tools are helping guide the 
oncologist in assessing a particular patient’s risk of treatment failure. In addition to such 
predictive biomarkers, the development of response biomarkers may help confirm drug 
resistance early in treatment, such that non-responding patients can be moved more rapidly to 
alternate and potentially more beneficial treatments. The development of agents to prevent or 
combat resistance to anthracyclines and taxanes in select or multiple cohorts of breast cancer 
patients would help further improve the therapeutic benefit to patients with breast cancer. Given 
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that the majority of patients do not receive a survival benefit from adjuvant or neoadjuvant 
chemotherapy with anthracycline and taxanes (112, 113), there is still significant and challenging 
work to be done. 
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3.2: Abstract 
 
 Many clinical studies involving anti-tumor agents neglect to consider how these agents 
are metabolized within the host and whether the creation of specific metabolites alters drug 
therapeutic properties or toxic side effects. However, this is not the case for the anthracycline 
class of chemotherapy drugs. This review describes the various enzymes involved in the one 
electron (semi-quinone) or two electron (hydroxylation) reduction of anthracyclines, or in their 
reductive deglycosidation into deoxyaglycones. The effects of these reductions on drug 
antitumor efficacy and toxic side effects are also discussed. Current evidence suggests that the 
one electron reduction of anthracyclines augments both their tumor toxicity and their toxicity 
towards the host, in particular their cardiotoxicity. In contrast, the two electron reduction 
(hydroxylation) of anthracyclines strongly reduces their ability to kill tumor cells, while 
augmenting cardiotoxicity through their accumulation within cardiomyocytes and their direct 
effects on excitation/contraction coupling within the myocytes. The reductive deglycosidation of 
anthracyclines appears to inactivate the drug and only occurs under rare, anaerobic conditions. 
This knowledge has resulted in the identification of important new approaches to improve the 
therapeutic index of anthracyclines, in particular by inhibiting their cardiotoxicity. The true 
utility of these approaches in the management of cancer patients undergoing anthracycline-based 
chemotherapy remains unclear, although one such agent (the iron chelator dexrazoxane) has 
recently been approved for clinical use.  
Keywords: Anthracyclines, anti-tumor effects, cardiotoxicity, deoxyaglycone, hydroxylation, 
metabolites, optimization, semi-quinone, therapeutic index.  
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3.3: Introduction 
 
  Since their introduction in the 1960’s, anthracyclines have been used in the treatment of 
many neoplastic diseases, including both solid tumors and hematological cancers. They are 
planar molecules consisting of a rigid hydrophobic tetracycline ring, with a daunosamine sugar 
attached through a glycosidic bond (1). The quinone and hydroquinone substitutions on two of 
four planar rings are important in their metabolism (1). Used as a single agent or as part of a 
regimen, the anthracyclines are key components of neoadjuvant, adjuvant, curative, or palliative 
treatments for several types of malignancies. Derived from the pigment-producing Streptomyces 
peucetius bacterium, doxorubicin (DOX) and daunorubicin (DNR) are two naturally occurring 
anthracyclines (2). Due to their success in treating cancers from various tissue types, a 
significant amount of effort has been devoted into creating and characterizing novel 
anthracyclines. This has resulted in the development of approximately 2,000 anthracycline 
analogs. A number of these analogs are now in widespread clinical use, including idarubicin, 
epirubicin, carminomycin, pirarubicin, aclarubicin, valrubicin and zorubicin (3, 4). As with other 
chemotherapy agents, the clinical success of anthracyclines is compromised by innate or 
acquired resistance to these agents (5) and by their significant toxic side effects in cancer 
patients, in particular cardiotoxicity (6, 7). Consequently, all anthracyclines have an associated 
maximum recommended cumulative dose in an effort to avoid congestive heart failure.  
  DNR and DOX, the first anthracycline antibiotics to be isolated over the past 50 years, 
are among the most effective antineoplastic agents currently used in the treatment of human 
cancers. DNR is used mainly to treat acute lymphoblastic or myeloblastic leukemias, while DOX 
has efficacy against both solid and non-solid tumors. The latter is widely used for the treatment 
of breast cancer, Wilms’ tumors, soft tissue sarcomas, leukemias, Hodgkin’s disease, non-
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Hodgkin’s lymphomas and several other cancers (8). Although differing from DOX by a single 
hydroxyl group, this alteration in structure gives DNR distinct reaction kinetics (9). 
Nevertheless, the use of both DOX and DNR is limited by their toxic side-effects within the 
host, including necrosis of tissue at the injection site, mucositis, alopecia, nausea, vomiting, 
stomatitis, and cumulative cardiotoxicity. Consequently, the maximum recommended 
cumulative doses for DNR and DOX are set at 550 mg/m
2
 and 450-550 mg/m
2
, respectively (10, 
11).  
  Epirubicin (EPI) is obtained by an axial-to-equatorial epimerization of the 4’-hydroxyl 
group of DOX (Figure 3-1). It is currently widely used to treat carcinomas of the breast, 
stomach, gut, endometrium, lung, ovary, esophagus, and prostate (as well as soft tissue 
sarcomas) (12). While EPI has almost equivalent antitumor activity to that of DOX, it possesses 
different pharmacokinetic and metabolic characteristics. For example, EPI is more 
glucuronidated, which facilitates excretion in bile and urine. It therefore has a greater margin of 
safety and has almost double the recommended cumulative dosing of DOX (900-1,000 mg/m
2
 
for EPI) (13).  
 Idarubicin (IDA), an analog of DNR, lacks the C-4 methoxy group and has been shown 
to have improved activity for the treatment of acute myelogenous leukaemia. It is also found to 
be active against multiple myeloma, non–Hodgkin's lymphoma, and breast cancer (12). IDA is 
the only anthracycline that can be administered orally or through intravenous injection. The 
absence of a methoxy group in IDA’s structure (Figure 3-1) results in a longer half-life than 
DNR and significantly enhances lipophilicity. This results in more rapid cellular uptake, superior 
DNA-binding capacity, and consequently greater cytotoxicity compared to DOX and DNR (14). 
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Comparative information regarding the half-life and toxicities of the above anthracyclines is 
presented in Table 3-1.  
© 2015 Bentham Science Publishers 
 The mechanism by which anthracyclines enter cells is still not completely known, but 
one mechanisms that has been demonstrated involves their passive diffusion through the plasma 
membrane, followed by their selective transport into the nucleus by binding to proteasomes (15). 
Once in the nucleus, the anthracyclines dissociate from proteasomes and bind to DNA due to 
their higher affinity DNA (16, 17). Anthracyclines are thought to inhibit the proliferation of 
rapidly dividing cells through multiple mechanisms, including their ability to intercalate between 
and cross-link DNA strands, to alkylate DNA, and to inhibit topoisomerase II (18-20). These 
 
Figure 3-1 Chemical structures of Daunorubicin (DNR), Doxorubicin (DOX), Epirubicin 
(EPI) and Idarubicin (IDA). 
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actions are also highly effective in preventing DNA unwinding and strand separation, thereby 
blocking DNA replication and transcription (19). In addition, the ability of anthracyclines to 
generate highly reactive free radicals can result in abundant damage to DNA and to the plasma 
membrane through lipid oxidation (21-24). In addition to their cytostatic and cytotoxic effects 
against tumor cells, anthracyclines have been documented to accumulate in other tissues such as 
the liver, heart, white blood cells, and bone marrow contributing to their systemic toxic side 
effects (25).  
  In humans, it is estimated that approximately 50% of DOX is eliminated from the body 
without any change in its structure, while the remainder of the drug is processed through three 
major metabolic pathways (25). Metabolism of anthracyclines occurs through hydroxylation, 
semiquinone formation, or deoxyaglycone formation, which can result in the formation of 
metabolites that either augment or suppress the anticancer properties of anthracyclines (26, 27).  
  Hydroxylation of anthracyclines at the C-13 carbonyl group, more commonly referred to 
as two electron reduction, results in the formation of secondary alcohol metabolites that have 
been implicated in anthracycline-induced cardiotoxicity (14). This major pathway of 
anthracycline biotransformation is mediated by a heterogeneous family of cytosolic NADPH-
dependent carbonyl (CBR) and aldo-keto (AKR) reductases (collectively referred to as carbonyl 
reducing enzymes) that catalyze the formation of daunorubicinol (DNROL), doxorubicinol 
(DOXOL), epirubicinol (EPIOL), or idarubicinol (IDAOL) from their parent drugs (28). The 
AKRs are the primary enzymes involved in DOX hydroxylation in the human heart, whereas the 
CBRs play more of a role in DNR hydroxylation (29). The hydroxylation reactions occur in all 
cell types as the enzymes involved are ubiquitous, and have also been studied extensively in red 
blood cells, liver, and kidney (30).  
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  The one electron reduction of anthracyclines is catalyzed by cytochrome P-450 reductase 
(CPR), NADH dehydrogenase (NDUFS), nitric oxide synthase (NOS), and xanthine oxidase, 
leading to the conversion of the quinone moiety of anthracycline drugs to a semiquinone radical 
(17). Although this radical is stable under anoxic conditions, in the presence of oxygen, the 
semiquinone radical is readily re-oxidized to regenerate the parent quinone and results in the  
Table 3-1 Comparison of the four major anthracyclines used in clinical oncology and their 
differences in clinical use, pharmacokinetics, and toxicities. 
 
generation of a superoxide anion and hydrogen peroxide, thereby increasing the formation of 
reactive oxygen species (ROS). The resulting free radicals can cause peroxidation of lipids 
within cellular membranes, protein aggregation, and cell death (31). This redox cycling of DOX, 
DNR, and other anthracycline analogues has been observed in the cytoplasm, mitochondria, and 
sarcoplasmic reticulum and has been implicated in the production of toxic aldehydes that are able 
to escape from the cell and contribute to anthracycline toxicity (8).  
  The final metabolic pathway, deglycosidation, accounts for approximately 1-2% of 
anthracycline metabolism (29). The reductive cleavage of the glycosidic bond and the side chain 
Drugs Maximum 
Recommended Dose 
Half-Life 
(hr) 
Side Effects 
Daunorubicin 550 mg/m
2
 14-20 Cardiotoxicity, mucositis, 
myelosuppression, nausea, vomiting, 
alopecia 
Doxorubicin 450 - 600 mg/m
2
 1-3  Cardiotoxicity, mucositis, nausea, 
vomiting 
Epirubicin 900-1,000 mg/m
2
 33 Myelosuppression, cardiotoxicity, 
nausea, vomiting, mucositis 
Idarubicin >160 mg/m
2
 12-27 Cardiotoxicity, myelosuppression 
mucositis, nausea, vomiting, alopecia 
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carbonyl group results in the formation of 7-deoxyaglycones and hydroxyaglycones (32). It has 
been reported that this reaction is catalyzed by poorly characterized NADPH-dependent 
hydrolase- and reductase type glycosidases (NADPH quinone oxidoreductases (NQO1) and 
NADPH-cytochrome P450 reductase (CPR)) along with the involvement of xanthine 
dehydrogenase (XDH) (29). The formation of hydroxyaglycones results from NADPH-
dependent enzymes that are present in the cytosol, whereas the 7-deoxyaglycone formation may 
be initiated by microsomal or mitochondrial oxidoreductases (32). Several studies report that the 
anthracycline aglycones may generate ROS, but the resulting 7-deoxyaglycone metabolites have 
been shown to possess no cytotoxic activity (33). The aglycones produced have a higher 
lipophilicity than the parent anthracyclines, and are thought to intercalate into mitochondrial 
membranes (34). Moreover, studies suggest that the anthracycline aglycones may cause 
myocardial damage due to their prominent oxidizing properties that divert more electrons to 
oxygen in the mitochondria (35). While anthracycline metabolic pathways and metabolites vary 
from tissue to tissue and between in vitro and in vivo conditions, the two electron reduction 
(hydroxylated) product is generally the predominant metabolite for anthracyclines, with 
considerably lower percentages of the aglycone, 7-deoxy aglycone and 7-deoxy hydroxylated 
aglycone products (33, 36).  
  Having summarized the various pathways by which anthracyclines are metabolized in 
humans, this review will describe how this metabolism can affect the above-described 
biochemical and biological properties of this important class of chemotherapy agents. We will 
focus particularly on how the metabolism of anthracyclines affects their ability to combat the 
growth of tumors and to produce toxic side effects in patients. In addition, we will explore how 
variations in anthracycline metabolism within cancer patients and their tumors can impact 
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treatment efficacy and discuss recent strategies to improve the therapeutic index of 
anthracyclines. A schematic summary of the major points of this review is provided in Figure 
3-2. 
3.4: Two Electron Reduction of Anthracyclines (Hydroxylation)  
 
  Anthracyclines hydroxylated at the C13 position are more polar than the parent 
compound and have higher water solubility. However, contrary to what might be expected, these 
hydroxylated metabolites are excreted from certain tissues at slower rates than the parental 
compound. They are also considerably less potent antineoplastic agents, while having greater 
cardiotoxicity due to their enhanced ability to accumulate in cardiac tissue relative to the parent 
compounds (37). Peters et al. showed that the levels of DOXOL in rats administered DOX were 
greatly enhanced in cardiac muscle compared to other tissues, including liver and skeletal 
muscle. The reason for this preferential accumulation of DOXOL in cardiac muscle is unknown 
(38). With the exception of IDA, the C-13 metabolites for DNR, DOX and EPI are all less 
cytotoxic than their unhydroxylated forms (39, 40). IDAOL is equally cytotoxic as IDA (39, 40).  
3.4.1: Carbonyl Reductases (CBRs)  
 
  CBRs have recently been extensively reviewed regarding their function as drug 
metabolizing agents by Malatkova and Wsol in 2014 (41). Thus, for this review, we will only 
briefly discuss their role in anthracycline metabolism. While AKRs and CBRs are both carbonyl 
reducing enzymes, this section focuses specifically on the carbonyl reductases CBR1 and CBR3 
(41, 42). These enzymes are found in a wide variety of tissues with a very broad range of 
substrates. They are generally associated with detoxifying toxic substrates to protect cells and 
organs (44, 45). CBR1 is the predominant reductase that hydroxylates DOX in the liver, kidney, 
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and gastrointestinal tract (43). In a recent study, Kassner and colleagues (43) assessed the 
relative roles of the AKRs and CBRs in the two electron reduction (hydroxylation) of DOX. 
Interestingly, the kidney, liver, and gastrointestinal tract (which are collectively responsible for 
the clearance of DOX from the body) express carbonyl reducing activity (ies) with an apparent 
Km of 140 μM. Enzymes with Km values in this range include carbonyl reductase 1 (CBR1) and 
AKR1C3. CBR1 was found to be expressed in the above three organs at higher levels than 
AKR1C3, while the latter exhibited a higher catalytic efficiency. An inhibitor capable of 
discriminating between the CBR1 and AKR1C3 activities was able to equally block the carbonyl 
reducing activity of CBR1 and human liver cytosol, but not AKR1C3. This suggests that CBR1 
plays the predominant role in the liver’s ability to hydroxylate DOX. As previously discussed, 
this is distinct from the human heart, where AKRs play the predominant role in the 
hydroxylation of DOX (29).  
3.4.2: Aldo-Keto Reductases (AKR)  
 
  All members of the AKR superfamily of proteins reduce ketones and aldehydes into 
secondary and primary alcohols in a NADPH-dependent manner (44). The superfamily contains 
more than 140 members, sub-categorized into 15 families. AKR families share a minimum of 
40% protein sequence identity, while their sub-families share >60% sequence identity (44). 
Individual AKRs are named beginning with AKR, followed by: a number indicating the family 
of AKRs, a letter denoting the sub-family, and finally a number designating the individual 
member. The AKR1 family is the largest of the 15 families, and is one of three families 
including the mammalian AKRs (44). While the AKR superfamily is comprised of many 
members, this review focuses primarily on family members that are known to hydroxylate 
anthracyclines and/or whose expression changes upon selection for anthracycline resistance.  
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Figure 3-2 Main pathways of intracellular doxorubicin (DOX) biotransformation in 
mammalian cells, including catalytic enzymes involved in its metabolism and their inhibitors. 
The downstream effects of the metabolites are also listed. Similar pathways are involved in 
metabolism of other anthracyclines. 
 
3.4.3: AKR1 Family  
 
  The AKR1 family contains six sub-families, the largest of which is the AKR1C 
subfamily. AKR1C members primarily function as steroid metabolizing enzymes, with AKR1C1 
to 1C4 sharing >86% sequence homology (44, 45). AKR1C3, also known as 17-hydroxy-
steroid-dehydrogenase type V (17-HSD) or 3-hydroxysteroid-dehydrogenase type I (3-HSD), 
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plays a role in the conversion of androstenedione into testosterone and estrone (E1) into estradiol 
(E2) (45-47). In addition, AKR1A1, AKR1C1, AKR1C2, and AKR1C3 have been shown to 
play a role in the metabolism and detoxification of chemotherapy agents (48, 49), with AKR1A1 
being specifically identified as the likely AKR involved in the conversion of the anthracycline 
DOX into DOXOL in cancer patients (50). A variety of AKR members (AKR1A1, AKR1B1, 
AKR1B10, AKR1C1, AKR1C4 and AKR7A2) also play a role in the detoxification of reactive 
aldehydes, some of which may be created by anthracycline-generated ROS (44, 45, 51). AKRs 
are differentially expressed in various tissues throughout the body. AKR1A1 is most highly 
expressed in kidneys, followed by the liver with the lowest expression being in the lungs (44). 
AKR1B1, AKR1B10 and the AKR1C isoforms 1 through 4 have been shown to be primarily 
expressed in the liver, with AKR1C4 being exclusively expressed in this organ. While most 
studies focus on the AKR1 family of enzymes and their ability to metabolize anthracyclines, it 
should be noted that AKR7A2 has also been shown to have some metabolic activity towards 
these substances in a wide variety of organs (52).  
 While belonging to a different family of enzymes, this ability of AKR7A2 demonstrates 
the potential that other AKR family members may play yet undiscovered roles in anthracycline 
metabolism. Due to their roles in xenobiotic detoxification and steroid synthesis, AKR1C 
isoforms 1 through 3 are also highly expressed in the intestine, mammary glands, prostate, 
ovary, and lungs (44, 53), with AKR1C3 the predominant AKR in mammary glands. The 
widespread distribution of AKRs in tissue ensures that a substantial amount of the anthracyclines 
administered to cancer patients is rapidly hydroxylated.  
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3.4.4: Specific Roles of AKR1C2, AKR1C3 and AKR1B10 in Anthracycline Metabolism 
and Resistance  
 
  While several AKRs have been studied for their role in anthracycline metabolism, only a 
subset specifically affect the biochemical and cytotoxic properties of anthracyclines. Heibein et 
al. showed recently that while exogenously added DOX localizes to the nucleus of breast tumor 
cells, exogenous DOXOL accumulates in lysosomes (54). This suggests that the hydroxylation 
of this anthracycline prevents the drug from entering the nucleus, possibly due to its poorer 
affinity for binding to proteasomes. In addition, Heibein et al. observed that DOXOL (54) had 
significantly less affinity for DNA compared to DOX, which may also account for the former’s 
lack of localization to the nucleus. We also showed that selection of MCF-7 breast tumor cells 
for DOX resistance resulted in increased transcription of the AKR1C2, AKR1C3 and AKR1B10 
genes (54, 55). Interestingly, the AKR inhibitor β-cholanic acid was able to restore localization 
of DOX (but not DOXOL) to the nucleus in DOX-resistant cells (54), suggesting that the 
inhibitor blocked DOX hydroxylation. Consistent with this view, the intracellular DOX 
concentration in the DOX resistant cells increased in the presence of β-cholanic acid (54).  
  As stated previously, anthracyclines have been shown to be potent inhibitors of DNA 
topoisomerase II (20) and to induce substantial DNA damage (23) in tumor cells. Interestingly, 
the hydroxylation of the C-13 carbonyl group in two anthracyclines (DOX and IDA) was found 
to have little effect on their ability to inhibit topoisomerase II (40). Moreover, both of these 
anthracyclines and their alcohol metabolites had a strong ability to induce DNA damage. In fact, 
in isolated nuclei, the hydroxylated forms of the drugs induced twice the DNA damage as their 
parental compounds (40). Given that hydroxylation of most anthracyclines dramatically reduces 
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their cytotoxic effects (39, 40), the above findings suggest that their cytotoxicity (at least in 
vitro) is not dependent upon their ability to inhibit topoisomerase or to induce DNA damage.  
3.4.5: Host toxicity  
 
  The major toxic side effect of anthracyclines in cancer patients relates to the high cardio 
toxic properties of their hydroxylated metabolites, particular for DOX. DOXOL appears to have 
a direct effect on excitation/contraction coupling in ventricular myocytes (56). In humans, the 
hydroxylated anthracyclines induce delayed onset cardiomyopathy, which can manifest itself 
during the course of treatment or even weeks or months post-treatment (32). In recent years, 
studies on the host toxicity of anthracyclines have been largely focussed on the role that 
carbonyl reductases play in this phenomenon. In one study, mice exhibiting a CBR1 null allele 
were shown to exhibit substantially reduced cardiotoxicity compared to wildtype mice, when 
both were administered DOX (57). In another study, the overexpression of human carbonyl 
reductase in transgenic mice advanced the development of DOX-induced cardiotoxicity (58). 
Mechanistically, it is generally believed that the anthracyclines become metabolized within 
cardiomyocytes by carbonyl reducing enzymes into their alcohol metabolites. These metabolites 
are not easily expelled from the myocytes, where they increasingly activate calcium release from 
calcium release channels (59). This leads to a general dysfunction in the cardiomyocyte which 
leads to cell death and eventual cardiac myopathy. Interestingly, a subsequent study by Shadle et 
al. (60) demonstrated that the anthracycline DNR opened calcium release channels in 
sarcoplasmic reticulum preparations from rabbit atria with a potency 20 times that of the 
quinone-deficient analogue, 5-iminodaunorubicin. Moreover, neither anthracycline induced free-
radical formation, suggesting that DNR impairs the contraction of the myocardium by 
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interference with sarcoplasmic reticulum function via a mechanism not involving free radical 
formation.  
  The specific involvement of polymorphisms in CBR genes and patient cardiotoxicity 
after anthracycline treatment remains controversial. In one study, two polymorphisms in two 
carbonyl reductase genes (CBR1 1096G>A; CBR3 V244M) were identified as genetic 
biomarkers associated with susceptibility to cardiac damage from anthracycline treatment in 
pediatric oncology patients (61). In contrast, another study found no relationship between any 
polymorphisms in AKR or CBR genes and cardiotoxicity associated with anthracycline treatment 
(62). Despite this discrepancy as to the role of CBR polymorphisms in the cardiotoxicity of 
anthracyclines, the link between carbonyl reductases and cardiotoxicity resulting from 
anthracycline treatment is supported by a number of additional recent studies (63-65). A 
convincing line of evidence supporting this link is a very recent study showing that the 
compound, 23-hydroxybetulinic acid, inhibits carbonyl reductase activity and was able to reduce 
both the accumulation of DOXOL in mice hearts and DOX-induced cardiotoxicity (66). There is 
less support for the role of AKRs in promoting the cardiotoxicity of anthracyclines. For 
example, DOX is considered to have the greatest effect on cardiotoxicity; however, it has the 
lowest affinity for AKR enzymes (48), in particular for AKR7A2, which has been shown to have 
very low specific activities towards DOX and DNR (52). In contrast, IDA, which has one of the 
lowest cardiotoxicities of the anthracyclines has one of the highest affinities for metabolism by 
AKR’s (48).  
3.5: One Electron Reduction of Anthracyclines (Semiquinone Formation)  
 
  Anthracycline semiquinone formation involves a one-electron reduction of the quinone 
moiety. This reaction is thought to be catalyzed by a variety of cellular NADH- and NADPH-
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dependent reductases. The semiquinone metabolites of anthracyclines are generally agreed to be 
more cytotoxic than the parental molecules, both in combating tumor growth and in their effects 
on host tissues. The semiquinone anthracycline may elicit its cytotoxic effects by facilitating the 
alkylation of cellular macromolecules (67) or through the generation of oxygen radicals (68, 69). 
Enzymes that are likely to catalyze the one-electron reduction of the anthracycline include 
NADPH-cytochrome P450 reductase (70), endothelial nitric oxide synthase (71), and NADH 
dehydrogenase (ubiquinone) Fe-S (72).  
3.5.1: Host toxicity via Anthracycline Semiquinone Metabolites  
 
  Along with their efficacy in treating a variety of human neoplasms, the anthracyclines 
are known to cause various hematological toxicities, in particular neutropenia associated with 
DOX treatment (73). Along with myelosuppression, DOX treatment can also cause symptoms 
such as nausea, vomiting, and cardiac arrhythmias, all of which are clinically manageable (74). 
It is currently unclear whether these effects are dependent on the reductive conversion of 
anthracyclines to their semiquinone form; however, cardiotoxicity is thought to be particularly 
dependent on the formation of the semiquinone metabolite (71, 72).  
  At the subcellular level, anthracycline-induced cardiomyopathy is thought to be 
associated with the drug’s ability to induce mitochondrial dysfunction (68, 69). As with other 
muscle tissues, cardiomyocytes rely on mitochondria for ~90% of their ATP production (75). In 
fact, mitochondria make up about 20-40% of the cardiomyocyte volume, which is greater than 
that of skeletal muscle (76). The presence of particular reductive enzymes within heart 
mitochondria may account for the ability of anthracycline containing regimens to induce 
cardiotoxicity in cancer patients. Anthracyclines and their semiquinone metabolites have been 
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well studied for their often irreversible damage to the heart, which can become apparent between 
four and twenty years after the completion of chemotherapy (77).  
3.5.1.1: NADH dehydrogenase (Ubiquinone) Fe-S (NDUFS)  
 
  NADH dehydrogenase (ubiquinone) Fe-S is associated with complex I of the respiratory 
chain within the inner mitochondrial membrane. It typically catalyzes the transfer of electrons 
from NADH to coenzyme Q10 (78). This high molecular weight iron sulfur protein complex 
(~1,000 kDa) consists of 45 subunits, seven of which are encoded by mitochondrial DNA and 
the remainder by the nuclear genome (79). Anthracycline semiquinone formation is particularly 
favorable in the membranes of heart mitochondria. A study by Nohl et al. found that 
mitochondria from the heart easily shuttle single electrons to DOX to promote semiquinone 
formation. In contrast, they found that liver mitochondria are ineffective in producing 
semiquinones from DOX (72). Nohl et al. further suggested that NADH dehydrogenase of 
complex I catalyzes DOX semiquinone formation in heart mitochondrial membranes and that 
this enzyme is absent in liver mitochondria. The semiquinone metabolite can be reoxidized non-
enzymatically to produce superoxide radicals that can lead to DOX aglycone semiquinone 
formation. The latter metabolite, due to its increased lipophilicity, can accumulate in the inner 
mitochondrial membrane where it disrupts other electron carriers of the respiratory chain (72).  
3.5.1.2: Endothelial Nitric Oxide Synthase (eNOS)  
 
  Endothelial nitric oxide synthase (eNOS) is a membrane-bound enzyme located in 
coronary endothelial cells (80). Typically, this enzyme oxidizes the amino acid L-arginine to 
produce L-citrulline and the nitric oxide radical NO
•
. This process involves the transfer of 
electrons from NADPH, or FAD, among other electron donors, as well as cofactors including 
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Ca
2+
 and the Ca
2+
-binding protein calmodulin (81, 82). The depletion of one or more of these 
substrates or cofactors can impair NO
•
 synthesis (83). eNOS accounts for most of the NO
• 
production in the heart, and regulation of its activity controls the amounts of nitric oxide 
produced (80). In the cardiovascular system, the basal release of NO
• 
is necessary for healthy 
vasodilatory tone (84). Production of this vasodilator regulates blood pressure and vascular flow 
to tissues, including the brain, heart and lungs (84). Supporting the role of eNOS in 
anthracycline semiquinone formation, Vasquez-vivar et al. demonstrated that DOX binding to 
the reductase domain of eNOS resulted in a one-electron reduction of DOX to DOX 
semiquinone in a NADPH dependent manner (71). They also showed that this metabolite was 
able to reduce oxygen independently of the enzyme, producing superoxide (O2
-
) (71).  
  Among its many effects on cells, DOX has the ability to induce eNOS gene transcription 
and increases the activity of the enzyme in bovine aortic endothelial cells (85). Moreover, an 
antisense RNA targeting eNOS gene transcripts was able to abrogate DOX-induced apoptosis 
(85), suggesting that semiquinone formation was associated with DOX cytotoxicity. Similarly 
eNOS appears to play a role in mediating the toxic side effects of DOX in the host, since Neilan 
et al. have shown that eNOS gene knock-out in mice protected against DOX-induced cardiac 
dysfunction, injury, and mortality (86). These investigators further demonstrated that 
overexpression of eNOS transcripts in cardiomyocytes of mice resulted in greater increases in 
left ventricular dimensions and larger reductions in systolic function after a single dose of DOX 
than in eNOS knockout or wild-type mice. DOX administration led to superoxide production in 
the hearts of wild-type mice but not in eNOS-deficient mice and DOX-induced superoxide 
production was even greater in eNOS-overexpressing mice than in wild-type mice (86). By 
measuring apoptosis in cardiomyocytes using TUNEL assays, the group further provided 
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evidence that a lack of eNOS protects mice against DOX-induced cardiac dysfunction, at least in 
part by preventing cardiac cell death via apoptosis.  
  While the above evidence lends support for eNOS’s role in anthracycline semiquinone-
dependent cardiac damage, eNOS (along with inducible nitric oxide synthase (iNOS) and 
neuronal nitric oxide synthase (nNOS)) play important roles in the regulation of vascular tone by 
producing nitric oxide (83). This may be disrupted if anthracyclines like DOX compete with L-
arginine as substrates for eNOS. Consistent with this view, as DOX concentrations increase in 
cells, eNOS activity becomes devoted to semiquinone and superoxide generation rather than 
nitric oxide production (68, 69). This would result in vasoconstriction of blood vessels in the 
heart, which may negatively affect heart health under stress. In rabbits, the level of systemic 
nitric oxide decreases considerably after the administration of DOX (87). In humans, 
endothelial-dependent and -independent vasodilation were found to decrease considerably after 
DOX treatment (along with a significant decrease in serum nitrate levels (87)), consistent with 
inhibition of eNOS-mediated oxidation of L-arginine. Redox cycling, a term used when there is 
no net increase in the semiquinone because it is continuously reoxidized by molecular oxygen, 
would exacerbate the inhibition of L-arginine oxidation by eNOS in the presence of 
anthracyclines, since the spontaneous re-oxidation of the semiquinone would provide a 
continuous replenishment of the quinone substrate. Moens et al. have argued that the uncoupling 
of eNOS is known to be a major contributor in pressure-overload induced heart failure (88).  
  The role of iNOS in DOX semiquinone production and DOX-induced cardiotoxicity has 
been more controversial. It has been suggested that iNOS may elicit cardioprotective effects due 
to the production of nitric oxide (89), while death-promoting effects may be caused by its 
facilitation of peroxynitrite formation. Peroxynitrite formation is the result of a reaction between 
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nitric oxide and superoxide radicals (68, 69), which can have DNA damaging effects (90). The 
role of nNOS in DOX-mediated cellular toxicity is also unclear. One study reported no change 
in myocardial nNOS transcript levels upon administration of DOX (91). Nevertheless, it is 
suggested that the enzyme catalyses the one-electron reduction of DOX to the semiquinone form 
(92).  
  Other enzymes such as xanthine dehydrogenase (XDH) (93, 94), NADPH dehydrogenase 
(NQO1) (94), and NADPH oxidase (NOX) (94) have been implicated in anthracycline-
dependent oxygen radical generation, but they may or may not directly catalyse anthracycline 
semiquinone formation. For example, NQO1 is suggested to contribute to oxygen radical 
formation during anthracycline treatment (94) and is thus an important factor in treatment related 
cardiotoxicity; however, it is known to catalyse two-electron reductions and is even suggested to 
inhibit one-electron reductions, such as semiquinone formation (95). The NOXs have also been 
examined for their roles in DOX-related superoxide production and cardiotoxicity. Gilleron et 
al. demonstrated that DOX-activated NOXs contributed to superoxide formation and oxidative-
stress leading to apoptosis in rat cardiomyoblasts. Moreover, inhibition of NOXs by 
diphenyliodonium and apocynin strongly reduced DOX-induced oxygen radicals, as well as cell 
death (96). Supporting this view, experiments using a Nox2 knock-out model revealed that the 
left ventricular ejection fraction (8 weeks after DOX treatment) was considerably higher in 
Nox2-deficient mice compared to wild-type mice (97). Interestingly, the study also showed that 
the adverse effects of DOX could be diminished by treatment with the vasodilator losartan (97).  
3.5.2: Tumor Toxicity via Anthracycline Semiquinone Metabolites  
 
  Generally, the semiquinone metabolite of anthracyclines is thought to be more cytotoxic 
to tumors than the unmodified quinone. Although the ability of DOX to generate reactive 
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oxygen species in tumors has been well demonstrated, several studies suggest that its ability to 
create covalent modifications or adducts in cellular materials accounts for the enhanced effect of 
the semiquinone metabolite relative to the quinone (67, 98). Cummings et al. have suggested 
that within tumors, DOX metabolism is mostly impacted by NADPH-cytochrome P450 
reductase (99). 
3.5.2.1: NADPH-Cytochrome P450 Reductase (CPR)  
 
  NADPH-cytochrome P450 reductase (CPR) is a membrane-bound enzyme localized to 
the endoplasmic reticulum (100). It is an essential reductase, as its ability to transfer electrons is 
required for the functionality of most cytochrome P450 enzymes (101) and heme oxygenases 
(102). It is also an important component of xenobiotic metabolism and plasma cholesterol 
homeostasis (102). CPR catalyses the conversion of DOX to its semiquinone form and it is 
suggested that this transformation can occur in a variety of benzanthroquinones, including DNR 
and DNROL (70). Bartoszek observed that MCF-7 cells treated with varying doses of DOX in 
the presence of exogenous purified rat P450 reductase and NADPH were considerably more 
sensitive (6-fold) to cell killing than cells incubated with drug alone (67). Additional 
experiments showed that the potentiation of the drug was abrogated when the experiment was 
performed by incubating the drug with P450 reductase and NADPH for an hour at physiological 
temperatures prior to administration to tumor cells. This suggested that the semiquinone species 
is short-lived, becoming reoxidized back to the quinone form even in the absence of cells (103). 
The enhanced biological effect in this study was not associated with altered drug uptake, since 
the concentration of isotopically labeled DOX in the cell was unaffected by the presence of the 
reductase (67, 103). It was also observed that the one-electron reduction of DOX catalysed by 
P450 reductase took place only under aerobic conditions (103) and involved extensive NADPH 
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consumption (67). The oxygen requirement in the one-electron reduction was explained using 
quantum calculations, which showed that the quinone anthracycline (when in complexes with 
singlet oxygen) is a better electron acceptor than the free quinone (104) (reviewed in 67).  
  The possible role of P450 reductase, oxygen radical formation, and lipid peroxidation in 
tumor cell killing by anthracyclines was recently assessed (67). Malondialdehyde (MDA) levels, 
a measure of lipid peroxidation in cells, were only slightly (but not significantly) increased in the 
presence of both DOX and P450 reductase relative to the drug alone. Moreover, the correlation 
between MDA levels and drug cytotoxicity was quite weak (67). A variety of radical scavenging 
agents have been previously shown to affect DOX induced oxygen radical production (105, 
106), but Bartoczek et al. observed that oxygen radical formation was not responsible for tumor 
cell death in the presence of CPR (103). These researchers and others further showed that CPR 
caused a significant increase in the amount of irreversible associations between radiolabeled 
DOX and both cellular proteins and DNA and that the formation of these adducts correlated with 
drug cytotoxicity (67, 103). These findings thus suggested that CPR’s ability to enhance DOX 
cytotoxicity appeared to be related to the formation of alkylating metabolites rather than 
augmented redox cycling.  
  Kostrzewa-Nowak et al. investigated the effects of human liver CPR on reductive 
activation of DOX during the treatment of human promyelocytic HL60 cells and multi-drug 
resistant derivatives of these cells overexpressing either P-glycoprotein or MRP-1 (98). The 
study involved the reductive activation of DOX by CPR and NADPH extracellularly, followed 
by treatment of the cells, allowing the metabolite to diffuse into the cells. Their findings 
indicated that NADPH is a necessary cofactor for CPR-dependent reductive conversion 
(semiquinone formation) and this formation does not occur at NADPH concentrations below 500 
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M. Only at high NADPH concentrations was CPR effective at both reductive conversion of 
DOX and achieving between a two and three-fold increase in toxicity in both the DOX-sensitive 
and DOX-resistant human leukemia cell lines (98). The study was conducted at clinically 
relevant doses of DOX, since DOX levels can reach 1-2 μM in the plasma of patients receiving 
treatment (14). Interestingly, since drug potentiation occurred in cells overexpressing drug 
transporters capable of exporting DOX out of the cells, it was further proposed by Kostrzewa-
Nowak et al. that the reactive metabolite is able to bind to cellular targets and escape MDR 
protein pumps (98). These investigators also showed that the addition of superoxide dismutase, 
an oxygen radical-scavenging enzyme, abrogated reductive conversion of DOX by CPR in the 
presence of sufficient NADPH (98). Given that superoxide dismutase is known to scavenge 
singlet oxygen (107), this is consistent with the proposal by Tempczyk et al. that quinone 
anthracyclines interacting with singlet oxygen are better electron acceptors than free quinones 
and that a DOX-singlet oxygen complex may be required for semiquinone formation (104).  
  As recognized by Kostrzewa-Nowak et al., there is some evidence that contradicts CPR's 
potential role in DOX activation. Niitsu et al. have also shown an inverse relationship between 
CPR expression and DOX cytotoxicity (108). However, Kostrzewa Nowak et al. address this 
discrepancy by arguing that the reductive activation of DOX by CPR “could be influenced by 
many factors such as bioavailability of NADPH, levels of other competing metabolic enzymes, 
and tissue-specific antioxidant defence systems" (98).  
  Another study supports the notion that reductive conversion of DOX increases its 
cytotoxic effect in tumor cells (109). In this study, two acute lymphoblastic leukemia (ALL) cell 
lines were characterized for their ability to reduce DOX to the semiquinone. One cell line was 
sensitive to DOX (EU3-Sens) and the other was resistant (EU1-Res). The levels of transcripts 
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and activities for a variety of enzymes and cofactors required for the reductive conversion of 
DOX were monitored in the cell lines and it was found that the DOX-sensitive cells exhibited 
lower intracellular quinone levels and higher NADPH levels than the DOX-resistant cells. This 
is consistent with CPR-dependent reductive conversion of the drug to the semiquinone form. It 
was also determined that the DOX-resistant cells had higher levels of the superoxide-generating 
enzyme NADPH oxidase 4 (NOX4) and lower glucose-6-phosphate dehydrogenase (G6PDH) 
expression. The latter enzyme is responsible for regenerating cellular NADPH. The authors 
suggest that these changes in NOX4 and G6PDH expression favour the redox cycling and 
reduced cytotoxicity of DOX in DOX-resistant cells. Interestingly, these investigators conducted 
similar experiments at lower DOX concentrations (100 nM) and found increased quinone 
accumulation in the drug-sensitive cell line relative to the drug-resistant cell line (109).  
  Given all of the above investigations, there is strong evidence for DOX semiquinone 
formation in both cardiac tissue and tumor tissue and this is associated with its increased 
cytotoxicity. The mechanism by which the semiquinone metabolite promotes cell death appears 
to differ considerably between cardiac and tumor tissue. Oxygen radical production resulting 
from DOX, the semiquinone metabolite, and redox cycling between the two, occurs in 
cardiomyocytes and is important in cardiotoxicity (105, 110). In contrast, redox cycling and 
oxygen radical formation does not appear to contribute to tumor toxicity. Rather, alkylation of 
cellular targets by the semiquinone metabolite appears to promote increased DOX cytotoxicity 
(67, 103). The enzymes responsible for anthracycline semiquinone formation also appear to 
differ considerably between tumor and host tissues, especially since malignant transformation 
itself has been shown to be associated with increased levels of CPR (111). The differences 
between host and tumor tissue with respect to the enzymes involved in semiquinone formation 
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as well as the mode of toxicity of the semiquinone metabolite may highlight some inherent 
differences between healthy and malignant tissue, the latter being considerably more genetically 
unstable. This genetic instability may help to explain why reductive conversion seems to be a 
requirement for killing tumor tissue but redox cycling may be sufficient for damaging cardiac 
tissue, as tumor cells may be more adaptable to increased oxygen radical production. Moreover, 
DOX-resistant tumor cells may have alterations in their cellular physiology that favor redox 
cycling. These differences in anthracycline metabolism between host and tumor tissue may 
present unique opportunities to improve tumor killing by anthracyclines, while sparing host 
toxicities.  
3.6: Reductive Deglycosylation of Anthracyclines (Deoxyaglycone Formation)  
 
  The third, and minor, route of anthracycline metabolism involves the reductive 
deglycosidation of anthracyclines to 7-deoxyaglycone metabolites. The 7-deoxyaglycone form 
of an anthracycline is essentially the drug with the sugar moiety removed. The formation of 7-
deoxyaglycone requires a two-electron reduction and absolutely requires an anaerobic 
environment and NADPH (27). It is generally believed that the formation of the 7-
deoxyaglycone metabolite inactivates the parent molecule. However, the 7-deoxyaglycone 
metabolite has been implicated in the production of ROS by intercalating with the inner 
mitochondrial membrane due to the increase in lipid solubility that accompanies the loss of the 
sugar moiety (14, 112). This intercalation into membranes has also been thought to cause a form 
of benign acute toxicity in the human myocardium via ROS production (32), although the 
cardiotoxicity is not to the extent of that observed for the parent molecule. For DOX, the 7-
deoxyaglycone metabolite can be produced from both the parent DOX molecule and also from 
the metabolite DOXOL. Considering that the four main anthracyclines (DOX, EPI, DNR, and 
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IDA) share very similar structures it can be inferred that the formation of 7-deoxyaglycone 
would occur in similar ways for all four anthracyclines. Formation of the 7-deoxyaglycone 
metabolite occurs via three enzymes: NAD (P)H Quinone Oxidoreductase 1 (NQO1), 
Cytochrome P450 Reductase (CPR), and Xanthine Dehydrogenase (XDH).  
3.6.1: NQO1  
 
  NAD (P)H Quinone Oxidoreductase 1 (NQO1), also known as DT-diaphorase, is an 
NADH- or NADPH-dependent enzyme (99). The main role of NQO1 is to detoxify quinones via 
a two-electron reduction (27). Other roles that NQO1 fulfills include the maintenance of 
antioxidants (113), the stabilization of p53 (114, 115), acting as a superoxide scavenger (116) 
and a 20S proteasome gatekeeper (117). However, NQO1’s ability to perform a two-electron 
reduction of anthracyclines to form the deoxyaglycone metabolites depends heavily upon the 
physiological environment at the tumor site (99), with the deoxyaglycone only forming under 
hypoxic conditions (118). In this way the harmful semiquinone metabolite is bypassed in favour 
of the inactive deoxyaglycone metabolite. NQO1 has also been implicated in the formation of 
semiquinone radicals of anthracyclines in an aerobic environment (27, 94), noting, however, that 
the deoxyaglycone metabolite is the predominant metabolite under anaerobic conditions (99). 
Interestingly, NQO1 is predominantly found in the cytosol of cells (99), with the highest levels 
of the enzyme found in cardiovascular tissues and the liver (119).  
  NQO1 expression is induced by many xenobiotics via the Keap1/Nrf2/ARE pathway 
(120). While Nrf2 is a critical transcription factor involved in cellular protection from toxic 
xenobiotics, it is kept at low levels under unstressed conditions by Keap1 (121). The promoter 
region of the NQO1 gene contains multiple antioxidant response elements (AREs) and a 
xenobiotic response element (XRE) (119, 120) that bind Nrf2 and regulate NQO1 expression. 
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Nrf2 has been implicated in chemotherapy drug resistance in vitro. Increased Nrf2 expression 
and activity have been associated with increased NQO1 levels and DOX resistance in both 
A2780 ovarian tumor cells and MCF-7 breast cancer cells (54, 122, 123). While inactivation of 
Nrf2 in these cell lines can restore DOX cytotoxicity (124), it has been shown in rabbits that 
continuous treatment with anthracyclines does not elevate Nrf2 levels, while NQO1 levels are 
down-regulated (125).  
 Recently, a number of NQO1 polymorphisms have been identified and their relationship 
to patient survival after anthracycline chemotherapy was assessed. One such NQO1 
polymorphism (C609T) results in a Pro187Ser substitution, which results in the increased 
ubiquitination and degradation of the protein (126). Due to the degradation of NQO1, there is an 
impairment in ROS detoxification and reduced survival after chemotherapy (127). If a patient is 
homozygous for the T allele (Ser substitution), the enzyme activity appears to be reduced to only 
2% of the wild type enzyme (homozygous for the C allele) (126, 128, 129). Although the T 
allele has not been found to be significantly related to patient survival for all common cancer 
sites (127, 130, 131), there is a clear trend toward an increased overall cancer risk associated 
with this polymorphism (130). Moreover, this lack of significance could be attributed to the 
small sample size associated with the low frequency T allele (130, 131). Interestingly, inhibition 
of NQO1 by dicoumarol was found to be associated with an increase in DOX-induced 
cardiotoxicity, suggesting NQO1 may play a protective role against DOX-induced cardiotoxicity 
(132).  
3.6.2: CPR and XDH  
 
  Cytochrome P450 Reductase (CPR) is also dependent on NADPH (99). CPR can 
catalyze both redox cycling in an aerobic environment and 7-deoxyaglycone formation in an 
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anaerobic environment (99). It has been shown that DOX is stoichiometrically converted to the 
inactive 7-deoxyaglycone metabolite by CPR, and, similar to NQO1, this formation was 
completely abolished in an aerobic environment (99). CPR is found predominantly in the liver; 
however, it can be found in other organs such as the lung or the kidney (133). Interestingly, the 
anthracyclines DNR and DOX have been shown to suppress the activity of CPR in rabbit 
hepatocytes in vitro (134).  
  Xanthine Dehydrogenase (XDH) is less effective than both NQO1 and CPR at 
generating 7-deoxyaglycone metabolites of anthracyclines (99). Consequently, its role in this 
process is less studied. XDH has also been implicated in the formation of the semiquinone 
radical (94).  
3.7: Strategies to Improve Clinical Response and/or Reduce Clinical Toxicity to 
Anthracyclines 
 
  As mentioned previously, one of the most prevalent and serious side effects that limits 
the use of anthracyclines is their cardiotoxicity. This is particularly the case for breast cancer 
patients undergoing anthracycline-based adjuvant or neoadjuvant chemotherapy (135). To 
reduce the incidence of cardiac toxicity, longer infusion rates are employed to reduce peak 
plasma levels of anthracyclines. Their cumulative doses are also closely monitored. 
Nevertheless, these strategies do not completely eliminate the risk of cardiotoxicity (136). 
Reduced cardiotoxicity with anthracyclines using liposomal formulations of DOX or DNR to 
selectively target tumor tissue has shown some efficacy in a clinical setting (137). Another 
method for preventing anthracycline-induced cardiotoxicity involves the use of pharmacological 
cardioprotective agents, such as dexrazoxane (138), ascorbic acid (139), and an engineered 
bivalent neuregulin (140). To date, the only agent in this class that has been approved for use 
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and has shown significant clinical efficacy is the iron chelator dexrazoxane (DEX) (138, 141). 
While other pharmacological cardioprotective agents have been tested in an in vitro setting, their 
use clinically is uncertain at this time.  
  Two approaches have been used to improve the therapeutic index of anthracyclines. One 
involves altering the metabolism of the drugs in order to enhance their cytotoxic effects on 
tumors by enhancing their therapeutic mechanism of action. This could include nucleic acid 
intercalation, topoisomerase II inhibition, iron mediated generation of ROS, and other processes 
that could lead to improved killing of tumors in vivo (14). A second approach is to reduce the 
systemic toxicity of anthracyclines by further chemical modification of anthracyclines or by 
selectively inhibiting off target effects of the drug and its metabolites, such as cardiotoxicity. 
Examples of these approaches are illustrated below.  
3.7.1: Modulators to enhance the tumor cytotoxicity of anthracyclines  
3.7.1.1: AKR and CR Inhibitors  
 
  As mentioned previously, the 13-hydroxylation of anthracyclines by AKRs substantially 
reduces their tumor cytotoxicity (37, 39, 40). Thus, blocking the formation of hydroxylated 
metabolites could improve the efficacy of anthracyclines. Inhibiting AKRs with agents such as 
2-hydroxyflavanone (48) or β-cholanic acid (54, 55) have been shown to increase anthracycline 
cytotoxicity in anthracycline-resistant cell lines overexpressing AKRs, but it is unclear whether a 
similar improvement in clinical response to anthracyclines would be realized in patients with 
tumors that have intrinsic or acquired resistance to these agents. The semisynthetic flavonoid 7-
mono-O- (-hydroxyethyl)-rutoside, commonly known as mono-HER, is known to effectively 
inhibit CBR1. However, unlike the AKR inhibitors, mono-HER has been documented in a phase 
II clinical trial to protect metastatic cancer patients from DOX-induced cardiotoxicity (142). 
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This may be through its ability to reduce production of the cardiotoxic metabolite DOXOL. 
Mono-HER has also been shown to potentiate the cytotoxicity of DOX in human liposarcoma 
cells by reducing NF-B activation and promoting DOX-induced apoptosis (143). In vitro and in 
vivo experiments have shown that mono-HER does not interfere with the antitumor effect of 
DOX. Interestingly, high doses of mono-HER (>1500 mg/m2) can augment DOX’s anti-tumor 
effect, while considerably lower doses are required to achieve mono-HER’s cardioprotective 
effect (68).  
3.7.2: Strategies to Reduce the Systemic Toxicity of Anthracyclines  
3.7.2.1: Iron Chelators (Dexrazoxane)  
 
  Iron is known to potentiate the toxicity of anthracyclines by transforming relatively safe 
species like O2 • and H2O2 into much more reactive and toxic hydroxyl radical (OH•) or iron-
peroxide complexes that have the capacity to damage DNA, proteins, and lipids (8, 144). It has 
also been proposed that the redox cycling of the quinone moiety would allow anthracyclines to 
increase cellular levels of iron by mobilizing ferritin, a ubiquitous intracellular protein that stores 
and releases iron (145). In addition, doxorubicin treatment has been shown to result in the 
preferential accumulation of iron inside the mitochondria of cardiomyocytes (146). This results 
in amplification of iron-mediated oxidative stress (147, 148). Moreover, doxorubicin-induced 
DNA strand breaks and changes in gene expression that lead to defective mitochondrial 
biogenesis and ROS formation (and subsequently cardiotoxicity) appear to be reduced in mice 
having cardiomyocytes possessing Top2b deletion mutations, suggesting that cardiotoxicity by 
doxorubicin involves the action of topoisomerase II (149). Perhaps one of the best pieces of 
evidence that iron plays a pivotal role in the ROS-mediated toxicity of DOX comes from 
numerous studies showing that the iron chelator dexrazoxane (DEX) can effectively block 
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anthracycline cardiotoxicity (138). DEX has been repeatedly shown to mitigate anthracycline 
toxicity, and is approved for clinical use (150-152). Marty et al have shown in a randomized 
phase III study of 164 breast cancer patients that in comparison to patients receiving an 
anthracycline alone, patients treated with both an anthracycline and DEX experienced 
significantly fewer and less severe episodes of congestive heart failure, without affecting the 
tumor response rate (116). Other antioxidants have also been shown to reduce both the ROS 
generation and toxicity of anthracyclines, but their current use remains limited (138).  
3.7.2.2: Statins, Β Blockers, ACE inhibitors, and COX inhibitors  
 
  Recent studies have shown that several statins such as lovastatin (153), β blockers such 
as Nebivolol (154), ACE inhibitors (e.g. Enalapril) (155, 156) and COX inhibitors demonstrate 
notable cardioprotective effects, when used in conjunction with DOX (157). Interestingly, in a 
recent review of randomized trials and observational studies, where a prophylactic intervention 
was compared with a control arm in patients with a normal ejection fraction and no past history 
of heart failure, the authors demonstrated that prophylactic treatment with DEX, a β-blocker, a 
statin, or angiotensin antagonists all can reduce cardiotoxicity (157). Statins have been suggested 
as an alternative cardioprotective strategy for anthracycline treatments (158). In mice, DOX 
increases the cardiac mRNA levels of B-type natriuretic peptide, interleukin-6 and connective 
tissue growth factor, while lovastatin appeared to counteract these anthracycline-induced cardiac 
stress responses (159). Zofenopril, an ACE inhibitor, inhibits cardiotoxicity in rats; however, it 
is unclear whether the mechanism is direct ACE inhibition or another off target cardioprotective 
effect (160). The same can be said for statins, β blockers and cyclooxygenase-2 inhibitors. The 
mechanisms by which these agents prevent cardiotoxicity are not well understood, limiting their 
use and study as agents to combat anthracycline cardiotoxicity (154). Moreover, no randomized 
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studies have been published comparing the cardioprotective efficacy of statins, β blockers, ACE 
inhibitors, or COX inhibitors relative to DEX.  
3.7.2.3: Glucuronidase-Mediated Release of Anthracycline Prodrugs  
 
  Another mechanism for reducing the systemic toxicity of anthracyclines, including 
cardiotoxicity, is to restrict drug action to tumor sites. For example, a series of glucuronide 
prodrugs have been synthesized that render DOX nontoxic to host tissues, since the hydrophilic 
glucuronide group added to DOX prevents entry across hydrophobic cellular membranes. 
However, the high levels of β-glucuronidase in tumors then permits the release of cytotoxic 
DOX and tumor-specific cell killing (161-163). While such prodrugs have shown promise in 
pre-clinical models (164, 165), none, to our knowledge, have yet to enter clinical trials in 
humans. This may be due to wide variations in β-glucuronidase levels amongst patient tumors, 
necessitating screening of patient tumors for high glucuronidase expression (166).  
3.7.2.4: Fullerenol  
 
  The chemical modification of fullerenes (specifically, the polyhydroxylation of C60 
nanoparticles) results in C60 (OH)x structures with differing degrees of antioxidant activity in an 
aqueous environment (167). One particular fullerene (fullerenol) was able to protect rat hearts 
from DOX-induced cardiotoxicity (168). It has been proposed that fullerenol protects 
cardiomyocytes by acting as a ROS scavenger and/or by removing free iron through the 
formation of a fullerenol-iron complex (168). Previous studies have shown that application of 
DOX to Wistar rats causes damage to the heart and baroreceptors, which results in diastolic 
dysfunction characterized by increased left ventricle end-diastolic pressure (169). Fullerenol 
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attenuated these DOX-induced heart disturbances (168). Fullerenol was also able to successfully 
treat DOX-induced nephrotoxicity (170), pulmotoxicity (171), and hepatotoxicity (172) in rats.  
3.7.2.5: Synthesis of Non-Cardiotoxic Anthracyclines  
 
  An alternate strategy for combating anthracycline-induced cardiotoxicity is to synthesize 
anthracyclines with reduced capacity for cardiotoxicity. For example, a prodrug of DOX 
(aldoxorubicin) can be administered at significantly higher concentrations in patients, without 
acute cardiotoxicity. Moreover, recent findings further suggest that aldoxorubicin exhibits stable 
levels in blood without accumulation in body compartments such as the heart. This may explain 
why the drug is significantly less cardiotoxic than DOX (173). The DOX analog GPX-150, 
modified at two sites to reduce the formation of cardiotoxic metabolites or ROS, has shown 
promise in a recent phase I trial, where it was administered safely to patients with acceptable 
toxicity and no cardiotoxocity (174). Another anthracycline with protein kinase C-activating 
properties (AD 198) has also shown significant anti-tumor activity. However, unlike DOX, little 
ventricular damage was observed in mice administered the agent (175).  
3.8: Concluding Remarks  
 
  In the case of anthracyclines, a knowledge of the metabolism of these drugs has provided 
significant insight into how they exert their anti-tumor effects and their toxic side effects on the 
host. Some anthracycline metabolites facilitate the ability of these drugs to combat the growth of 
tumor cells, while others suppress cytotoxicity. The hydroxylation of anthracyclines is of 
particular interest, since the hydroxylated metabolites have considerably reduced antitumor 
activity, but substantially increased cardiotoxicity. By identifying the precise enzymes that play 
a role in anthracycline metabolism, it has been possible to identify novel chemical agents that 
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can augment the anti-tumor effects of anthracyclines and/or prevent negative side effects within 
the host, including cardiotoxicity, nephrotoxicity, and hepatotoxicity. While successful new 
strategies to improve the therapeutic index of anthracyclines have recently been identified, it will 
only be through future clinical trials in multiple, independent cohorts of patients that the true 
efficacy of these strategies will be known. For one such agent (dexrazoxane), its incorporation 
into standard clinical practice clearly appears to be on the horizon.  
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4.1: Introduction 
 To study the phenomenon of acquired chemotherapy resistance, a series of chemotherapy 
resistant cell lines were developed. Briefly, this was accomplished by growing MCF-7 breast 
cancer cells in increasing concentrations of chemotherapy agents beginning at a concentration 
approximately 1,000 fold below the IC50 for each chemotherapy agent  (1–3). Cells would be 
maintained at this concentration, termed “dose 1”, for a period of 2-3 passages or 2 weeks  (2). 
The concentration would then be increased by 3 fold  (2). This process would be repeated until 
the cells were no longer able to adapt to the increasing concentrations of chemotherapy drug and 
did not grow  (2). This final dose selection was termed the terminal selection dose  (2). To 
control for possible changes in gene expression due to prolonged propagation of the cells rather 
than exposure to chemotherapy, co-culture control cells were propagated in parallel which were 
never exposed to chemotherapy  (2).  
 Microarray analysis was performed on the terminally selected cells comparing mRNA 
expression levels  (2). Analysis of the data indicated significant changes in gene expression of 
over 3,000 genes  (2). Among the largest changes, between the MCF-7DOX2-12 (terminal selection 
dose) cells and co-culture control cells, were members of the aldo-keto reductase family, 
specifically AKC1C3 and AKR1B10  (1, 3). Aldo-keto reductases (AKR) comprise a 
superfamily of proteins. All members of the AKR enzyme superfamily function by reducing 
ketones and aldehydes into secondary and primary alcohols  (4). They perform this action in an 
NADPH-dependent manner  (4). As of July 24, 2017, the superfamily contained more than 180 
members, sub-categorized into 15 families. AKRs are classified into families based on sharing a 
minimum of 40% protein sequence identity and into sub-families by sharing more than 60% 
sequence identity  (4). Individual members are identified using a nomenclature where the proper 
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name begins with AKR, designating the superfamily of proteins, followed by a number 
designating the family, then a letter to denote the sub-family and finally a number designating 
the individual member (e.g. AKR1C3 (for the gene) or AKR1c3 (for the protein))  (4). The 
AKR1 family is the largest of the 15 families and is one of three families corresponding to the 
mammalian AKRs  (4). 
 Most AKRs are monomeric proteins ranging in size from 34-37 kDa, however some 
multimeric forms have been identified. These latter proteins are members of the AKR2, AKR6 
and AKR7 families  (4). Of the 25 known crystal structures of AKRs, all have been shown to 
exhibit an alternating (α/β)8 barrel motif. The folded form of the enzyme contains binding sites 
for both the substrate as well as for the co-factor (NADPH), both of which converge at the active 
site of the enzyme  (4). While the co-factor binding site and the active site are highly conserved 
among members of the AKR superfamily, the substrate-binding sites show high levels of 
variation in the sequence of amino acids comprising the connecting loops between the helices 
and the β sheets of the enzyme  (4). 
 The AKR1 family contains six sub-families, the largest of which is the AKR1C 
subfamily  (4). AKR1C members primarily function as steroid-metabolizing enzymes. Molecules 
of the AKR1C1-1C4 all share more than 86% sequence identity  (4). AKR1C3, also known as 
17β-hydroxy-steroid-dehydrogenase type V (17β-HSD) or 3α-hydroxy-steroid-dehydrogenase 
type I (3α-HSD), is involved in estrogen metabolism  (4). AKR1C3 is responsible for the 
conversion of steroid molecules into their active forms; in particular, it converts androstenedione 
into testosterone and estrone (E1) into estradiol (E2). In addition to their ability to metabolize 
steroid molecules, the AKR1C family has been shown to metabolize chemotherapeutic agents  
(4). AKR1B10 and AKR1C2 have been shown to convert the anti-tumour agent doxorubicin into 
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doxorubicinol  (4). AKRs have been implicated in a number of other biological processes, 
including but not restricted to: carcinogenesis through the activation of polycyclic aromatic 
hydrocarbons (AKR1C3-AKR1C4), and detoxification of nicotine carcinogens (AKR1C1, 
AKR1C2, and AKRC4), aflatoxin (AKR7A family members), and reactive aldehydes (AKR1A1, 
AKR1B1, AKR1C1, AKR1C4 and AKR7A2)  (4).  
 AKR expression is generally regulated in response to environmental signals such as 
osmotic pressure and the production of reactive oxygen species (ROS)  (4). This regulation 
occurs as a response of transcriptional elements found in the promoter region of the genes. As of 
2007, three different environmental response elements have been identified in the AKR promoter 
region. An osmotic response element has been identified in the 5’ flanking region of AKR1B1  
(4). AP-1 consensus sequences have been identified in the AKR1B1 promoter as well as in the 
promoters of members of the AKR1C family  (4). However, these sites have yet to be 
demonstrated as functional  (4). As it has been shown, that AP-1 sites are embedded within many 
antioxidant response elements (AREs), cellular responses to ROS may, in part, be mediated via 
the AP-1 sites  (4). The expression of the AKR1C1-1C3 enzymes are all regulated by AREs 
through Nrf2-Keap-1 complexes  (4). 
 The AKR1C1-AKR1C4 enzymes have all been shown to interact with a variety of 
substrates in vitro. In the case of AKR1C3, its structure may be related to its multi-specificity for 
substrates  (5). AKR1C3 provides a well-described example of plasticity. It is capable of 
metabolizing several different steroid molecules, including 4-androstenedione and estrone (E1)  
(6). These molecules are steroid precursors to testosterone and estradiol (E2) respectively.  
Estrogen synthesis is of particular interest in breast cancer studies, due to the effects of 
estrogen on breast epithelial cell proliferation  (4, 7) and survival  (8). Estrogen signaling begins 
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with the binding of an estrogen molecule to one of two receptors, estrogen receptor α (ERα or 
ESR1) or estrogen receptor β (ERβ or ESR2). Both receptors belong to the superfamily of steroid 
nuclear receptors and have a common structural makeup  (8). Binding occurs when an estrogen 
molecule diffuses across the membrane and enters the cytosol  (9). The estrogen molecule then 
binds to either cytoplasmic or plasma membrane-bound receptor. Upon binding, the receptor 
undergoes phosphorylation via cyclin A/CDK2 or TFIIH cyclin dependent kinase. Although the 
best defined action of estrogen receptors is to function as a nuclear transcription factor  (9), it has 
recently been demonstrated that E2 can affect cellular processes more quickly than is possible by 
affecting gene transcription. In some cases, these effects may be mediated by membrane bound 
estrogen receptors or other surface receptors such as the G-protein coupled receptor 30 (GPR-30)  
(9, 10). Upon phosphorylation of membrane bound receptor α, the MAPK (growth promoting), 
or PI3K (survival) pathways can be activated by a mechanism not requiring gene transcription  
(11–14). Another estrogen signaling pathway is the classical genomic signaling pathway. In this 
situation, phosphorylated receptors dimerize to form active complexes, enter the nuclei of cells, 
and bind to estrogen response elements (EREs) in the promoter regions of specific genes  (9). 
Once bound to the ERE, the active ER complex will recruit other transcription factors and 
activate transcription of associated genes  (9). 
ERα has long been used as a prognostic biomarker in cancer, in particular for female 
cancers. ERα expression is generally associated with good prognosis in breast cancer as many 
therapies exist to target this receptor or the pathways upstream of the receptor  (15). Recently, 
ERβ has emerged as a possible new prognostic biomarker in breast cancer  (15). In histological 
studies, ERβ was shown to be a marker of good prognosis in post-menopausal women; this 
included patients diagnosed with triple negative breast cancer (i.e. lacking ERα)  (15). The 
123 
 
importance of studying ERα and ERβ, their interactions with each other, and how they influence 
the development and prognosis of breast cancer, has been recognized for many years  (16–19). In 
both breast cancer and prostate cancer, steroid hormones have been shown to protect cells from 
undergoing apoptosis. This was demonstrated by removing testosterone and estrogen from 
prostate and mammary epithelial cells, respectively  (8). When they are grown in the absence of 
steroid hormones, the cells underwent apoptosis. Previous studies have shown that MCF-7 cells 
pretreated with estrogen show resistance to killing by TNF-α and other chemotherapeutics, 
including the ERα antagonist tamoxifen  (20). The ability of estrogens to interfere with apoptosis 
is generally attributed to their ability to promote overexpression of the apoptotic suppressor 
proteins BCL-2 or BCL-XL. Although BCL-2 does not contain an ERE in the promoter region of 
the gene, it does contain one within the coding region  (21). In addition, the anti-apoptotic effects 
of estrogens have been shown to involve the mitogenic MAPK/ERK pathway as well as the anti-
apoptotic PI3K/AKT pathway via activation of membrane-associated ERα. In MCF-7 cells, it 
has been shown that estrogens have differential effects on the expression of the BCL family of 
proteins; treatment with estrogens increases the expression of BCL-2, while reducing expression 
of BCL-xL  (22, 23), Since both of these proteins have anti-apoptotic effects, this phenomenon is 
generally regarded as being paradoxical in terms of promoting cell survival. In addition to having 
anti-apoptotic effects, estrogens have also been shown to stimulate the growth of MCF-7 cells  
(24). This was shown in previous studies by growing cells in serum depleted of all steroids. 
These cells showed a marked reduction in cell proliferation, possibly by preventing estrogen-
dependent activation of the MAPK pathway or by permitting apoptosis resulting from the 
absence of estrogen dependent BCL-2 expression  (24–26). The latter was disproven using live 
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microscopic techniques which showed that in the absence of estrogens, the cells were still able to 
move and act as they would normally, but at a reduced rate. 
Most hormone-dependent cancers rely on locally synthesized hormones for signaling as 
opposed to systemic steroids  (24). In many cases, the tumours themselves act as the source for 
these growth hormones. This is of particular advantage for the cancer cells since it is more 
energetically favorable to use an intracrine system of signaling, which requires a lower level of 
hormones as opposed to endocrine or paracrine systems  (27). The two latter systems require 
higher levels of hormones to achieve the same results on signal activity, since the signal gets 
diluted as it diffuses further away from the source of synthesis  (27). 
4.2: Hypothesis and Specific Aims of Study 1 
I postulate that the increase in AKR1C3 expression will result in higher levels of 
serum estradiol. This will result in one of two possibilities: 1) An increase in estrogen 
signaling will resulting in enhanced survival and increased growth of the cells, or 2) 
increased estradiol levels that will result in a negative feedback in turn reducing the ERα 
levels and resulting in a down regulation of the growth-promoting signal. Based on the 
above hypotheses, the primary aims of this thesis are to: 
Aims: 
1) Assess AKR1C3 protein levels in wildtype and anthracycline-resistant MCF-7 breast 
tumour cells, 
2) Determine if overexpressing AKR1C3 in wildtype MCF-7 cells impart resistance to 
anthracyclines, 
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3) Use siRNA approaches in MCF-7DOX2-12 cells to reduce levels of AKR1C3 and 
AKR1B10 and determine the effect on resistance to doxorubicin 
4) Assess the ability to convert estrone to estradiol in MCF-7 anthracycline-resistant 
and AKR1C3-transfected cells, 
5) Assess the estrogen receptor signaling activity in MCF-7 Anthracycline-resistant cells 
by assessing expression levels of BCL-2 and Cyclin D1 as indicators of genomic 
signaling, 
6) Assess the growth rate of MCF-7 Anthracycline resistant and AKR1C3 transfected 
cells to confirm the reduced rate of growth in anthracycline resistant cells, 
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5.1: Abstract 
Intrinsic or acquired drug resistance is a major impediment to the successful treatment of women 
with breast cancer using chemotherapy. We have observed that MCF-7 breast tumor cells 
selected for resistance to doxorubicin or epirubicin (MCF-7DOX2 and MCF-7EPI cells, 
respectively) exhibited increased expression of several members of the aldo-keto reductase 
(AKR) gene family (in particular AKR1C3 and AKR1B10) relative to control MCF-7CC cells 
selected by propagation in the absence of drug. Normal cellular roles for the AKRs include the 
promotion of estrogen (E2) synthesis from estrone (E1) and the hydroxylation and detoxification 
of exogenous xenobiotics such as anthracycline chemotherapy drugs. While hydroxylation of 
anthracyclines strongly attenuates their cytotoxicity, it is unclear whether the enhanced AKR 
expression in the above anthracycline-resistant cells promotes E2 synthesis and/or alterations in 
E2 signaling pathways and whether such changes contribute to enhanced survival and 
anthracycline resistance. To determine the role of AKRs and E2 pathways in doxorubicin 
resistance, we examined changes in the expression of E2-related genes and proteins upon 
acquisition of doxorubicin resistance. We also assessed the effects of AKR overexpression or 
downregulation or the effects of activators or inhibitors of E2-dependent pathways on previously 
acquired resistance to doxorubicin. In this study we observed that the enhanced AKR expression 
upon acquisition of anthracycline resistance was, in fact, associated with enhanced E2 
production. However, the expression of estrogen receptor α (ERα) was reduced by 2- to 5-fold at 
the gene transcript level and 2- to 20-fold at the protein level upon acquisition of anthracycline 
resistance. This was accompanied by an even stronger reduction in ERα phosphorylation and 
activity, including highly suppressed expression of two proteins under E2-dependent control 
(BCL-2 and cyclin D1). The diminished BCL-2 and cyclin D1 expression would be expected to 
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reduce the growth rate of the cells, a hypothesis which was confirmed in subsequent cell 
proliferation experiments. AKR1C3 or AKR1B10 overexpression alone had no effect on 
doxorubicin sensitivity in MCF-7CC cells, while siRNA-mediated knockdown 
of AKR1C3 and/or AKR1B10 expression had no significant effect on sensitivity to doxorubicin in 
MCF-7DOX2 or MCF-7EPI cells. This suggested that enhanced or reduced AKR expression/activity 
is insufficient to confer anthracycline resistance or sensitivity to breast tumor cells, respectively. 
Rather, it would appear that AKR overexpression acts in concert with other proteins to confer 
anthracycline resistance, including reduced E2-dependent expression of both an important 
apoptosis inhibitor (BCL-2) and a key protein associated with activation of cell cycle-dependent 
kinases (cyclin D1). 
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5.2: Introduction 
Anthracyclines are a class of drugs that are commonly used in adjuvant or neoadjuvant 
chemotherapy for breast cancer, often in conjunction with other anti-cancer agents (1). Of this 
class of chemotherapy agents, doxorubicin or epirubicin are most widely used. Anthracyclines 
are believed to be cytotoxic to tumor cells through three mechanisms: intercalation between 
strands of DNA/RNA molecules resulting in interference with normal DNA/RNA synthesis in 
rapidly dividing cells (2, 3), inhibition of topoisomerase II activity (4), and the creation of iron-
mediated oxygen free radicals (5, 6). 
Despite their clear utility in the clinical management of breast cancer, many factors 
negatively affect their efficacy when administered to cancer patients. One such factor is the 
ability of tumors to resist the cytotoxic action of anthracyclines (7). This can occur via two 
distinct mechanisms. First, some tumors exhibit innate resistance to chemotherapy drugs, such 
that they do not respond to first-line chemotherapy (often referred to as “primary 
chemotherapy”) (8). In other instances, patient tumors acquire resistance to anthracyclines and 
other chemotherapy agents over time. In this latter case, the tumors initially respond partially or 
almost fully to the administered drugs. However, drug-resistant cells within the tumor cell 
population survive treatment and continue to replicate, resulting in recurrent disease and disease 
progression. In some instances, tumors acquire resistance to a wide variety of chemotherapeutic 
agents, a phenomenon known as multi-drug resistance (7). Chemo-resistant tumors are usually 
treated with alternative chemotherapy drugs (9, 10) or alternate downstream treatments such as 
surgery or radiation therapy (10, 11). 
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One tool used to study the phenomenon of drug resistance is to look at genotypic and 
phenotypic changes that take place as tumor cells acquire resistance to chemotherapy drugs in 
the laboratory. We recently established a panel of MCF-7 breast cancer cell lines, which were 
selected for survival in increasing concentrations of various chemotherapy agents including the 
anthracyclines (12). Microarray studies comparing parental and anthracycline-resistant cells 
revealed many changes in gene expression accompanying the acquisition of anthracycline 
resistance, including increased transcripts for several members of the aldo-keto reductase (AKR) 
family (13) and decreased transcription of genes for estrogen receptor α (ERα) and BCL-2 (13). 
The higher levels of expression of AKRs in the above anthracycline-resistant MCF-7 cells 
relative to drug-sensitive control cells has also been correlated with reduced cellular doxorubicin 
content, strongly reduced doxorubicin localization to the nucleus, and substantial sequestration 
of doxorubicin into perinuclear lysosomes (14). 
The AKRs are a superfamily of proteins that hydroxylate various endogenous cellular 
substrates and chemotherapy drugs (reviewed in (15) and (16)). Individual members are 
identified using a nomenclature method beginning with AKR, followed by a number designating 
the family, then a letter to denote the sub-family, and finally a number designating the individual 
member within the sub-family (e.g. AKR1C3 (for the human gene) or AKR1c3 (for the protein)) 
(17). The AKR1 family is the largest of the 15 AKR families and is one of three mammalian 
AKR families (17). AKRs are differentially expressed in various tissues throughout the 
body. AKR1C1 and AKR1C4 transcripts have been shown to be primarily expressed in the liver, 
intestine, mammary glands, prostate, and lungs (17–19). AKR1c3 is the dominant AKR found in 
mammary glands. It is also responsible for the hydroxylation of steroid molecules into their 
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active forms; specifically, it converts androstenedione into testosterone and estrone (E1) into 
estradiol (E2) (20). 
E2 is a potent signaling molecule which is active in host tissues and tumors that are 
positive for estrogen receptors (21–23). E2 belongs to the E2 family of signaling steroids, which 
includes the precursor molecules E1 and estriole (E3). Like all steroid molecules, E2 is 
synthesized from cholesterol (24). The primary source for E2 in physiological systems differs 
between males and females. In pre-menopausal women, the majority of E2 is synthesized in the 
ovaries (25, 26) and serves as the primary source of circulating E2. However, in post-
menopausal women and in men, synthesized E2 acts in a paracrine fashion in tissues such as the 
breast (25). E2 synthesis is of particular interest in breast cancer studies, due to the effects of E2 
on breast epithelial cell proliferation (20, 25, 27) and survival (28) via phosphorylation and 
activation of ERα (29, 30). Epidermal growth factor (EGF), a known promoter of cell 
proliferation is also known to activate ERα phosphorylation (31). 
ER signaling has a wide range of effects within cells, including the regulation of 
transcription (32, 33) and the activation of anti-apoptotic and pro-growth pathways (34, 35). The 
genes and pathways affected by E2 vary depending upon which of two E2 receptors is activated 
(ERα or ERβ) (36). Both receptors share a common structural homology but differ in size (66 
kDa and 56 kDa for ERα and ERβ, respectively) (28, 36). 
While ERα expression promotes breast tumor growth, it is generally associated with a 
favorable outcome for breast cancer patients, as many therapies exist to inhibit ERα function or 
pathways upstream of this receptor (37–39). Recently, ERβ has emerged as a possible new 
prognostic biomarker in breast cancer (40, 41). Most hormone-dependent cancers rely on locally 
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synthesized hormones for signaling as opposed to systemic hormones (24). In many cases, the 
tumors themselves act as the source for these growth-promoting hormones. This is of particular 
advantage for cancer cells, since it is more energetically favorable to use a local autocrine system 
to promote growth, as opposed to the higher hormone levels required for endocrine or paracrine 
systems (24). 
In this study, we examined, in ER+ MCF-7 breast tumor cells, the effects of selection for 
anthracycline resistance and/or the altered expression of one or more AKRs on E2 metabolism, 
E2-dependent signaling pathways, expression of E2-dependent genes, cellular growth kinetics, 
and cellular survival in the presence of anthracyclines. We postulated that, in addition to effects 
on doxorubicin catabolism and cellular levels of active doxorubicin, the increased expression of 
AKRs in anthracycline-resistant or AKR-transfected cells will result in higher levels of E2 
production and increased cellular proliferation. In addition, we expected to observe increased 
expression of E2-dependent genes that promote increased tumor cell survival in the presence of 
anthracyclines. 
5.3: Methods 
5.3.1: Culture of wildtype and drug-resistant breast tumour cell lines 
The MCF-7 breast cancer cell line was purchased from the American Type Culture 
Collection (ATCC, Manassas, VA) and maintained in high glucose D-MEM medium 
supplemented with 10% FBS, 100 μg/ml streptomycin, and 100 units/ml penicillin (Hyclone, 
Mississauga, Ontario) at 37° C in 5% CO2. For subculturing, cells in T75 Sarstedt flasks were 
washed once with sterile PBS followed by the addition of 3 ml of a sterile 0.25% Trypsin, 10 
mM EDTA solution (Invitrogen, Burlington Ontario). MCF-7 cells were selected for resistance 
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to increasing doses of either doxorubicin or epirubicin as described previously (12). Cells at the 
various drug selection doses (1 through 12) were stored for subsequent studies. Cells were 
named based on the selection process, the selection agent and the selection dose. For example, 
MCF-7DOX2-9 cells represent the second time that MCF-7 cells were selected for resistance to 
doxorubicin up to selection dose 9. Similarly, MCF-7EPI-12 cells represent the first time that 
MCF-7 cells were selected for resistance to epirubicin up to selection dose 12. The various 
selection doses employed are described in our previously published study (12). Cells were also 
selected in the absence of drug to control for genotypic and phenotypic changes due to continued 
propagation in culture (at identical passage numbers to drug-selected cells). The nomenclature 
used for these cell lines reflect the absence of drug (co-cultured control or “CC” cells) and the 
number of passages. For example, MCF-7CC-12 cells are cells selected in the absence of drug for 
an equivalent number of passages as anthracycline-selected cells (selected to dose 12). Drug-
resistant cells were maintained in media supplemented with the corresponding selection dose of 
doxorubicin or epirubicin. They were, however, placed in drug-free medium media for 3–4 days 
prior to use in experiments. 
5.3.2: Dextran charcoal filtering of cell culture media 
To remove endogenous steroid compounds and growth factors, D-MEM media 
supplemented with 10% FBS and antibiotics were treated with 0.5% (w/v) dextran-coated 
charcoal (Sigma Chemical, St. Louis, MO), and heated to 50°C with constant shaking for 30 
min. The charcoal-treated media was then sterile-filtered using a Sarstedt 0.22 μm, 500 ml 
vacuum filter. Dextran charcoal-treated D-MEM media (DC-DMEM) were supplemented with 
10
−7
 M E2 for ER signaling experiments, or 10
−7
 M estrone (E1) for E1 metabolic experiments 
(Sigma Chemical, St. Louis, MO). 
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5.3.3: Assessment of cellular E2 levels 
Estradiol (E2) levels in wildtype and drug-resistant cells were determined using a 
standard enzyme-linked immunosorbent assay (ELISA). Briefly, 5x10
5
 cells/well were plated in 
6 well plates (Sarstedt), in D-MEM media supplemented with 10% FBS and antibiotics and 
allowed to adhere overnight. D-MEM media was replaced with dextran/charcoal-stripped D-
MEM medium (DC-DMEM) 18 hours after plating. Cells were treated with one of: a vehicle 
control solution (5% DMSO), 10
−7
 M E1, 10
−7
 M E1 with 5x10
-9
 M letrozole (aromatase 
inhibitor), or 10
−7
 M E1 (E1) with 0.2 mM β-cholanic acid (in 5% DMSO) (AKR1c3 inhibitor). 
Aliquots of media were collected 24h post treatment and stored at -20°C. E2 levels in the media 
were then assayed using E2 competitive ELISA kits (US Biological Life Sciences) as per the 
manufacturer’s protocol. 
5.3.4: Assessment of cellular sensitivity to anthracyclines using clonogenic assays 
The sensitivity of the above-described cell lines to various doses of anthracyclines was 
determined using a clonogenic assay, which monitors the ability of drug-treated cells to form 
colonies in drug-free semi-solid methylcellulose medium, as previously described in (13). The 
mean number of viable colonies was determined in 12 randomly selected field’s ± the standard 
error of the mean. Each clonogenic experiment was repeated twice. 
5.3.5: Creation of a mammalian AKR1C3 expression plasmid and transfection in MCF-7 
cells 
A plasmid (pENTR211) containing the open reading frame (ORF) for the AKR1C3 gene 
was purchased from Invitrogen (Burlington, ON) and transfected into E. coli DH5α cells using 
standard methods. Successful transformants were cultured on LB-Agar plates containing 50 
μg/ml of kanamycin as the selective agent. Plasmid DNA from a positive bacterial clone 
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(propagated in kanamycin-containing LB medium) was isolated using QIAprep miniprep 
plasmid extraction kits (Qiagen). The ORF for AKR1C3 was amplified by PCR using the purified 
plasmid as template and the following AKR1C3-specific primers (Forward: 5’- GCT AAG ATC 
TTC ATG GAT TCC AAA CAC CAG TGT G -3’, Reverse: 5’- TCG ACT CGA GGT ACA 
AGA AAG CTG GGT TCT AAT ATT CAT C -3’ (IDT)). After cleavage with appropriate 
restriction endonucleases, the AKR1C3 cDNA within the amplified ORF product was ligated into 
identical cleavage sites within the pCMV-FLAG plasmid (Stratagene), such that the FLAG Tag 
was incorporated in frame with the C-terminal domain of the protein-coding sequence. The 
ligation reaction was transformed into competent DH5-α E. coli bacteria and cultured on 
kanamycin-containing plates to select for clones harboring the pAKR1C3-FLAG plasmid. The 
recombinant plasmid was purified from bacterial transformants using Qiagen QIAprep maxiprep 
kits (Qiagen). Plasmid concentrations and purity were determined by monitoring absorbance at 
260 nm and 280 nm. The AKR1C3-Tag insert within pAKR1C3-FLAG was sequenced 
(MOBIX) to confirm that no mutations were introduced into the AKR sequence during DNA 
cloning. 
Clones of cells stably expressing the AKR1C3 cDNA were generated by transfecting 
MCF-7CC-12 cells with pAKR1C3-FLAG DNA using Lipofectamine 2000
TM
 medium 
(Invitrogen). Cells were incubated overnight, and then subjected to selective screening in D-
MEM medium containing 2.0 mg/ml G418 (Sigma, St. Louis, MO) until G418-resistant clones 
were obtained. Cells transiently overexpressing AKR1C3 were also generated by transfection 
with 24 μg of plasmid DNA complexed to 60 μl of Lipofectamine 2000. The cells were 
transfected for 18 h and then re-plated for subsequent experiments. The amount of 
140 
 
overexpression of AKR1c3 protein was assessed in immunoblotting experiments employing an 
anti-human AKR1c3 antibody (Sigma, St. Louis, MO) using the protocol described below. 
5.3.6: siRNA-mediated knockdown of AKR1C3 and AKR1B10 expression 
Silencer select siRNA oligoribonucleotides were obtained from Life Technologies 
(Burlington, ON) to induce the specific degradation of AKR1C3 and AKR1B10 transcripts. Two 
different siRNAs were used to reduce expression of these genes (16448 (KD1) and 225013 
(KD2) for AKR1C3, and 32583 (KD3) and 32584 (KD4) for AKR1B10). In addition, a 
scrambled control siRNA (SCRAM, also from Life Technologies) was also used as a negative 
control to identify any possible off-target effects, including those induced by the transfection 
process itself. Cells were transfected with 5 ng of siRNA using Lipofectamine 2000, as per the 
manufacturer’s directions. Knockdowns were confirmed by quantitative PCR and western blot 
analyses. The effect of the siRNAs on cellular sensitivity to anthracyclines was also assessed 
using clonogenic assays. 
5.3.7: Immunoblotting experiments with epitope- and phospho-specific antibodies 
Cells were lysed by incubation in standard RIPA buffer supplemented with 1x Complete 
protease inhibitor cocktail (Roche), 10 μM NaF, 2 mM Na3VO4 and 1 μM PMSF (Sigma, St. 
Louis, MO). The amount of protein in each whole cell extract was quantified using the BCA 
assay, as per the manufacturer’s protocol (Pierce). Extracts were aliquoted into 1.5 ml tubes 
containing standard Laemmli sample buffer (1X final concentration) and boiled for 5 min, after 
which the proteins in the extracts were resolved by standard SDS acrylamide gel electrophoresis 
procedures. The resolved proteins in the extracts were transferred by electrophoresis to 
nitrocellulose membranes and the membranes probed with specific primary antibodies and 
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appropriate HRP-conjugated secondary antibodies using standard immunoblotting procedures. In 
some instances, blots were stripped for 1 h at 50°C in a buffer containing 6.24 mM Tris pH 6.7, 
2% (w/v) SDS, and 100 mM β-mercaptoethanol before re-probing with another antibody. 
5.3.8: Assessment of estrogen receptor α and estrogen receptor β transcript expression 
The level of human ERα gene (ESR1) transcripts in the above cell lines was assessed by 
quantitative PCR (Q-PCR). Qiagen RNeasy kits (Qiagen) were used to extract total RNA from 
the above cell lines. Prior to Q-PCR, all RNA samples were assessed for RNA integrity by 
capillary electrophoresis on an Agilent 2100 Bioanalyzer using RNA 6,000 Nano Assay Lab 
Chips as per the manufacturer’s directions (Agilent Technologies). RNA to be used in Q-PCR 
experiments had to exhibit an RNA integrity number (RIN) of ≥ 8 and a 28S/18S ratio of ≥ 1.8. 
All RNA samples were subjected to DNase treatment prior to reverse transcription as previously 
described (42). The expression of ESR1 transcripts was then assessed by Q-PCR as described 
(42). The ESR1 primers used were (Forward: 5’-CCACCAACCAGTGCACCATT-3’, 
Reverse: 5’-GGTCTTTTCGATTCCCACCTTTC-3’). All RNA samples were assessed 
for ESR1 transcript expression in triplicate with the transcript for the S28 ribosomal protein as 
the reference gene. 
5.3.9: Immunohistochemical Assessment of Estrogen Receptor Α Protein Expression 
The expression of human ERα protein expression in the above cell lines was assessed by 
immunohistochemistry with a human ERα antibody. Cells were harvested and the cell pellets, 
collected after centrifugation, were delivered on ice to the Pathology Department of Health 
Sciences North, Sudbury, ON. Cell pellets were fixed in a 5% (v/v) formalin solution for 24 h. 
The samples were then embedded in Histogel
TM
 prior to embedding in paraffin blocks. 
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Histological slices were taken from the paraffin blocks and prepared for Hematotoxin and Eosin 
(H&E) staining for visualization of tumor cells and immunohistochemical staining using an 
HRP-conjugated human ERα antibody. 
5.3.10: Quantitative Determination of Cellular Levels of Activated ERα 
Levels of active (nuclear) ERα in cells were quantified using human ERα TransAM™ 
kits purchased from Active Motif (Carlsbad, CA), using the manufacturer’s protocol. 
5.3.11: Artemisinin-induced Reduction in Cellular ERα Protein Expression 
In some experiments, cellular ERα protein expression was strongly reduced by their 
incubation with Artemisinin (Sigma, St. Louis, MO). This enabled us to assess changes in 
cellular phenotypes associated with strongly reduced ERα levels. Cells were plated at 30% 
confluence in 10 cm plates containing D-MEM supplemented with 10% FBS and antibiotics. 
After cells had adhered for 24 h, the media was removed and replaced with D-MEM 
supplemented with 10% FBS and either 300 μM Artemisinin or 0.1% v/v DMSO as the control. 
Cells were allowed to grow at 37°C at 5% CO2 for 72 h. Following the treatment period, proteins 
were extracted from the cells as previously described. 
5.3.12: Data Analysis 
All graphs were prepared using GraphPad Prism V5.0 software. All data points depicted 
represent the mean ± standard error of mean (SEM). Statistical analyses were performed using 
GraphPad Prism V 5.0 software. Analysis of Variance (ANOVA) tests were performed, 
assuming a normal distribution for all data sets, followed by a Bonferoni post hoc test for 
significance. Comparisons were made between drug-selected and co-cultured control cell lines at 
various selection doses, as well as between treated and untreated cell lines or between cells 
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expressing and not expressing specific transcripts or siRNAs. Due to the multi-parametric nature 
of the data analyses, an ANOVA was chosen as the most suitable method of data analysis. 
Differences between samples or cell lines were deemed to be significant if they had a p value of 
< 0.05 for the above statistical tests. 
5.4: Results 
5.4.1: Expression of AKR1C Isoforms 
Previously conducted DNA microarray studies comparing gene expression between 
MCF-7CC-12 and MCF-7DOX2-12 cells identified a number of differences in gene expression that 
accompany the acquisition of doxorubicin resistance (13). Among these were members of the 
AKR 1C gene family, although the probes used in the microarray experiments could not 
effectively distinguish between the various transcripts of AKR 1C isoforms. Subsequent Q-PCR 
experiments using isoform-specific primers confirmed that 
both AKR1C2 and AKR1C3 transcripts are elevated in MCF-7EPI-12 and MCF-7DOX2-12 cell lines 
(compared to MCF-7CC-12cells). AKR1C3 transcript levels were 11.9 ± 3.9-fold higher in MCF-
7DOX2-12 cells line (p<0.0001) and 4.5 ± 0.9-fold higher in MCF-7EPI-12 cells compared to the 
MCF-7CC-12 cells. Similarly, AKR1C2 transcript levels were 5.8 ± 1.1-fold and 4.6 ± 1.2-fold 
higher in MCF-7EPI-12and MCF-7DOX2-12 cells compared to MCF-7CC-12 cells, respectively (13). 
Given that AKR1C3 was the most strongly upregulated aldo-keto reductase gene in the 
anthracycline-resistant cell lines, we recently assessed protein extracts of the above cell lines 
across the various selection doses for their level of AKR1c3 protein expression, as measured 
using standard immunoblotting procedures (Figure 5-1 A). As shown in Figure 5-1 B, no 
statistically significant differences in AKR1c3 expression were observed between MCF-7DOX2-
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7 or MCF-7DOX2-8 cells and their co-cultured control cell lines (MCF-7CC-7 and MCF-7CC-8 cells). 
However, beginning at selection dose 9 (MCF-7DOX2-9), we observed an 8.7±1.5 fold (p≤ 0.01) 
induction in AKR1c3 protein expression relative to its co-cultured control cell line. MCF-7DOX2-
10 cells showed a 7.4±1.4 fold (p≤ 0.05) induction, while cells selected to doses 11 and 12 
showed 12.5 ± 2.3-fold and 10.2 ± 4.5-fold inductions, (p≤ 0.001 and p≤ 0.01, 
respectively; Figure 5-1 B). Interestingly, the expression of another AKR isoform not involved 
in estrogen biosynthesis (AKR1b10) also increased in a dose-dependent manner as the 
doxorubicin selection dose was increased beyond selection dose 8 (Figure 5-1 A). In contrast, 
continued propagation of MCF-7 cells in the absence of doxorubicin (MCF-7CC cells) resulted in 
reduced AKR1c3 protein expression, suggesting that cell propagation under optimal cellular 
conditions in the absence of a cell stressor (such as doxorubicin) reduces the expression of aldo-
keto reductases. 
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Figure 5-1 Assessment of AKR1c3 and AKR1b10 and γ-tubulin expression in various stable 
cell lines using immunoblotting approaches. 
 (A) Representative immunoblots for assessing AKR1c3, AKR1b10 and γ-tubulin protein 
expression in extracts of unselected MCF-7CC cells or doxorubicin-selected MCF-7DOX2cells 
(selection doses 7 through 12). Blots represent one 4 independent experiments. (B) Fold change 
in AKR1C3 levels relative to corresponding co-cultured control cell lines for doxorubicin-
selected cell lines across selection doses 7 through 12 (based by densitometry). Fold changes are 
expressed as the average ± S.E.M. for 4 independent experiments. The significance of 
differences in AKR1c3 expression between the designated doxorubicin-elected cell line and its 
corresponding co-cultured control cell line was assessed using an ANOVA test, followed by a 
Bonferoni correction. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001. 
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5.4.2: Transient and Stable Overexpression of AKR1c3 Protein in MCF-7CC-12 Cells 
We then assessed whether stable or transient expression of 
recombinant AKR1C3 transcripts in MCF-7CC-12 cells could, by itself, induce doxorubicin 
resistance. Figure 5-2 depicts the level of AKR1c3 protein expression in untreated MCF-7CC-
12 cells, MCF-7CC-12 cells exposed to transfection conditions with DNA empty vector control, and 
MCF-7CC-12 cells transiently (panel A) and stably (panel B) transfected with a 
human AKR1C3 expression vector (pCMV-AKR1C3-FLAG). Cellular levels of AKR1c3 protein 
were determined in immunoblotting experiments using an AKR1c3-specific antibody, with a γ-
tubulin antibody being used as a loading control. After densitometric quantification of the 
AKR1c3 bands, the levels of total AKR1c3 expression relative to MCF-7CC-12 cells was then 
determined for the transiently and stably transfected cells. We found that while transient 
transfections did not result in permanent elevations in AKR1c3 expression, the fold increase in 
total AKR1c3 immunoreactivity was much greater (up to 5-fold) for transiently transfected 
MCF-7CC-12 cells than stable transformants (up to 1.7-fold). It should be noted that during 
optimization experiments, AKR1c3 levels were found to increase when cells were treated with 
an empty vector (pCMV-FLAG; see Figure 5-2 A), suggesting that the stresses associated with 
the transfection process are sufficient to induce AKR1c3 expression. This was confirmed in 
subsequent experiments where cells transfected under identical conditions in the absence of 
expression plasmids also exhibited increased AKR1c3 expression (data not shown). 
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Figure 5-2 Assessment of AKR1c3, AKR1b10 and γ-tubulin expression in various stably and 
transiently transfected cell lines using immunblotting approaches. 
A) Optimization of transfection using lipofectamine 2000. Lane 1 represents untreated MCF-7CC-
12 cells, lane 2 is for identical cells transfected with an empty vector (pCMV-FLAG) in the 
presence of lipofectamine (1:2 ratio), while lanes 3, 4 and 5 are cells transfected with FLAG-
tagged AKR1c3 expression vector (pCMV-AKR1C3-FLAG) at vector to lipofectamine ratios of 
1:1, 1:1.5 and 1:2, respectively. B) A representative western blot assessing AKR1C3 protein 
expression in MCF-7CC-12 cells stably transfected with an empty vector (lanes 1, 2 and 3) or 
pAKR1C3-FLAG (lanes 4 and 5). C) A representative western blot assessing AKR1c3 protein 
expression in cells transfected with a random RNA sequence (scrambled) or with an AKR1C3-
specific siRNAs (KD-1 and KD-2). D) A representative western blot assessing AKR1b10 and 
AKR1c3 protein expression in cells transfected with a scrambled siRNA or AKR1B10-specific 
siRNAs (KD-3 and KD-4). 
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5.4.3: Effect of AKR1c3 Overexpression on Cellular Doxorubicin Sensitivity 
We then assessed whether the transient or stable expression of recombinant AKR1c3 
alters the sensitivity of MCF-7CC-12 cells to doxorubicin using a clonogenic assay. The two 
clones having the highest stable expression of recombinant AKR1c3 (MAT36 and 
MAT32, Figure 5-2 A) had a higher IC50 for doxorubicin (110 ± 93 nM) than stable clones with 
little to no AKR1C3 expression (46 ± 29 nM) (see Figure 5-3 A). This translates into a 2.4-fold 
decrease in doxorubicin sensitivity, consistent with a possible role for AKR1c3 in doxorubicin 
resistance; however, this difference was not deemed to be significant using an ANOVA. Perhaps 
the modest fold increase (1.5-fold) in total AKR1C3 expression was insufficient to confer a 
statistically significant reduction in doxorubicin sensitivity. We thus examined whether the ~5-
fold change in total AKR1C3 expression found in MCF-7CC-12 cells transiently transfected with 
pCMV-AKR1C3-FLAG might be sufficient to induce statistically significant changes in 
doxorubicin sensitivity. As shown in Figure 5-3 B, no significant change in doxorubicin 
sensitivity was observed. The IC50 for doxorubicin in untransfected MCF-77CC-12 cells was 16.2 
nM, while mock-transfected and pCMV-AKR1C3-FLAG-transfected cells had IC50s for 
doxorubicin of 14.4 nM and 12.7 nM, respectively. Taken together, the data suggests that simply 
increasing the expression of one AKR isoform (AKR1c3) was insufficient to confer doxorubicin 
resistance in MCF-7CC-12 cells. 
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Figure 5-3 Differences in sensitivity to doxorubicin, as measured using clonogenic assays for 
MCF-7CC-12 cells stably or transiently transfected with various constructs. 
Survival curves are depicted for: (A) stable clones of MCF-7CC-12 cells transfected with 
pAKR1C3-FLAG, (B) MCF-7CC-12 cells, with or without transient transfection with the 
pAKR1C3-FLAG plasmid, (C) MCF-7DOX2-12 cells, with or without transient transfection with 
scrambled or AKR1C3-specific siRNAs, (D) MCF-7DOX2-12 cells, with or without transient 
transfection with scrambled or AKR1B10-specific siRNAs, (E) MCF-7DOX2-12cells, with or 
without transient transfection with scrambled or both AKR1C3- and AKR1B10-specific siRNAs. 
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In order to further assess the relationship between the expression of AKRs and 
doxorubicin resistance, we then assessed the effect of AKR1C3- and AKR1B10-specific siRNAs 
on doxorubicin sensitivity in MCF-7DOX2-12 cells. siRNAs against AKR1C3 were designated KD1 
and KD2, while siRNAs against AKR1B10 were designated KD3 and KD4. Interestingly, 
transfection of MCF-7DOX2-12 cells with a scrambled control siRNA strongly increased both 
AKR1c3 and AKR1b10 expression (Figure 5-2 D), similar to our observations of increased 
AKR1c3 expression in MCF-7CC-12 cells upon transfection with an empty vector (pCMV-
FLAG; Figure 5-2 A). Nevertheless, transient transfection of MCF-7DOX2-12 cells with 
the AKR1C3- or AKR1B10-specific siRNAs resulted in an average reduction in AKR1c3 or 
AKR1b10 expression of 50 to 80% relative to the scrambled control siRNA (Figure 5-2 C and 
D, respectively). The KD-1 and KD-3 siRNAs gave the highest knockdown of AKR1c3 and 
AKR1b10 protein expression, respectively (at near 80%; Figure 5-2 C and D). Despite the high 
data variability, the IC50s for doxorubicin in MCF-7DOX2-12 cells transfected with 
the AKR1C3 siRNAs (680 nM and 460 nM), were very similar to that of untransfected MCF-
7DOX2-12 cells (490 nM; see Figure 5-3 C). Similarly, knockdown of AKR1b10 expression in 
MCF-7DOX2-12 cells resulted in IC50s for doxorubicin of 560 nM and 690 nM for the two siRNAs 
(Figure 5-3 D), very similar to that of MCF-7DOX2-12 cells. Knockdown of one of the AKR 
isoforms did not induce an upregulation of the expression of the other AKR isoform (Figure 5-2 
D). To address possible effects of compensatory gains in the expression of one AKR isoform due 
to the loss of another isoform, we performed a dual-knockdown experiment in which we treated 
cells with both AKR1C3- and AKR1B10-specific siRNAs (KD1 and KD3 or KD2 and KD4). 
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Transfection of MCF-7DOX2-12 cells with both siRNAs did not result in any significant change in 
doxorubicin sensitivity (Figure 5-3 E). 
5.4.4: Factors Affecting E1 to E2 Conversion in Various Breast Tumor Cell Lines 
Since AKR1C3 is known to play a role in E1 to E2 conversion, the above-documented 
increases in AKR1C3 expression in MCF-7DOX2 cells and MCF-7EPI cells would be expected to 
result in higher cellular E2 levels. Given that E2 promotes cell growth and survival in breast 
tumor cells (43, 44), the elevated E2 levels could, in turn, contribute to the observed 
anthracycline resistance phenotype. To assess the former hypothesis, MCF-7CC-12, MCF-7DOX2-12, 
and MCF-7EPI-12 cells (selected to dose level 12) were treated with exogenous E1 (100 nM) and 
the amount of E2 released in the medium determined in the presence or absence of various 
pathway inhibitors. These included letrozole (which inhibits the aromatization of androgens 
androstenedione and testosterone to estrone and estradiol, respectively) and β-cholanic acid, a 
known AKR inhibitor. E2 secreted into the media of cells was monitored over a 24 h period. By 
inhibiting the aromatase pathway we were able to monitor the effects of β-cholanic acid on the 
direct conversion of E1 to E2. As shown in Figure 5-4 A, even in the absence of exogenously 
added E1, both MCF-7DOX2-12 and MCF-7EPI-12 cells secreted elevated levels of E2 in the medium 
relative to MCF-7CC-12 cells. This is consistent with the induction of AKR1c3 and the enzyme’s 
ability to promote the conversion of endogenous E1 to E2. Upon addition of exogenous E1, 
media levels of E2 dramatically increased in all examined cell lines (MCF-7CC-12, MCF-7EPI-
12and MCF-7DOX2-12 cells). Pre-treatment of cells with the aromatase inhibitor 1etrozole (100 
ng/ml) for 1 h prior to the addition of 0.1 μM exogenous E1 reduced E2 secretion into media, but 
this reduction was only significant for MCF-7EPI-12 cells (p≤ 0.001). Pre-treatment of cells with 
the AKR inhibitor β-cholanic acid (200 μM) for 1 h prior to the addition of E1 had little effect on 
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media E2 levels for MCF-7CC-12 cells (1.8±0.2 ng/ml), consistent with the considerably lower 
levels of AKR1C3 expression in MCF-7CC-12 cells compared to MCF-7EPI-12 and MCF-7DOX2-
12cells. In contrast, the latter two cell lines exhibited significant reductions in media E2 levels in 
the presence of β-cholanic acid (p≤ 0.01 and p≤ 0.001, respectively). 
Stable AKR1c3-FLAG-expressing clones (MET-17, MAT-32, and MAT-36) were 
analyzed for E2 levels in the absence or presence of E1 and/or pharmacological inhibitors of 
aromatase or AKR1c3. While all stable transfectants exhibited dramatically enhanced E2 
production in the presence of exogenous E1, there were no differences in E2 production among 
the E1-treated stable transfectants. The addition of letrozole had no effect on E1 to E2 
conversion, while β–cholanic acid treatment consistently reduced E1 to E2 conversion in stably 
transfected cells, but these reductions were not statistically significant using an ANOVA test 
(Figure 5-4 B). Treatment with E1 also induced strong E1 to E2 conversion in transiently 
transfected cells, and even in untransfected and mock-transfected cells (Figure 5-4 C). Similar to 
the stably transfected cells, addition of letrozole had no effect on the conversion of E1 to E2. In 
contrast, β–cholanic acid treatment significantly reduced E1 to E2 conversion in mock (p≤ 0.01) 
and pAKR1C3-FLAG-transfected cells (p≤ 0.05). Untransfected wildtype cells also exhibited a 
reduction in E2 production, but this was not significant using an ANOVA test (Figure 5-4 C). 
As only AKR1C3 is known to convert E1 to E2 conversion, AKR1B10 overexpressing 
constructs were not assessed for their effects on E2 metabolism. 
 
153 
 
 
Figure 5-4 Degree of Production of Estradiol (E2) from Estrone (E1) in various cell lines 
under varying conditions. 
 (A) MCF-7DOX2-12, MCF-7EPI-12, and MCF-7CC-12 cells. (B) Clones of MCF-7CC-12 cells stably 
transfected with pAKR1C3-FLAG. (C) MCF-7CC-12 cells, with or without transient transfection 
with pAKR1C3-FLAG. Some cells were pre-treated with an AKR inhibitor (β-cholanic acid) or 
an aromatase inhibitor (letrozole) for 1 h prior to the addition of 100 nM estrone. Estradiol levels 
were quantified using E2 ELISA kits. Bars represent the mean from 3 independent trials with 
technical duplicates ± S.E.M. Statistical analysis was done using an ANOVA test, followed by a 
Bonferoni correction. * p< 0.05, ** p< 0.01, *** p< 0.001. 
 
 
5.4.5: Changes in ERα Transcript Levels upon Selection for Anthracycline resistance 
The elevated E2 production in anthracycline-resistant cell lines would be expected to 
result in their enhanced proliferation (20, 25, 27) through E2’s ability to bind to and activate ERα 
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(45, 46). This is providing ERα expression and activity is unaltered upon selection for 
anthracycline resistance. We thus examined the level of expression of ERα transcripts throughout 
selection of MCF-7 cells for survival in increasing concentrations (doses) of doxorubicin or 
epirubicin. As shown in Figure 5-5 A, during selection for doxorubicin resistance, dose 7 cells 
exhibited a 2.0 ± 0.2-fold (p≤ 0.05) reduction in ERα transcript (ESR1) levels compared to MCF-
7CC-12 cells. As selection progressed through doses 8 through 12, ESR1 transcript levels further 
decreased by up to 6-fold (p≤ 0.01 for doses 8–12). MCF-7 cells selected for resistance to 
epirubicin (MCF-7EPI-12 cells) also showed a 2.6 ± 0.1-fold (p≤ 0.01) reduction in ESR1 levels 
relative to MCF-7CC-12 cells (Figure 5-5 A). All Q-PCR Ct values were normalized to the 
expression of the S28 reference gene. All fold changes in transcript levels were expressed 
relative to levels in MCF-7CC-12 cells. No significant differences in ERα transcript levels were 
observed upon selection in the absence of doxorubicin or epirubicin (MCF-7CC selection doses 7 
through 12; Figure 5-5 B). 
5.4.6: Estrogen Receptor Expression and Activity Levels in Anthracycline-resistant Cells 
We then conducted immunoblotting experiments to assess changes in ERα protein levels 
upon selection for anthracycline resistance (Figure 5-6 A-C). Consistent with ESR1 transcript 
levels, we did observe reductions in ERα protein expression in both MCF-7EPI-12 and MCF-
7DOX2-12cells relative to MCF-7CC-12 cells, although only the decrease in MCF-7DOX2-12 cells was 
found to be statistically significant using an ANOVA test (p<0.001). Interestingly, as shown 
inSupplemental Figure 5-1, no changes in the expression of estrogen receptor β (ER-β) were 
observed during selection for doxorubicin resistance (selection doses 7 through 12). 
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Figure 5-5 Differences in ESR1 transcript levels in various cell lines, as determined by 
quantitative PCR (Q-PCR). 
 (A) ESR1 transcript levels in MCF-7 cells selected for survival in increasing concentrations 
(doses) of doxorubicin or epirubicin (relative to MCF-7CC-12 cells). Data for doxorubicin 
selection doses 7 through 12 and for epirubicin at selection dose 12 are depicted. (B) A similar 
approach was used to quantify ESR1 transcript levels in MCF-7 cells selected in the absence of 
drug to similar passage numbers as MCF-7DOX2 cells (selected to dose levels 7 through 12. 
All ESR1 expression values were normalized to the expression of transcripts for ribosomal 
protein S28. Values depicted represent the mean ± S.E.M. for three independent trials. The 
significance of differences in ESR1 transcript levels between the designated cell line and MCF-
7CC-12 cells was assessed using an ANOVA test, followed by Bonferoni correction. n = 3, * p< 
0.05, ** p< 0.001 
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Figure 5-6 Differences in the expression of estrogen receptor α (ERα), phosphorylated 
estrogen receptor α at serine 118 (P-Ser118 ER), and γ tubulin in various cell lines, as 
measured in immunoblotting experiments with epitope- or phospho-specific antibodies. 
 (A) Immunoblots were conducted using extracts of cells with or without incubation in the 
presence of 100 nM E2, 100 mg/ml epidermal growth factor (EGF), or a combination of E2 and 
EGF. Primary antibodies purchased from Cell Signaling and used at 1:1,000 dilution in 0.5% 
BSA overnight at 4°C. (B) Fold change in Ser-118 phosphorylated estrogen receptor relative to 
untreated MCF-7CC-12 cells, normalized to γ-tubulin expression (left) and to basal ERα 
expression (right). Data is expressed as the mean fold change observed in 3 independent 
experiments (± S.E.M., with the value of untreated MCF-7CC-12 cells set to 1.0. (C) Fold change 
in ERα levels, in a manner identical to that of P-Ser118 ER. The significance of differences 
between the test sample and that of untreated MCF-7CC-12 cells was assessed using an ANOVA 
test, followed by Bonferoni correction. * = p< 0.05, ** = p< 0.001 
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The observation that E1 to E2 conversion was increased in MCF-7EPI-12 and MCF-7DOX2-
12 cells, prompted an analysis of whether this was associated with increased levels of 
phosphorylated (active) ERα, as determined using an antibody that binds to ERα when 
phosphorylated at Ser118. Cells were serum-starved overnight and then treated in hormone-
depleted media for 30 min with either 100 nM E2, 100 ng/ml EGF, or a combination of the two 
agents. Previously published studies have shown that E2 and EGF are strong activators of ERα 
phosphorylation (29, 31, 44). As shown in Figure 5-6 A, E2 (but not EGF) was able to strongly 
induce ERα phosphorylation in MCF-7CC-12 cells. Interestingly, ERα phosphorylation was 
undetectable and considerably lower in MCF-7DOX2-12 and MCF-7EPI-12 cells, respectively, 
relative to that seen in MCF-7CC-12 cells (Figure 5-6 A). Only levels of phosphorylated ERα in 
MCF-7DOX2-12 cells were found to be significantly reduced relative to MCF-7CC-12 cells in the 
presence of exogenous E2 (p≤ 0.01). This finding held true even when levels of phosphorylated 
estrogen receptor were standardized to total estrogen receptor (Figure 5-6 B). In three 
independent experiments, treatment of MCF-7CC-12 cells with E2, EGF or a combination of the 
two had little to no effect on ERα receptor levels. However, both MCF-7EPI-12 and MCF-7DOX2-
12 cells showed overall reductions in ERα receptor levels. 
In subsequent experiments (Figure 5-7), we examined changes in ERα receptor levels 
during selection for doxorubicin resistance (selection doses 7 to 11). Cells exhibited reductions 
in both phosphorylated ERα and total ERα levels during selection for doxorubicin resistance, 
particularly the former. Reductions in total ERα expression relative to untreated MCF-7CC-10 
were first observed as early as selection dose 7 relative to untreated co-culture control cells. This 
was mirrored by a similar reduction in ERα levels in cells treated with E2. The total ERα levels 
continued to decline at higher selection doses (Figure 5-7). Reductions in P-Ser118-ERα levels 
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across the selection doses mirrored that observed above for ERα levels with significant 
reductions observed at doses 8 and 9 (p≤ 0.001) and dose 10 (p≤ 0.01), when compared to MCF-
7CC-10 cells treated with E2.  
5.4.7: Changes in ERα Transcriptional Activity in Anthracycline Resistance 
The observed reductions in ERα expression and phosphorylation (activation) upon 
selection for doxorubicin resistance would be expected to result in reduced ERα activity, as 
assessed by the receptor’s ability to bind the E2 response element (ERE). For this assessment a 
TransAM
TM
 kit from Active Motif, Inc. (Carlsbad, CA) was used, where the amount of ERα 
binding to the ERE sequence in the presence of E2 was expressed as the corrected absorbance at 
450 nm (after subtraction of background) divided by the corrected absorbance at 655 nm (after 
subtraction of background). As shown inFigure 5-8, MCF-7CC and MCF-7DOX2 cells at selection 
dose 7 had very similar absorbance ratios. However, at selection dose 12 (where significant 
doxorubicin resistance is obtained), the absorbance ratio for MCF-7CC cells increased, while the 
absorbance for MCF-7DOX2-12 cells decreased. This represented roughly a significant 2.6-fold 
reduction in the level of active ERα in the nucleus of MCF-7DOX2-12 cells (p≤ 0.01). 
The reduction in the ability of ERα to bind the ERE sequence in MCF-7DOX2 cells would 
be expected to result in a concomitant reduction in the expression of genes whose expression is 
positively regulated by ERα namely Bcl2 and cyclin D1 (45, 47, 48). We thus examined in 
immunoblotting experiments the expression of BCL-2 and Cyclin D1 in MCF-7CC and MCF-
7DOX2 cells at selection doses 7 and 12 using antibodies that specifically recognize these proteins 
(Figure 5-9 A and C, respectively). Expression of these proteins was quantified by densitometry  
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Figure 5-7 Differences in the expression of estrogen receptor α (ERα), phosphorylated 
estrogen receptor α at serine 118 (P-Ser118 ER), and GAPDH during selection for survival in 
the absence or presence of increasing concentrations (doses) of doxorubicin 
Immunoblots were conducted using extracts of cells without or with a treatment with 100 nM E2. 
Primary antibodies purchased from Cell Signaling and used at 1:1,000 dilution in 0.5% BSA 
overnight at 4°C. (A) Representative western blots for Era and GAPDH. (B) Data for P-Ser118 
ER is expressed relative to untreated (NT) MCF-7CC-12 cells. (C) Data for ERα is expressed 
relative to untreated (NT) MCF-7CC-12 cells. All expression values were first normalized to 
GAPDH expression. Bars represent the mean ± S.E.M. for three independent experiments. The 
significance of differences between the test sample and that of treated or untreated MCF-7CC-
12 cells was assessed using an ANOVA test, followed by Bonferoni correction. * p< 0.05,** p< 
0.01, *** p< 0.001 
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Figure 5-8 Relative levels of active ERα in nuclear extracts. 
Active ERα levels were measured in MCF-7CC cells and MCF-7DOX2 cells at selection doses 7 
and 12, as determined by ERα TRANS-AM kits. Absorbance were corrected for background and 
expressed as a ratio (450 nM to 655 nm). Extracts were performed under basal conditions with 
cells grown in D-MEM to 90% confluence. Values depicted are the mean ± S.E.M. of three 
independent experiments, each made up of a duplicate technical replicate. The significance of 
differences in active ERα levels between samples was assessed using an ANOVA test, followed 
by Bonferoni testing. n = 3, ** p< 0.01 
 
and expressed relative to that of a reference protein (γ tubulin). As shown in Figure 5-9 A and B, 
BCL-2 levels were significantly higher (p≤ 0.001) in MCF-7DOX2 cells at selection dose 7 
compared to MCF-7CC cells at similar passage number (MCF-7CC cells at dose 7). The elevated 
expression of this apoptosis inhibitor may have helped facilitate resistance to doxorubicin at the 
early selection doses. However, BCL-2 levels were dramatically reduced in MCF-7DOX2 cells as 
selection progressed to dose level 12 compared to MCF-7CC-12 cells (p≤ 0.001). This would be 
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consistent with the reduced and dramatically reduced levels of ERα and phosphorylated ERα in 
MCF-7DOX2-12 cells relative to MCF-7CC-12 cells, respectively (Figure 5-6). Cyclin D1 levels 
were slightly reduced upon selection for doxorubicin resistance to dose level 7 (MCF-7DOX2-
7 cells) compared to MCF-7CC-7 cells. At selection dose 12, however, the difference in cyclin D1 
expression between MCF-7DOX2-12 and MCF-7CC-12 cells became significantly different (p≤ 
0.001) and could be due to reduced levels of ERα and phosphorylated ERα in MCF-7DOX2-
12 cells. Interesting, the expression of a number of ER-β-dependent genes (CCNA1, HSD11B2, 
and TMOD1), as measured by quantitative PCR, was not significantly changes during selection 
for doxorubicin resistance (Supplemental Figure 5-1). 
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Figure 5-9 Expression of BCL-2, cyclin D1, and γ tubulin proteins in various cell lines, as 
determined in immunoblotting experiments with epitope-specific antibodies. 
 (A) A representative western blot for BCL-2 expression in MCF-7CC and MCF-7DOX2 cells at 
selection doses 7 and 12. Results shown are representative of 3 independent trials. (B) Fold 
change in BCL-2 levels in MCF-7DOX2 cells (relative to the appropriate co-cultured control cell 
line). Results shown are the average of 3 independent trials. (C) A representative western blot for 
cyclin D1 expression in MCF-7CC and MCF-7DOX2 cells at selection doses 7 and 12. Results 
shown are representative of 3 independent trials. (D) Fold change in cyclin D1 levels in MCF-
7DOX2 cells (relative to the appropriate co-cultured control cell line). Results shown are 
normalized to the expression of γ tubulin and are the average of 3 independent trials. The 
significance of differences in expression levels for BCL-2 and cyclin D1 between samples was 
assessed using an ANOVA test, followed by Bonferoni testing. n = 3, *** p< 0.001 
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5.4.8: Knock-down of ERα Expression with Artemisinin 
In order to assess the relationship between estrogen receptor signaling and the expression 
of estrogen-dependent genes involved in cellular growth and survival, we initially chose to knock 
down ERα expression using an siRNA approach. As shown in SupplementalFigure 5-2, the 
selected siRNAs only reduced ERα transcript expression by approximately half. This level of 
ERα transcript suppression had no significant effect on doxorubicin sensitivity (Supplemental 
Figure 5-2) or the expression of ERα-dependent genes. As an alternate approach, MCF-7CC cells 
were treated for 72 hours with 300 μM artemisinin. Artemisinin is a known potent blocker of 
ERα gene transcription and it would be expected that the expression of ERα-regulated genes 
such as Bcl2 and cyclin D1 would be strong affected by artemisinin (despite the lack of 
doxorubicin resistance in MCF-7CC cells). Since artemisinin has been shown to be toxic to cells, 
we used the maximum concentration of artemisinin that had no effect on cell growth. Figure 
5-10 A shows representative immunoblots for ERα, BCL-2, and Cyclin D1 in the absence or 
presence of artemisinin, with densitometry values for the expression of ERα, BCL-2, and cyclin 
D1 in various cell lines normalized to the expression of γ-tubulin depicted in Figure 5-10 B, C 
and D, respectively. As expected, artemisinin treatment resulted in a clear reduction in the 
expression of ERα and concomitant reductions in the expression of BCL-2 and cyclin D1 
(p<0.001 for all observations). 
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Figure 5-10 Artemisinin-mediated knockdown of ERα expression and its consequent effects 
on BCL-2 and cyclin D1 expression in MCF-7CC-7 and MCF-7CC-12 cells. 
 (A) MCF-7CC-7 and MCF-7CC-12 cells were treated with either DMSO or 300 μM artemisinin. 
Whole cell extracts of these cells were then monitored for BCL-2, cyclin D1, and γ tubulin 
protein expression using immunoblotting approaches with epitope-specific antibodies. γ tubulin 
was used as loading control. Blots are representative of 3 independent trials. (B) Fold changes in 
ERα levels induced by artemisinin in MCF-7CCcells at selection doses 7 and 12. (C) Fold 
changes in BCL-2 levels induced by artemisinin in MCF-7CC cells at selection doses 7 and 12. 
(D) Fold changes in cyclin D1 levels induced by artemisinin in MCF-7CC cells at selection doses 
7 and 12. All values depicted are the mean ± S.E.M. for 3 independent experiments. The 
significance of artemisinin-induced changes in the expression of the above proteins was assessed 
using an ANOVA test, followed by a Bonferoni correction. n = 3, *** p< 0.001 
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The changes in expression of cyclin D1 would be expected to have an influence on the 
proliferation rate of cells. To ascertain if doxorubicin-resistant cells had differing rates of cell 
division compared to wildtype cells, MCF-7CC-12, MCF-7DOX2-12, and MCF-7EPI-12 cells were 
plated in 10 cm plates at low densities (10
6
 cells per plate) and allowed to grow until saturation. 
Cells were counted at daily intervals. It was observed that MCF-7CC2-12 cells had a maximum 
growth rate of 180,000 cells h
-1
, while MCF-7DOX2-12 and MCF-7EPI-12 cells had maximum 
growth rates of 130,000 cells h
-1
 and 104,000 cells h
-1
, respectively (Figure 5-11). Comparisons 
of curves generated by the Gompertz equation showed that the maximum specific growth rates 
differed significantly between all three cell lines (p<0.001). 
 
Figure 5-11 Cell growth curves for MCF-7CC-12, MCF-7DOX2-12, and MCF-7EPI-12 cells. 
Exponentially growing cells were counted using a hemocytometer and introduced into T75 flasks 
at a density of 10
6
 cells per 10 ml of D-MEM medium. Specific growth plots were generated 
using Graphpad Prism 5.0, modelled after the Gompertz growth equation. n = 3 
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5.5: Discussion/Conclusions 
Resistance to cytotoxic chemotherapy drugs can be the result of several factors working 
in collaboration to protect tumor cells from drug-induced death. Previous microarray 
experiments comparing gene expression between the wildtype and the anthracycline-resistant 
MCF-7 cell lines used in this study (MCF-7DOX2 and MCF-7EPI cells), revealed a number of gene 
expression changes associated with the acquisition of anthracycline resistance (13). Many of 
these changes in gene expression were subsequently validated using Q-PCR. Among the more 
prominent genes whose expression was altered upon acquisition of anthracycline resistance were 
members of the ATP-binding cassette (ABC) family of drug transporters as well as drug 
metabolizing proteins such as the AKRs. Coupled with findings from a previously published 
study (12) and a subsequent study (14), it became clear that two of the largest changes in gene 
expression for MCF-7EPI cells were the Abcb1 drug transporter (a known efflux transporter of 
epirubicin) and the aldo-keto reductase AKR1c2 (or genes highly homologous to it). For MCF-
7DOX2 cells, three of the largest changes in gene expression were the Abcc1 drug transporter (a 
known efflux transporter of doxorubicin) and both AKR1c3 and AKR1b10. The above ABC 
drug transporters would be expected to actively excrete anthracyclines from tumor cells, thereby 
reducing their accumulation in tumor cells and their cytotoxicity. Supporting this view, the 
uptake of doxorubicin into MCF-7DOX2-12 and MCF-7EPI-12 was found to be significantly lower 
than that of MCF-7CC-12 cells (12). The ability of the aldo-ketoreductases to hydroxylate and 
inactivate anthracyclines would also be expected to contribute to anthracycline resistance. 
However, AKR1c3 has a clear preference for hydroxylation of idarubicin and daunorubicin over 
doxorubicin (49, 50). Moreover, while AKR1C3 was able to hydroxylate doxorubicin as a 
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purified protein, these studies were unable to demonstrate the ability of AKR1c3 to hydroxylate 
doxorubicin within cells. 
In the current study, we specifically examined the role that the overexpression of AKR 
proteins may play in E2 metabolism in MCF-7DOX2 and MCF-7EPI cells and whether alterations 
in E2 metabolism may also contribute to the anthracycline-resistant phenotype in these cells. 
5.5.1: AKR1c3 Expression and Function in Anthracycline Resistant MCF-7 Cells 
In the present study, we confirmed the overexpression of AKR1c3 protein in MCF-
7DOX2 cells, with MCF-7DOX2-11 cells having the highest expression of AKR1c3 gene and protein 
expression (Figure 5-1 A). This increase in AKR1c3 expression occurred upon acquisition of 
anthracycline resistance and the level of expression of AKR1c3 increased with increasing 
resistance to doxorubicin (Figure 5-1 A). Due to the relationship between increased AKR1c3 
expression and elevated E2 synthesis from E1 (20, 51), we theorized that the higher cellular 
expression of AKR1c3 could potentially have broad impacts on E2-dependent signaling 
pathways that may also contribute to anthracycline resistance. Specifically, it was expected that 
the increased AKR1C3 expression would promote E2 synthesis from E1, which in turn would 
activate ERα-dependent survival pathways through either the non-genomic pathway via AKT or 
through the genomic pathway by increasing expression of BCL-2 (30, 52, 53). Such events 
would perhaps lead to enhanced survival and growth in the presence of anthracyclines (see 
further discussion below). While we observed that AKR1B10 levels in MCF-7 cells were 
dramatically increased upon selection for doxorubicin resistance (Figure 5-1 A), it is important 
to note that there is no published evidence that AKR1B10’s promotes estrogen biosynthesis from 
estrone. 
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We subsequently demonstrated in this study that the increased expression of AKR1C3 in 
doxorubicin-selected cells (to dose level 12) did have a dramatic effect on the cells’ ability to 
synthesize and secrete E2. As expected, cells that had higher levels of AKR1C3 expression also 
exhibited higher levels of basal and E1-induced E2 synthesis and excretion (Figure 5-4 A). This 
supports the idea that increased levels of AKR1C3 expression could be related to cell survival in 
chemotherapy resistant cell lines by promoting elevated production of E2 and subsequent 
activation of ERα-dependent growth and survival pathways, including the activation of AKT and 
the inhibition of apoptosis (30, 48, 54). 
5.5.2: Overexpression of AKR1c3, by Itself, Does not Confer Anthracycline Resistance 
To assess whether elevated expression of AKR1c3, by itself, could induce resistance to 
doxorubicin, we stably or transiently transfected MCF-7 cells with a vector for the constitutive 
expression of AKR1c3. Elevated levels of AKR1c3 expression relative to mock-transfected cells 
were observed in these transformants (Figure 5-2). Specifically, it was observed that transient 
transfection resulted in a greater induction of AKR1c3 protein expression (relative to mock 
transfected cells) than stably transfected cells (Figure 5-2 C and D). Clonogenic assays 
performed on stably selected clones showed on average of a 2.4 fold increase in resistance to 
doxorubicin relative to empty vector controls (Figure 5-2 A), but this difference was not found 
to be statistically significant in an ANOVA test. This increase in drug resistance was unlikely to 
be biologically relevant, since even a higher level of AKR1c3 induction in transiently transfected 
cells resulted in no change in doxorubicin sensitivity (Figure 5-2 B). 
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5.5.3: AKR1C3 Knockdown in Doxorubicin-resistant Cells did not Restore Doxorubicin 
Sensitivity 
Since overexpression of AKR1c3 transcripts and protein in MCF-7CC-12 cells showed 
little ability to induce doxorubicin resistance, we attempted to determine if elevated levels 
of AKR1C3 and/or AKR1B10 transcripts were required to maintain resistance in MCF-7DOX2-
12 cells. Knockdown experiments were conducted using two different siRNAs targeting different 
regions of the AKR1C3 or AKR1B10 mRNAs. In addition, a scrambled control siRNA was used, 
to determine if any off-target effects and/or the process of transfection affected cellular 
sensitivity to doxorubicin. While individual transfections with the siRNAs resulted in as much as 
an 80% knockdown of AKR1c3 protein expression in the cells (Figure 5-2), no significant 
change in doxorubicin sensitivity was observed in the presence of either siRNA (Figure 5-3 C 
and D). To rule out compensatory effects with the individual knockdowns, we proceeded to 
knock down both AKR1c3 and AKR1B10 expression simultaneously by co-transfecting MCF-
7DOX2-12 cells with both siRNAs. Knockdown with both siRNAs achieved the same level of 
knockdown of their respective RNAs as the individual transfections (up to 80%). However, no 
significant change in doxorubicin sensitivity was observed (Figure 5-3 E). To assess whether the 
effects of the AKR1C3 and AKR1B10 siRNAs are specific for their respective transcripts (with 
no effect on other AKR transcripts), we examined siRNA-transfected cells for expression of 
AKR1c3 and AKR1b10 proteins. We observed only minor changes in AKR1c3 levels in cells 
transfected with the AKR1B10 siRNA (despite dramatically reduced AKR1b10 levels). Reduced 
expression of the target transcripts was verified in all siRNA experiments using western blotting 
experiments with AKR1c3 and AKR1b10 antibodies. Images in Figure 5-2 are representative of 
these controls. The observation of a lack of effect of AKR1c3 knockdown on doxorubicin 
resistance suggests that the AKRs, while upregulated in doxorubicin resistance, did not actually 
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contribute to the drug resistant phenotype. Supporting this view, Hoffman et al. (49) observed 
that while AKR1c3 can convert doxorubicin to the less toxic doxorubicinol in a cell-free system, 
it has a relatively low affinity for doxorubicin and could not hydroxylate doxorubicin 
in AKR1C3-transfected cells. It should be noted that this is in contrast to studies involving the 
overexpression of an AKR1C3 cDNA into cancer cells. A recent study by Zhong et al showed 
that overexpression of recombinant AKR1c3 in MCF-7 cells increased their resistance to 
doxorubicin (55). While our observations differ from these findings, we suggest that the 
differences observed are due to the level of overexpression. We were only able to increase the 
AKR1C3 level in MCF-7 cells by a maximum of 7-fold using Lipofectamine 2000. In contrast, 
Zhong et al. were able to overexpress AKR1C3 by nearly 200 fold over non-transfected cells 
using a viral expression vector (55). It is possible that there is a minimum threshold of over-
expression required in order for AKR1C3 to promote estrogen production and/or have a 
significant impact on cell survival in the presence of doxorubicin. Moreover, this very high level 
of AKR1c3 overexpression may permit doxorubicin hydroxylation in cells, despite its poor 
affinity for doxorubicin as a substrate in cells (49, 50). The higher level of AKR1c3 expression 
in MCF-7DOX2 cells appears to be clearly sufficient to promote E2 biosynthesis and the activation 
of ER-dependent survival pathways. This may be particularly relevant at lower selection doses, 
where induction of the ABC transport proteins is minimal or much lower (12). We therefore 
postulate that in the MCF-7DOX2 cell model we present here, the AKRs contribute to the 
resistance phenotype. However, selection for survival in the presence of doxorubicin typically 
involves selection for multiple resistance mechanisms. Our previous studies have shown that 
MCF-7DOX2-12 cells strongly overexpress the Abcc1 drug transporter (12). Moreover, we have 
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recently observed that the Abcc1 inhibitor MK-571 can partially restore the sensitivity of MCF-
7DOX2-12 cells to doxorubicin (Chewchuk et al., manuscript in preparation, Chapter 7). 
5.5.4: E2 Biosynthesis and Cellular Growth Rates in Anthracycline-resistant Cells 
We next determined whether the overexpression of AKR1c3 in anthracycline-resistant 
cells was associated with alterations in E2 biosynthesis and cellular growth rate. Stably 
transfected clones showed no significant difference in E1 to E2 conversion between cells 
transfected with an “empty vector” and AKR1C3-transfected cells (Figure 5-4 B). This 
suggested that the level of increase in AKR1C3 expression in the stable transformants was 
insufficient to impact on E2 biosynthesis. Only a slight reduction in E1 to E2 conversion was 
observed when cells stably transfected with the AKR1C3 expression vector were treated with β-
cholanic acid, but not in the empty vector controls (Figure 5-4 B). This difference was 
statistically significant for clone MAT-32 using a Student t-test, but not by the more stringent 
ANOVA. However, β-cholanic acid was without effect when added to cells of the MAT-36 
stable cone, which exhibited the highest expression level of AKR1c3 (Figure 5-2 B and Figure 
5-4 B). Taken together our observations suggest that AKR1c3 overexpression is typically 
insufficient in the stable clones to promote additional E2 biosynthesis, which could be inhibited 
by β-cholanic acid. 
When cells transiently transfected with the AKR1C3 vector were assessed, no statistically 
significant increase in E2 biosynthesis was observed using an ANOVA or Student t-test (Figure 
5-4 C), including cells transfected with an empty vector (mock-transfected cells). This was 
despite the increased expression of endogenous and FLAG-tagged recombinant AKR1c3 
observed in these cells (Figure 5-2 A). However, a strong, highly significant reduction in E2 
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synthesis was observed upon treatment of empty vector- or AKR1C3-transfected cells with β-
cholanic acid (Figure 5-4 C). This was likely due to the effects of β-cholanic acid on both 
endogenous and/or recombinant AKR1c3 expression observed during transfection of MCF-7 
cells with the empty vector or AKR1C3 expression plasmid (Figure 5-2 A and C). 
In contrast to the above findings, E2 biosynthesis was considerably higher in drug-
resistant MCF-7DOX2-12 and MCF-7EPI-12 cells than drug-sensitive MCF-7CC-12 cells. (Figure 5-4 
A) This biosynthesis in the anthracycline-resistant cell lines was strongly inhibited by both the 
aromatase inhibitor letrazole and the aldo-keto reductase inhibitor β-cholanic acid. The 
considerably higher levels of E2 production in the resistant cell lines are likely due to their 
higher level of overexpression of AKR1c3 compared to MCF-7CC-12 cells and MCF-7CC-12 cells 
stably or transiently transfected with the AKR1C3 expression vector. These findings are 
consistent with those recently published by Byrns et al. (56). It may be possible to further 
increase the overexpression of AKR1c3 to more closely match the levels observed in the MCF-
7DOX2 and MCF-7EPI cells lines (possibly by other transfection methods such as electroporation 
or a retroviral vector. By increasing the overexpression of AKR1c3 to match more closely those 
of the chemotherapy drug resistant cell lines it may still be possible to induce doxorubicin 
resistance. However, more likely, the increase in AKR1c3 expression in transient or stable 
transfectants was insufficient to induce doxorubicin resistance. 
5.5.5: Effects of Selection for Anthracycline Resistance on Cellular ERα Expression 
E2 is a known promoter of growth in breast tumor cells (20, 25, 27). Thus, it would be 
expected that the elevated production of E2 in MCF-7DOX2-12 and MCF-7EPI-12 cells would result 
in higher growth rates for these cells relative to the co-cultured control cell lines. However, we 
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observed in this study a reduction in growth rates for MCF-7DOX2 and MCF-7EPI cells compared 
to MCF-7CC cells (Figure 5-11). It is therefore likely that some defect in the E2 signaling 
pathway exists in the anthracycline-resistant cells that prevents the elevated E2 levels from 
promoting growth. We thus looked at the levels of ERα and phosphorylated ERα (at Ser118) in 
the above cell lines in the absence or presence of estrogen and/or EGF. It has been reported that 
the phosphorylation of ERα on Ser118 is critical for the function of the non-genomic E2 
signaling pathway, which regulates cell proliferation through effects on ERK and/or BCL-2 
survival pathways (34, 43, 54). We observed that while EGF had no effect on ERα 
phosphorylation, MCF-7CC-12 cells treated with 100 nM E2 exhibited dramatic increases in ERα 
phosphorylation on Ser118 residues. Phosphorylation was substantially lower in MCF-7EPI-12 
cells and undetectable in the MCF-7DOX2-12 cells (Figure 5-6 A and B). This was not expected 
since MCF-7 cells are normally ER positive and have been shown to require E2 signaling for 
normal growth (43). Subsequent immunoblotting experiments using an antibody to ERα revealed 
that the reduced phosphorylation was due to, at least in part, a downregulation of ERα expression 
in the anthracycline-resistant cell lines, in particular for MCF-7DOX2-12 cells (Figure 5-6 A and 
C). The reduced ERα expression appeared to be due to reduced levels of ESR1 transcripts 
(Figure 5-5). The complete lack of detection of ERα phosphorylation for MCF-7DOX2-12 cells, 
suggests a complete downregulation of E2’s ability to phosphorylate any available ERα as some 
ERα expression is still evident in these cells; seeFigure 5-6. 
We then hypothesized that upon selection for anthracycline resistance, the increased 
production of E2 via AKR1C3 overexpression activated a compensatory negative feedback loop 
to reduce ERα synthesis. However, subsequent experiments revealed that the reduction in ERα 
transcript levels occurred prior to AKR1C3 upregulation (compare Figure 5-1 A and Figure 5-5 
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A). This would argue against a negative feedback mechanism as the increase in E2 concentration 
would not have occurred to induce the progressive loss of ERα. The mechanisms for the reduced 
expression of ERα in MCF-7DOX2 and MCF-7EPI cells relative to MCF-7CC cells have yet to be 
elucidated, but may include: increased methylation of CpG islands or decreased histone 
acetylation within the ESR1 promoter, resulting in reduced gene transcription (epigenetic 
changes), reduction in the activities of transcription factors associated with ERα expression such 
as the AP-1 transcription factors Fos and Jun (28), or reductions in ERα transcript stability. 
It is interesting to note that changes in tumor ERα expression have been observed after 
neoadjuvant chemotherapy for patients with breast cancer, although the percentage of patients 
exhibiting a loss of tumor ERα expression post-chemotherapy was found to be only 6% (57). 
This is in contrast to 19% of patients losing tumor progesterone receptor (PR) expression after 
chemotherapy (57). While there are some clear limitations associated with this study of 368 non-
randomized patients, it is possible that such losses in tumor ERα expression may be associated 
with resistance to anthracycline-based chemotherapy. The loss of tumor ERα expression status 
after neoadjuvant chemotherapy (if validated in future studies) would have very strong 
implications in terms of patient care. Patients with tumors lacking ERα expression post-
chemotherapy would likely be unresponsive to endocrine therapies targeting estrogen signaling 
pathways, such as tamoxifen and exemestane (58, 59). 
5.5.6: Effects of ERα Downregulation on the Growth of Anthracycline-resistant Cells 
The growth rate of the anthracycline-resistant cells at selection dose 12 was assessed, 
since ERα has been documented to regulate cell growth in breast tumor cells (34). It was 
observed that both MCF-7DOX2-12 and MCF-7EPI-12 cells exhibited significantly reduced growth 
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rates in comparison to MCF-7CC cells (Fig 11). This could be due to downregulation of ERα 
activity in these cells, although other pathways may also have been impacted on cellular growth 
rate. Despite this discrepancy, both cell lines exhibited lower growth rates which correlated with 
the loss of ERα expression and function. This observation led to the hypothesis that in acquiring 
resistance to chemotherapy, MCF-7 cells were selected for variants in the population with a 
slower growth rate. This could impart a survival advantage by allowing the cells more time to 
repair any cellular damage, before activation of cell death pathways. In addition, many 
chemotherapy agents such as doxorubicin selectively target rapidly dividing cells. In this light, it 
is reasonable to expect a growth promoting signaling protein, such as ERα, to be downregulated 
upon selection of breast tumour cells for anthracycline resistance. 
5.5.7: Changes in the Expression of ERα-specific Genes upon Acquisition of Anthracycline 
Resistance 
The reduction in ERα expression would be expected to strongly impact the expression of 
estrogen-dependent genes, in particular if this resulted in a change in the ability of the receptor to 
bind to the estrogen response element (ERE) regulating gene expression. To assess this, we first 
examined whether nuclear extracts from MCF-7DOX cells exhibited a lower ability to bind the 
ERE than nuclear extracts from MCF-7CC cells using the ERα TRANS Am kit. Nuclear extracts 
taken from MCF-7CC-7 and MCF-7DOX2-7 cells showed no statistically significant differences in 
the amount of active nuclear ERα (ERE binding) between the two cell lines. This was despite the 
reduced total levels of ERα in MCF-7DOX2-7 cells at this selection dose observed in western 
blotting experiments. This could indicate that while the total amount of ERα in the cells is 
reduced, the proportion of ERα that is active changes to maintain the basal requirements of the 
cells. However, MCF-7DOX2-12 cells showed a significant reduction in active ERα in nuclear 
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extracts relative to MCF-7CC-12 cells. This suggests that ER activity is also suppressed at high 
selection doses (consistent with the reduced phosphorylation of ERα), which involves more than 
the downregulation of ERα protein expression. Consistent with the abolished activity of ERα in 
MCF-7 cells, we observed reduced expression of two genes, whose expression is strong 
upregulated by ERα, namely BCL-2 and cyclin D1 (30, 60) (Figure 5-10). Both genes possess 
EREs in their promoter regions (36), and have been shown to be highly responsive to E2 
treatments (45, 48, 60). BCL-2 levels were significantly elevated in MCF-7DOX2-7 cells relative to 
co-cultured controls cell lines As BCL-2 is an anti-apoptotic/pro-survival protein, it stands to 
reason that the elevated levels of BCL-2 would be observed early in the selection for doxorubicin 
resistance. However, it should be noted that in previous studies conducted in our laboratory (13), 
doxorubicin resistance was only achieved when the doxorubicin selection dose reached 29.1 nM 
(dose 9; MCF-7DOX2-9 cells). At selection dose 7 (6.5 nM doxorubicin), MCF-7DOX2-7 cells did 
not exhibit statistically significant resistance to doxorubicin, despite the elevated expression of 
BCL-2. It is possible that a low level of doxorubicin resistance (mediated by BCL-2) was 
acquired at selection dose 7, but this could not be detected due to the limitations in the sensitivity 
of the clonogenic assay. However, BCL-2 expression dramatically decreased during selection for 
resistance to higher doses of doxorubicin, co-incident with loss of ERα phosphorylation. While 
one would expect levels of an anti-apoptotic protein such as BCL-2 to remain high or increase 
further at higher selection doses, the levels of this protein actually decreased. There was simply 
insufficient active ERα to drive its expression. The downregulation of BCL-2 at higher selection 
doses would nevertheless activate another survival pathway (autophagy), which promotes the 
degradation of damaged organelles and greater survival from the generation of reactive oxygen 
species generated by doxorubicin (48). BCL-2 is a known inhibitor of autophagy through its 
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ability to bind Beclin 1 (reviewed in (61)). Since BCL-2 has been shown to be regulated by ERα 
(48), it stands to reason that ERα can act as an indirect regulator of the autophagic pathway. The 
downregulation of ERα activity would result in reduced BCL-2 expression, resulting in 
disinhibition (activation) of the autophagic pathway. In addition to changes in BCL-2 expression, 
cyclin D1 levels were observed to be reduced as active ERα levels fell. Since cyclin D1 promotes 
progression through the cell cycle, low cyclin D1 would be expected to slow cell cycle 
progression, permitting greater time for repair of doxorubicin-induced cellular damage. 
The results from immunoblotting experiments suggest a clear correlation between the 
downregulation of ERα activity upon acquisition of doxorubicin resistance and changes in the 
expression of BCL-2 and cyclin D1. However, this correlation need not necessarily mean the 
relationship is causative. We thus examined the effects of Artemisinin on BCL-2 and cyclin D 
expression, since the drug is known to downregulate ERα expression, without inducing 
doxorubicin resistance (62). As expected when ERα levels were reduced due to treatment with 
Artemisinin, BCL-2 and cyclin D1 levels were also reduced as shown in previous studies. This 
suggests that the observed reduction in both cellular growth rate and saturation density as cells 
acquire anthracycline resistance may, in fact, be due to the loss of ERα protein levels and 
function, which in turn would reduce cell cycle progression and promote autophagic survival 
through negative effects on Cyclin D1 and BCL-2 expression, respectively. 
We further show in this study that while AKR1c3 and AKR1b10 might be expected to 
contribute to doxorubicin resistance through the hydroxylation/inactivation of the drug or 
through its ability to combat reactive oxygen species generated by doxorubicin, downregulation 
of AKR1c3 and/or AKR1b10 does not result in the restoration of doxorubicin sensitivity in 
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MCF-7DOX2-12 cells. In addition, others have shown that doxorubicin does not appear to be a 
good substrate for the above aldo-ketoreductases in cells (49, 50). However, we have also shown 
previously published studies that the aldo-keto reductase inhibitor β-cholanic acid can almost 
completely restore doxorubicin sensitivity to MCF-7DOX2-12 cells (13, 14). This would suggest 
that β-cholanic acid may have a wider effect on doxorubicin cytotoxicity than simply inhibiting 
the aldo-keto reductases, a hypothesis now supported by observations that β-cholanic acid also 
promotes selective accumulation of doxorubicin into MCF-7DOX2-12 cells, but not MCF-
7CC12 cells (Chewchuk et al., manuscript in preparation, Chapter 7). 
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5.6: Supporting information 
 
Supplemental Figure 5-1 Analysis of ER-β activity in doxorubicin-resistant cells. 
 (A) Representative western blot of ER- β expression levels in dose selection 7–12 resistant and 
co-culture control MCF-7 cells. Primary antibody for ER-β was purchased from Santa Cruz 
Biotechnology (sc-8974). Blot is representative of 3 trials. (B-D) Q-PCR results for selected ER-
β responsive genes in dose selections 7 and 12 with corresponding co-culture controls (n = 3), 
graphs represent fold expression relative to ribosomal protein S28 (RPS28) expression. Primers 
were purchased from Integrated DNA Technologies. (B) Relative expression of cyclin A1. 
Primer sequences for Cyclin A1were F: 5’- GCA CCC TGC TCG TCA CTT G -3’ R: 5’- CAG 
CCC CCA ATA AAA GAT CCA -3’, (C) Relative expression of HSD11B2. Primer sequences 
for HSD11B2 were F: 5’- CTG GCT GCT TCA AGA CAG AGT -3’ R: 5’- AGG CAG GTA 
GTA GTG GAT GAA -3’ and (D) Relative expression of TMOD1. Primer sequences for 
TMOD1 were F: 5’- CCG GTT CCA GCG TCA CA -3’ R: 5’- AGG AAA GGT CTG GGT 
TCC TAA GC -3’. No statistically significant changes were observed in overall protein levels of 
ER-β or in the expression of any of the tested ER-β responsive genes as a result of selection for 
resistance to Doxorubicin. 
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Supplemental Figure 5-2 Analysis of ER-α knock-down in MCF-7 wild type cells by siRNA. 
siRNA was purchased from Life Technologies. Sequences correspond to catalogue numbers 
4823 (ER-KD-3) and 4825 (ER-KD-5) (A) Q-PCR data for fold knock down of ER-α relative to 
scrambled control and was assayed in parallel with survival 24h post transfection. Graph is mean 
± SEM of 5 trials. (B) Representative clonogenic survival curve for MCF-7 cells with ER-α 
knockdown or scrambled control showing no significant shift in IC50 associated with 
knockdown of ER-α relative to control. (C) Average IC50 values of MCF-7 cells with siRNA 
knockdown of ER-α as derived from replicate survival curves. Graph represents the mean ± SEM 
of 5 trials. No significant difference in IC50 values was observed for either ER-α knockdown 
condition relative to scrambled control. 
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Chapter 6  
Additional Background/Rational for Investigation of Effects of β-Cholanic Acid on 
Chemotherapy Resistance 
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6.1: Introduction 
 In Chapter 5, we determined that while AKR’s do function to increase the level of 
estrogen production in doxorubicin resistant cells  (1), and they can contribute to metabolism of 
the drug  (2), they do not directly contribute to the resistance phenotype in a statistically 
significant manner  (1). It should be noted that this does not discount the role that drug 
metabolism can have on chemotherapy resistance. It is likely that in the model that was 
generated, other resistance mechanisms have a larger role in the resistance phenotype and thus 
overshadow the effects of metabolism. Regardless, an interesting observation was noted, 
resistance could be reversed by treating cells with β-cholanic acid  (1–3). This observation was 
originally attributed to the known effects of β-cholanic acid as an AKR inhibitor. However since 
AKR knockdown and overexpression experiments failed to demonstrate changes in doxorubicin 
sensitivity, β-cholanic acid must also therefore have an alternate effect that would account for its 
ability to reverse resistance. 
6.2: Bile Acids 
 β-cholanic acid, or ursodeoxycholic acid, belongs to a family of compounds known as 
bile acids. These compounds typically function to aid in digestion by emulsifying dietary fats to 
allow absorption through the small intestine  (4, 5). In the body, bile acids are produced in the 
liver through metabolism of cholesterol  (6). This process is carefully regulated through the 
action of various enzymes, including members of the AKR family  (6). The overall process of 
bile acid synthesis will follow one of 2 routes known as the neutral and alternative pathways  (7). 
The neutral pathway is centered around the metabolic action of the CYP7A1 protein which will 
begin with the hydroxylation of cholesterol  (7). CYP7A1 is an enzyme with a very short half-
life in hepatic cells and the expression of CYP7A1 is typically downregulated by most bile acids 
194 
 
allowing for very tight control of bile acid production through negative feedback  (7). Once 
modified by CYP7A1, the modified cholesterol molecule proceeds through a series of 16 
enzymatic reactions to form one of the two major bile acids found in humans: cholic acid and 
chenodeoxycholic acid. While the neutral pathway of bile acid synthesis is dominant in human 
hepatocytes, certain disease conditions lend themselves to activation of an alternative synthesis 
pathway  (7). 
 Unlike the neutral pathway, which originates in the smooth endoplasmic reticulum, the 
alternative pathway begins in the mitochondria with the enzyme CYP27A1. Another key 
difference between the two pathways is the rate limiting step: while the neutral pathways is 
limited by hydroxylation of cholesterol, the alternative pathway is limited only by the availability 
of cholesterol transported to the mitochondrial membrane  (7). This availability of cholesterol 
seems to be highly dependent on the expression of the cholesterol carrier StarD1  (7). Another 
major difference between these synthesis pathways is that unlike CYP7A1, which is only 
expressed in hepatocytes, CY27A1 is expressed in wide range of cell types throughout the body. 
With the broad range of cells that can make use of the alternative pathway, it is generally 
believed that the alternative pathway functions to regulate cholesterol levels in cells other than 
hepatocytes. In addition to synthesizing cholanic acid and chenodeoxycholic acids, the 
alternative pathway can also synthesize 25- or 27-hydroxycholesterol which can both function as 
regulatory oxysterols to control the expression of CYP7A1 by interacting with the Farnasoid X 
receptor in hepatocytes  (7). 
 Once synthesized in hepatocytes, bile acids become further modified where they become 
conjugated with either a taurine or glycine molecule  (8). They are then transported actively via a 
variety of different mechanisms to the gall bladder for storage where they are combined with 
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cholesterol and other phospholipids until they are needed to aid in digestion  (4, 7, 9). Upon 
sensing digestible material entering the small intestine through the release of alimentary 
hormones, bile acids are secreted from the gall bladder into the lumen of the intestine at the 
duodenum where they combine with the digesting food. They will then activate various lipases in 
the digestive tract and solubilize lipids into micelles. These micelles, containing various fat 
soluble nutrients, are then taken up by enterocytes in the intestines. The bile acids themselves 
can then be reabsorbed by sodium-dependent transport proteins and transported back to the liver 
for recycling  (7). Alternatively, the conjugated bile acids are digested by microbiota to remove 
the amino acid residues  (8). During these processes most of the bile acids are transported back to 
the liver to undergo conjugation again completing the enterohepatic cycle  (8). Very little of the 
bile acids will be found in circulating body fluids, and it is thought that what amounts are found 
there function primarily to regulate dissolved cholesterol levels throughout the body  (10). 
 While the canonical role of bile acids as emulsifying detergents is well known and 
characterized, a growing body of literature has implicated bile acids as signalling molecules 
capable of binding the farnasoid x receptor  (4). For instance, bile acids have been shown to play 
major roles in hepatocytes by increasing cell proliferation (of particular interest in cancer 
research), playing a role in liver regeneration, and liver fibrosis  (7, 8). Many of these features 
seem to be related to the ability of bile acids to activate cell proliferative pathways. In the case of 
fibrosis, this can be both detrimental and beneficial, as lower bile acid concentrations can 
increase cellular regeneration of the liver, while very high levels of bile acids can be very 
detrimental and activate apoptotic pathways  (4). In most cases, these high levels of bile acids 
only occur in disease states (liver disease, hepatitis infection, cirrhosis), and it should be noted 
that the best course of treatment for a build-up of secondary bile acids in the liver is ingestion of 
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ursodeoxycholic acid  (5, 7, 8). Rather than the typical cholic and chenodeoxycholic acids found 
in normal human hepatocytes, ursodeoxycholic acid is produced in bears. When ingested by 
humans, ursodeoxycholic acid is known to promote secretion of bile acids from the liver, as well 
as counteracting the toxicities of secondary bile acids  (7). Additionally ursodeoxycholic acid is 
known to activate alternative signalling pathways to cholic and chenodeoxycholic acids and 
prevent necrosis and apoptosis while also activating pro-survival pathways in human hepatocytes  
(4). 
 Given the broad range of effects of bile acids and the previous findings, as outlined in 
Chapter 5, we sought to determine how 5β-cholanic (ursodeoxycholanic) acid could function to 
sensitize the MCF-7DOX2-12 cell line to doxorubicin. As was previously described, we established 
that 5β-cholanic could restore sensitivity in MCF-7DOX2-12 breast cancer cells, and that it did 
inhibit AKR1C3 function as predicted by previous publications. However upon closer 
examination of the AKR1C3 resistance mechanism, we determined that AKR1C3 was not 
playing a primary role in chemotherapy resistance, although it may contribute to resistance. The 
question remained as to how 5β-cholanic acid was reverting chemotherapy resistance. Previous 
assessments of the MCF-7DOX2-12 cells indicated that other resistance mechanisms could be 
playing a role. Among the most likely candidates is the ABCC1 drug transporter. 
 
6.3: ABC Transporters 
 ABC proteins are a superfamily of proteins which are characterized by the presence of an 
ATP Binding Cassette domain. The members of the ABC family of proteins are transmembrane 
proteins which typically function to actively transport molecules across the cell membrane. 
These transport proteins are generally essential for moving molecules which do not easily 
197 
 
traverse the plasma membrane. This can include charged ions and other small molecules. The 
direction of transport (into or out of the cell) and the nature of the substrate transported are 
completely dependent on specific amino acid sequences known as substrate binding sites  (11). 
While each member of the ABC protein family has very specific substrates to transport, they 
each do so in an energy dependent manner  (12). The process by which ABC transporters 
perform their task is by active transport requiring ATP as an energy source. In addition to 
possessing an ATP binding cassette domain, all ABC transporter proteins are transmembrane 
proteins composed of a minimum of 1 transmembrane domain made up of a 6 pass 
transmembrane domain  (11, 12). While most ABC transporters contain 2 such domains for 
proper function, members such as ABCC1 contain 3 transmembrane domains and ABCG2 
contains only a single transmembrane domain. For the ABC transporters like ABCG2, which 
contain a single transmembrane domain, the proteins must form a dimer structure within the 
membrane to bring 2 domains into proximity with each other to function as an active transporter  
(11, 12). 
As a brief overview of transporter function I will outline the general process by which a 
transporter can “pump” a substance out from the cell to the extracellular space. The process 
begins with the transporter in the “open” position in that the substrate binding site and the ATP 
binding cassette are exposed to the intracellular space  (11). Once the appropriate substrate is 
bound to its domain, a conformational change occurs in the nucleotide (ATP) binding domain, 
increasing the affinity for ATP binding  (11). The addition of ATP induces a further 
conformational change “closing” the intracellular domain and “opening” the core of the protein 
to the extracellular space. This conformational change then alters the affinity of the transporter to 
its substrate, releasing the substrate to the extracellular space  (11). Once released, the ATP 
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molecules are hydrolysed to ADP which is then released and the transporter is restored to its 
original conformation  (11). It should be noted that while this is a generalized mechanism for 
ABC transport, differences may exist and are debated depending on the specific ABC transporter 
in question  (11). 
 
Figure 6-1 Structure of ABC transporters commonly associated with Chemotherapy 
resistance. Figure taken from Gillet et al. (13)  
A. schematic structure of ABCB type transporters. B. Schematic structure of ABCC type 
transporters. C. Schematic structure of ABC half transporters. D. Schematic structure of ABCG 
type transporters. 
 
199 
 
 
Figure 6-2 Schematic of common substrates and co-transported molecules of ABCC1 drug 
transporter. Taken from Col et al (14). 
 
As has been stated, ABC transporters have a broad range of substrates that they can 
transport substrates in and out of the cell. Certain members of the ABC transporter family are of 
particular interest in the study of chemotherapy resistance. The ABC transporters most 
commonly associated with chemotherapy resistance are ABCB1, ABCC1, ABCC2 and ABCG2  
(11, 15–18). Each of these ABC transporters has been shown to transport a variety of 
chemotherapy agents from the cell, removing the toxic agents before cellular damage can occur. 
Arguably one of the best understood transporters is ABCB1, also known as P-glycoprotein. This 
200 
 
transporter is normally expressed in a wide range of cells throughout the body, and has a very 
broad range of substrates that it can transport  (19). In particular ABCB1 is found at high levels 
in hepatic cells, intestine, kidneys, and cells of the blood brain barrier where it serves to remove 
toxic substances and protect sensitive tissues  (19). ABCG2 has a similar role in protecting cells 
from toxic compounds however its normal function is to remove toxic metabolites from dietary 
sources, specifically some of the breakdown products of chlorophyll  (19). ABCC1 has a 
significant role in chemotherapy resistance, specifically with regard to the anthracycline class of 
chemotherapy agents. In general, ABCC1 functions as a defence mechanism for cells against 
xenobiotic agents which would normally be toxic to the cells. ABCC1 has a secondary role in 
normal cell physiology by regulating the levels of intracellular glutathione which is critical in 
mediating the cellular response to oxidative stress as well as the cycling of cysteine residues (14, 
19). ABCC1 also plays an important role in regulating the inflammatory immune response in 
bone marrow-derived mast cells by secreting cysteinyl leukotriene  (19). ABCC2 functions 
primarily to transport organic anions and secrete them into bile or urine for excretion from the 
body. ABCC2 can also transport various drug metabolites and conjugates to detoxify the body. 
ABCC2 is primarily expressed in liver and kidney cells where it can most easily facilitate the 
removal of these harmful substances. In addition to their normal functions, each of these ABC 
transporters has been seen to actively remove a variety of chemotherapy agents from cells. 
ABCB1 has the widest range of substrate specificity for chemotherapy agents among the drug 
transporters  (20, 21). ABCC1 has a much narrower range of substrate specificity in relation to 
chemotherapy agents. 
ABCC1 is unique as a chemotherapy transport protein in that in addition to ATP it also 
requires the presence of glutathione as either a co-transported molecule or a drug conjugate. It is 
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also of particular interest in the current study as it is the primary ABC transporter showing 
elevated expression in the MCF-7DOX2-12 cell line. ABCC1 is a potent transporter of doxorubicin 
and is therefore a likely candidate to be a primary mechanism of chemotherapy resistance in this 
cell line. We have also previously observed that treatment with bile acids is capable of reverting 
resistance in the MCF-7DOX2-12 cells.  
6.4: Hypothesis and Specific Aims for Second Experimental Study 
We hypothesize that in addition to their role in modulating AKR1C3 function, bile 
acids also have a regulatory role in ABCC1-mediated drug transport. To test this 
hypothesis, we propose to examine the following aims: 
1. Monitor chemotherapy resistance in a variety of ABCC1 expressing cell lines 
including the MCF-7DOX2-12 cells, H69AR (doxorubicin resistance small cell lung 
carcinoma) cells, and HEK293MRP1 transfected with ABCC1. 
2. Monitor intracellular accumulation of doxorubicin in the aforementioned cells by 
flow cytometry. 
3. Verify that ABCC1 is being inhibited by monitoring glutathione levels intracellularly. 
4. Determine if the inhibition of chemotherapy transport is specific to ABCC1 or if 
ABCB1 can also be affected by bile acid treatment. 
5. Determine the nature of β-cholanic acid-mediated ABCC1 inhibition. 
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7.2: Abstract 
 Chemotherapy resistance is a complex phenomenon in cancer treatment, involving a 
broad spectrum of mechanisms to protect tumour cells from the cytotoxic effects of 
chemotherapy. Among the most studied mechanisms of drug resistance involve the 
overexpression of ABC transporters. These transporters facilitate the excretion of a variety of 
structurally distinct chemotherapy agents from the cytoplasm to the extracellular space. There 
has been considerable interest in the development of specific inhibitors for each of the ABC drug 
transporters. While inhibitors for specific ABC drug transporters have been developed, many of 
them affect the activity of more than one ABC transporter, particularly at elevated 
concentrations. It is also unclear whether they show clear efficacy for combatting resistance to 
specific drugs in tumour cells. In this study, we demonstrate the ability of two bile acids (β-
cholanic acid (ursocholanic acid) and deoxycholic acid) to specifically inhibit ABCC1-mediated 
drug transport, augmenting doxorubicin accumulation into ABCC1-expressing but not ABCB1-
expressing tumour cells. We also show that β-cholanic acid can restore sensitivity to doxorubicin 
in cells genetically engineered to overexpress the ABCC1 drug transporter and in cells that have 
acquired resistance to doxorubicin through the upregulation of ABCC1 expression.  
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7.3: Introduction 
 Cytotoxic chemotherapy agents are still widely used to treat human cancers in both the 
neoadjuvant and adjuvant settings  (1, 2). While combinations of cytotoxic and targeted 
chemotherapy drugs can be effective in improving patient survival, a major impediment to this 
approach is the innate presence or acquisition of a wide variety of resistance mechanisms that 
circumvent the action of chemotherapy drugs  (3).  
 Among the best described mechanisms of drug resistance are those associated with the 
elevated expression of one or more ATP-binding cassette (ABC) drug transporters  (4). These 
transporters, namely ABCB1, ABCG2 and ABCC1  (5–7), play a role in normal cell function, as 
they regulate cellular levels of a variety of small endogenous molecules that include (but are not 
limited to) cholesterol, its derivatives, and a variety of chemical substrates  (5, 6, 8, 9). The ABC 
transporters, especially ABCB1, also function at the blood brain barrier to protect the brain from 
exposure to toxic agents  (10). Unfortunately, these transporters also circumvent the action of 
chemotherapy drugs by promoting the ATP-dependent efflux of drugs from the cytoplasm to the 
extracellular space  (5). In contrast to their clear role in drug resistance in vitro, it remains 
unclear whether they play a critical or central role in clinical tumour resistance to chemotherapy 
agents in patients with specific cancers  (11, 12). However, their involvement in drug resistance, 
disease progression and clinical outcome is becoming increasing clear for haematological 
malignancies, such as Acute Lymphoblastic Leukemia (ALL) and Acute Myelocitic Leukemia 
(AML)  (13, 14). The ABCB1 inhibitor, tariquidar, has been shown to increase sensitivity to 
doxorubicin, paclitaxel, etoposide, and vincristine in phase III trials of lung cancer. However, 
none of these trials were completed due to high systemic toxicity  (15). This illustrates the 
limited utility of current ABC transporter inhibitors. 
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While many ABC transporters are thought to function in a similar fashion, their substrate 
specificities and tissue distribution vary greatly  (5,6,16,17). ABCB1, also known as P-
glycoprotein, is known to transport a large variety of commonly used chemotherapy agents, 
including the taxanes and anthracyclines  (5). ABCC1, also known as MRP1, transports a variety 
of chemotherapy agents, but transports taxanes very poorly  (16). One of the biggest challenges 
in combatting drug resistance mediated by ABC transporters is the lack of specificity of available 
inhibitors and/or their above-described toxic side effects on host tissues. 
 Bile acids are a class of chemical compounds derived from the metabolism of cholesterol  
(18,19). Their primary function is the solubilisation of fats and lipids during the digestive process  
(19,20). In general, bile acids are produced in the liver and transported to the gallbladder where 
they are stored until needed  (18,19). The bile acids are then released into the small intestine 
where they form micelles with lipids. These micelles facilitate the absorption of lipids through 
the wall of the small intestine into the blood stream. Serum levels of bile acids vary greatly, from 
0.3 µM to up to 3 mM, depending upon the tissue or organ in which they reside  (20,21). In 
addition to solubilizing lipids, bile acids also function as regulators of cholesterol metabolism by 
inhibiting enzymes of the aldo-keto reductase family. They also activate the farnasoid-X 
receptor, a transcription factor that regulates a variety of cellular functions  (20, 22–25). While 
there is some evidence that bile acids can affect the expression of various ABC transporters 
through the farnesoid-X receptor  (26, 27), in the present study we assessed the ability of bile 
acids to directly influence ABCC1 transport activity and ABCC1-mediated drug resistance. 
Previous studies have shown that membrane-perturbing agents and various bile acids such as 
deoxycholic acid and ursodeoxycholic acid can inhibit ABCC1-mediated transport of chemical 
agents in erythrocytes  (28, 29). Since some bile acids are known to interfere with other 
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mechanisms of chemotherapy resistance (such as the ability of aldo-keto reductases to 
hydroxylate and detoxify doxorubicin), the prospect of targeting two or more resistance 
mechanisms simultaneously would be of interest in treating chemotherapy-resistant cancers  (30, 
31). Here we show the ability of β-cholanic acid, a known inhibitor of AKR1C3, to inhibit 
ABCC1-mediated drug transport. At concentrations normally used to inhibit AKR1C3, β-
cholanic was able to inhibit ABCC1-mediated transport of doxorubicin. This same effect was not 
observed in cells where ABCB1-mediated drug transport is the primary mechanism of 
chemotherapy-resistance. We demonstrate that, even at high concentrations of deoxycholic acid 
and β-cholanic acid, doxorubicin retention is enhanced in chemotherapy-resistant cells that 
express ABCC1 but not ABCB1. This resulted in markedly improved doxorubicin sensitivity for 
the cells expressing ABCC1, but not for cells expressing ABCB1. 
7.4: Materials and Methods 
7.4.1: Cell Culture 
 
 The MCF-7 breast cancer cell line was originally purchased from the American Type 
Culture Collection and maintained in high glucose DMEM medium supplemented with 10% FBS 
and 100 μg/ml streptomycin and 100 units/ml penicillin (Hyclone, Mississauga, Ontario) at 37˚ 
C in 5% CO2. For subculturing, cells in T75 Sarstedt flasks were washed once with sterile PBS 
followed by the addition of 3 ml of a sterile 0.25% Trypsin, 10 mM EDTA solution (Invitrogen). 
MCF-7 cells were selected for resistance to increasing doses of either doxorubicin (MCF-7DOX2 
cells) and characterized for expression of ABC transporters as well as other chemotherapy-
resistance proteins by Hembruff et al and Veitch et al (30, 32). Doxorubicin-resistant cells were 
maintained in media supplemented with the corresponding selection dose of doxorubicin. 
Resistant cells were removed from drug-containing media 3-4 days prior to being used in 
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experiments. H69 small cell lung cancer cells, doxorubicin-resistant H69AR small cell lung cancer 
cells, HEK293 human endothelial kidney cells, and ABCC1-transfected HEK293 cells 
(HEK293MRP1) were kindly provided from Dr. Susan Cole of Queen’s University, Kingston, ON, 
Canada. HEK293 and HEK293MRP1 cells were maintained under the same conditions as the 
MCF-7 cells with the exception that media was supplemented with 500 μg/ml of G418 to 
maintain selection for clones overexpressing ABCC1. H69 cells were maintained under similar 
conditions, except in RPMI growth media. Additionally, H69 and H69AR cells grow as 
suspension cultures and consequently did not require the use of trypsin to subculture.  
7.4.2: Doxorubicin Accumulation Assay 
 
 Steady-state doxorubicin retention in cells was measured via flow cytometry, since the 
drug is fluorescent. Cells were seeded onto 6 well plates at a density of 200,000 cells per well 
and allowed to adhere. Cells were treated with 2 μM doxorubicin, various concentrations of β-
cholanic acid, deoxycholic acid, MK571, probenecid or a combination of these with doxorubicin 
for a period of 6 h. The concentration range for β-cholanic acid was varied in previous 
experiments to identify the maximally tolerated dose for MCF-7 cells  (30, 32). Deoxycholic acid 
was tested at a concentration identical to β-cholanic acid, with no observable changes in cell 
health or morphology for either bile acid. Concentrations for MK571 and probenecid were based 
on the manufacturer’s recommendation and also showed no discernible morphological effects on 
the cell population. Cells were collected using trypsin as described above and suspended in 1 ml 
PBS. Suspended cells were run on an FC500 flow cytometer (Beckman-Coulter) using an FL2 
(575 nm) filter to detect doxorubicin fluorescence. Data points shown are the mean of 3 
independent experiments and 10,000 events were measured in each experiment. 
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7.4.3: Glutathione Levels 
 
 Glutathione levels in MCF-7DOX2-12 whole cell extracts were measured using a 
glutathione quantification kit from ENZO Life Science, Inc. (Brockville, ON). Cells were plated 
in 10 cm plates at a density of 2 x 10
6
 cells per plate. Cells were pre-treated with the glutamate-
cysteine ligase inhibitor buthionine sulphoximine (50 μM for 1h) to prevent subsequent 
glutathione synthesis. Cell lysates were collected and glutathione assayed as per the 
manufacturer’s instructions. Data shown are mean of 3 independent experiments ± SEM. 
 
7.4.4: Clonogenic Assays 
 
 Cell viability was measured using a clonogenic assay as previously described (32). 
Briefly, cells were plated in 6 well plates at 200,000 cells per well. Cells were treated with 
increasing concentrations of doxorubicin in the presence or absence of test compounds for 24h. 
Cells were then collected and incubated in semi-solid methyl-cellulose medium until large 
colonies became visible, if possible (5-10 days). In each experiment, 12 random fields in each 
well were viewed and the number of colonies counted. IC50 values were calculated by 
determining the survival fraction relative to untreated control cells for each drug concentration. 
Each clonogenic experiment was repeated three times and thus the IC50 values reported are the 
means (+/- SEM) of three independent experiments. 
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7.4.5: Protein Isolation and Western Blot 
 
Cells were grown on 10 cm cell culture plates (Sarstedt) and grown to 80% confluency. 
Cells were lysed and protein extracts prepared as previously described (33). Briefly, RIPA 
(Radio Immuno-precipitation Assay) buffer was modified to contain 1% SDS (w/v), 1x protease 
inhibitor cocktail (Complete
TM), 10 μM sodium fluoride, and 2 mM sodium orthovanadate. This 
buffer was then used to lyse cells and solubilize proteins. Lysates were homogenized and sheared 
using a 21 gauge needle, and then subjected to centrifugation at 14,000 x g for 5 minutes at 4
o
C. 
The supernatant was then collected and aliquoted for western blotting. Protein content in the 
aliquots was assayed using a Pierce BCA protein assay prior to the addition of Laemmli sample 
buffer (1% w/v SDS, 0.25 M TRIS pH 6.8, 40% v/v glycerol, 0.133 M Dithiothreitol, 0.4% w/v 
bromophenol blue). The proteins in the samples were then denatured by boiling for 5 min, after 
which they were loaded on SDS PAGE gels.  
ABCC1 protein levels were quantified by immunoblotting. First, 30 μg of cell lysate was 
resolved on a 7% polyacrylamide gel. Proteins were resolved by electrophoresis at 90V, until the 
molecular weight range of interest (100-250kDa) was adequately distributed on the gel. The 
proteins were then transferred to nitrocellulose membranes using a semi-dry transfer apparatus 
applying 12V for 1 hour (Biorad). To detect ABCC1, membranes were first blocked using 5% 
skim milk in TBST (20 mM Tris pH 8.0, 137 mM NaCl, 0.1% (v/v) Tween 20) for 1 hour at 
room temperature. The membranes were then incubated overnight at 4
o
C in primary antibody 
(monoclonal QCRL-1 Santa Cruz Biotechnology, sc-18835) at a dilution of 1:200 in 5% skim 
milk in TBST. The secondary antibody (Santa Cruz Biotechnology goat anti-mouse HRP 
conjugate, sc-2005), at a 1:10,000 dilution in 5% skim milk in TBST, was applied the following 
day for 1 hour at room temperature. Images were captured on high-sensitivity film using 
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enhanced chemiluminescence reagent (Santa Cruz). Scanned images of the film were analyzed 
using AEaseFC 4.0 comparing pixel density levels of the bands relative to the background 
density of the film. Each band was normalized to a γ-tubulin loading control (Sigma, St. Louis, 
MO), with the same secondary antibody previously described. 
 
7.4.6: Data Analysis 
 
 All graphs were prepared and statistical analysis performed using GraphPad Prism V5.0 
software. All data points are representative of the mean ± standard error of mean (SEM). Due to 
the multi-parametric nature of the data analysis, an ANOVA was chosen as the most suitable 
method of analysis. Analysis of Variance (ANOVA) tests were performed, assuming normal 
distribution for all datasets, followed by Bonferoni post hoc testing for significance. 
Comparisons were made between multiple points, i.e. between control cell lines and their 
respective chemotherapy- resistant cell lines at various selection doses, as well as comparing 
differences between treated and untreated cell lines or between transfected or non-transfected 
cell lines. Differences between samples or cell lines were determined to be significant when P < 
0.05. 
 
7.5 Results 
7.5.1: Augmented Doxorubicin Accumulation by Bile Acids in Doxorubicin-resistant Cells 
 
 Since prior studies have shown that bile acids can inhibit ABCC1-mediated transport of 
chemical agents in erythrocytes  (28, 29), we first assessed whether β-cholanic acid could 
enhance drug accumulation into breast tumour cells. Cellular doxorubicin levels were monitored 
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by flow cytometry, while taxane levels were quantified by liquid scintillation counting of (
3
H)-
docetaxel in cells. These experiments were performed in a series of previously established cell 
line models known for their ABC transporter status  (33,34). As shown in Figure 7-1 A, 
ABCC1-overexpressing doxorubicin-resistant MCF-7DOX2-12 cells exhibited no change in (
3
H)-
docetaxel accumulation relative to cells “selected” in the absence of doxorubicin (MCF-7CC12 
cells). For this reason, no further tests were performed to measure docetaxel uptake in these cells. 
In contrast, when MCF-7TXT10 cells (known to express ABCB1, but not ABCC1) were assessed 
for their ability to uptake doxorubicin, these cells exhibited just 50% of the doxorubicin 
accumulation of MCF-7CC12 cells (Figure 7-1). Interestingly, treatment of these cells with β-
cholanic acid resulted in no statistically significant increase in doxorubicin accumulation (Figure 
7-1 B). Similarly, the doxorubicin-resistant, ABCB1-expressing A2780ADR ovarian cancer cell 
line exhibited only 4% of the doxorubicin uptake of parental A2780 cells and treatment of 
A2780ADR cells with β-cholanic acid (at 200 μM) also had no effect on their ability to accumulate 
doxorubicin. Tariquidar (100 nM) (an ABCB1-specific inhibitor) restored doxorubicin 
accumulation in A2780ADR cells to 58% of parental A2780 cells. This illustrates the role of 
ABCB1 as a primary mechanism of resistance to doxorubicin in MCF-7TXT and A2780ADR cells 
and the utility of tariquidar (but not β-cholanic acid) as an effective inhibitor of ABCB1-
mediated doxorubicin resistance (Figure 7-1 C). 
In contrast to the above observations, β-cholanic acid (at a 200 μM concentration) 
strongly restored sensitivity of ABCC1-expressing MCF-7DOX2-12 cells to doxorubicin and also 
increased doxorubicin accumulation (from 27% to 79% of drug-sensitive control MCF-7CC-12 
cells). At 80 μM, β-cholanic acid restored doxorubicin accumulation to just 41% of control 
cells). A comparable restoration in doxorubicin accumulation was also observed when MCF-
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7DOX2-12 cells were treated with 200 μM deoxycholic acid (to 76% of control cells). The small 
molecule ABCC1 inhibitor MK571 (80 μM) was also effective at restoring doxorubicin 
accumulation to 65% of control cells, as expected. However, while MK571 is claimed to be a 
specific inhibitor of ABCC1, treatment of ABCB1-expressing MCF-7TXT10 cells with an 
equivalent dose of MK571 resulted in significant restoration of doxorubicin uptake (Figure 7-1 
B). This cell line does not have detectable ABCC1 expression  (33). The general organic anion 
transporter inhibitor probenecid (500 μM) only partially restored doxorubicin accumulation in 
MCF-7DOX2-12 cells (to 45% of doxorubicin-sensitive MCF-7CC-12 cells). At 140 μM, MK571 was 
more effective than 200 μM β-cholanic acid in restoring accumulation of doxorubicin (to 97% of 
control cells) (Figure 7-1 D).  
Bile acids were also shown to be effective at restoring accumulation of doxorubicin into 
doxorubicin-resistant ABCC1-expressing H69AR lung cancer cells, with deoxycholic acid being 
slightly more effective than β-cholanic acid at restoring accumulation (95.5% and 87.8% of 
parental H69 cells, respectively) (Figure 7-1 E). As a control, probenecid also restored 
doxorubicin accumulation to 45% of parental cells.  
To determine if the observed effects of bile acids on doxorubicin uptake were the result 
of inhibiting ABCC1 and not through effects on other molecules contributing to doxorubicin 
resistance in MCF-7DOX2-12 cells, HEK293 cells stably transfected with an expression vector for 
ABCC1 were also treated with doxorubicin and/or bile acids. In these HEK293MRP1 cells, 
doxorubicin accumulation was 34.4% of untransfected HEK293 cells (Figure 7-1 F). β-cholanic 
acid (at 80 μM and 140 μM) augmented doxorubicin accumulation in HEK293MRP1 cells to 
44.4% and 64.4% of untransfected cells, respectively (Figure 7-1 F). At 200 μM, both β-
cholanic acid and deoxycholic acid increased doxorubicin levels in HEK293MRP1 cells to 75.2% 
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and 88% of untransfected cells, respectively. Probenecid (500 μM), a general organic anion 
transport inhibitor, caused a restoration of doxorubicin accumulation to 61.5 % of untransfected 
cells.  
ABCC1-mediated transport of doxorubicin has been shown to require the presence of 
glutathione (35). Consequently, we also measured glutathione levels in MCF-7DOX2-12 cells in the 
absence or presence of β-cholanic acid. Cells were first pre-treated with buthionine sulfoximine, 
which irreversibly inhibits glutathione biosynthesis, preventing cells from replenishing 
glutathione during the course of the experiment. As shown in  
Figure 7-2, MCF-7CC12 cells showed no significant change in glutathione levels under 
any treatment conditions. In contrast, MCF-7DOX2-12 cells showed significantly increased levels 
of intracellular glutathione when treated with β-cholanic acid (1.9-fold higher than untreated 
MCF-7DOX2-12 cells). This same increase (1.9-fold) was observed in MCF-7DOX2-12 cells treated 
with both β-cholanic acid and doxorubicin. 
7.5.2: Bile Acids Increase Sensitivity to Doxorubicin in Doxorubicin-resistant Cells  
 
Since increased uptake of doxorubicin would be expected to increase the cytotoxicity of 
the drug, the effect of bile acids (β-cholanic acid or deoxycholic acid) on doxorubicin sensitivity 
in doxorubicin-sensitive and -resistant breast tumour cell lines (MCF-7CC12 and MCF-7DOX2-12 
respectively) and lung cancer cell lines (H69 and H69AR, respectively) was assessed using 
clonogenic assays. Each of the above drug-resistant cell lines express elevated levels of ABCC1. 
MCF-7DOX2-12 cells exhibited a significant increase in doxorubicin sensitivity in the presence of 
the bile acids with IC50 values for doxorubicin of 790 nM for untreated cells and 170 nM and 98 
218 
 
nM for cells exposed to β-cholanic acid (200 μM) and deoxycholic acid (200 μM), respectively 
(Figure 7-3 F). Similarly, doxorubicin-resistant H69AR cells exhibited restored sensitivity to  
Figure 7-1 Measures of steady state uptake of doxorubicin or paclitaxel into various cell 
lines under various conditions. A. Tritiated docetaxel uptake into MCF-7
CC12
 and MCF-7
DOX2-
12
 cells. B. Uptake of doxorubicin into MCF-7
TXT-10
 cells relative to MCF-7CC10 cells, as 
measured by flow cytometry. C. Uptake of doxorubicin into A2780
ADR
 cells relative to A2780 
cells, as measured by flow cytometery. D. Effect of various agents on doxorubicin uptake into 
MCF-7
DOX2-12
 cells, relative to MCF-7CC10 cells. E. Effect of various agents on doxorubicin 
uptake into H69
ADR
 cells, relative to H69 cells. F. Effect of various agents on uptake of 
doxorubicin into HEK293 cells transfected with an ABCC1 expression vector relative to 
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untransfected HEK293 cells. Agents included β-cholanic acid (b-ch, green), deoxycholic acid 
(deox, orange), MK571 (blue), probenecid (prob, yellow) or Tariquidar (tari, purple). All 
experiments were performed in triplicate, with p-values being calculated using ANOVA with 
Bonferoni post-hoc tests. 
 
 
Figure 7-2 Effect of doxorubicin and β-cholanic acid on glutathione levels in buthionine-
treated MCF-7 cells. 
MCF-7CC12 cells A. and resistant MCF-7DOX2-12 cells B. were treated simultaneously with 
buthionine sulfoximine (50 μM for 1h) followed by combinations of doxorubicin (2 μM) and β-
cholanic acid (200 μM) for assessment of their glutathione levels. The data shows that treatment 
with β-cholanic acid in MCF-7DOX2-12 cells results in elevated cellular glutathione levels. All data 
are standardized to respective untreated controls. Experiments were performed in triplicate. 
Statistical analyses were conducted using an ANOVA with a post-hoc Bonferoni correction. 
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doxorubicin with IC50 values of 960 nM and 73 nM for untreated and β-cholanic acid treated 
cells, respectively (Figure 7-3 E and H). 
To determine if the effects of β-cholanic acid on doxorubicin sensitivity were limited to 
cells selected for anthracycline resistance, ABCB1-expressing MCF-7TXT10 cells were also 
treated with doxorubicin and/or β-cholanic acid. Unlike the above doxorubicin-resistant cells 
lines, MCF-7TXT10 cells exhibited no change in doxorubicin sensitivity (data not shown). This 
suggested that β-cholanic acid does not potentiate doxorubicin cytotoxicity in all drug-resistant 
cell lines and may demonstrate selectivity towards cells overexpressing ABCC1. Hembruff et al. 
showed that MCF-7TXT and MCF-7EPI resistant cells express high levels of ABCB1, while MCF-
7DOX2-12 cells express high levels of ABCC1 transporter (33). These cell lines were developed in 
our laboratory by selection for survival in increasing drug concentrations and all are isogenic 
with parental MCF-7 cells and cells “selected” in the absence of drug to control for increasing 
passage number (MCF-7CC cells). MCF-7DOX2-12 cells, however, do not express the very high 
levels of ABCC1 seen in H69AR cells (Figure 7-4). Thus, the differing levels and types of drug 
transporters in the above drug-resistant cell lines may account for the differing ability of β-
cholanic acid to increase cellular sensitivity to doxorubicin. Moreover, β-cholanic acid may 
selectively affect cells overexpressing ABCC1, given that ABCB1-overexpressing doxorubicin-
resistant A2780ADR cells did not exhibit increased doxorubicin sensitivity in the presence of β-
cholanic acid, while ABCC1-overexpressing doxorubicin-resistant ABCC1-overexpressing cells 
did. To test this hypothesis, HEK293 cells and HEK293MRP1 cells were examined for their 
sensitivity to doxorubicin in the absence or presence of bile acids. These cell lines only differ in 
their expression of ABCC1. As seen in Figure 7-3 C and E, both β-cholanic acid and 
221 
 
deoxycholic acid augmented doxorubicin cytotoxicity in HEK293MRP1 cells. HEK293MRP1 cells 
exhibited an IC50 for doxorubicin of 47 nM in the absence of bile acids and IC50 values of 12 
nM and 6.6 nM in the presence of β-cholanic acid and deoxycholic acid, respectively. 
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Figure 7-3 Effect of bile salts on sensitivity of human tumour cell lines to doxorubicin as 
measured by clonogenic assay. 
The cell lines used were MCF-7
CC12
, MCF-7
DOX2-12
, H69, H69
AR
, HEK293 and HEK293
MRP1
 
cells. A-C. show survival curves for MCF-7, H69 and HEK293 (with respective doxorubicin 
resistant counter-parts) cells treated with increasing concentrations of doxorubicin in the 
presence or absence of 200 μM β-cholanic acid. D-E. Doxorubicin sensitivity curves for MCF-7 
and HEK293 cells as a function of doxorubicin concentration in the presence or absence of 200 
μM deoxycholic acid. F. Effect of MK571 on doxorubicin sensitivity in wildtype and 
doxorubicin-resistant MCF-7 cells. G-I. Summary of IC50 values for doxorubicin in for various 
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cell lines under various conditions. *** p < .001 as determined by ANOVA analysis with a 
Bonferoni correction. 
 
 
 
Figure 7-4 Representative western blot of ABCC1 levels in MCF-7 sensitive and doxorubicin 
resistant cell lines 
H69 and H69AR cell lines, and HEK293 parental and ABCC1 transfected cell lines.  
 
7.6: Discussion 
 In this study, we provide strong evidence that the bile acid β-cholanic acid is an effective 
and specific inhibitor of ABCC1-mediated doxorubicin efflux. This results in a strong promotion 
of doxorubicin sensitivity in doxorubicin-resistant tumour cells, providing they express the 
ABCC1 drug transporter. Previous studies by our laboratory and others have shown that β-
cholanic acid is also an effective inhibitor of aldo-keto-reductase 1C3, which can promote 
resistance to anthracyclines by inducing their hydroxylation  (30, 32, 36). However, potentiation of 
doxorubicin cytotoxicity by β-cholanic acid in our study did not appear to be through inhibition of drug 
hydroxylation because another bile acid (deoxycholic acid), which has no aldo-keto reductase inhibitory 
activity  (37), and was able to potentiate doxorubicin cytotoxicity in our study at concentrations identical 
to β-cholanic acid. It should be noted that the potency of bile acids is approximately 2.5-fold lower 
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than a well-known inhibitor of ABCC1 activity, namely MK571. These are, nevertheless, well 
within the physiological range of bile acids in humans  (19). Moreover, while MK571 was more 
potent than bile acids at inhibiting ABCC1-mediated doxorubicin efflux from tumour cells in our 
study, our findings also show that at a lower but equally effective concentration of 80 μM, 
MK571 also inhibited doxorubicin efflux from docetaxel-resistant MCF-7TXT10 cells, which 
express ABCB1 and ABCC2 as their predominant drug transporters (Figure 7-1)  (33). 
Consistent with our findings, Molinas et al. showed that MK571 as well as cyclosporine A and 
probenecid were able to inhibit ABCB1 transport activity  (17). Probenecid, another inhibitor of 
ABCC1 was also able to partially inhibit ABCC1 transport but at a concentration more than 
double that of β-cholanic acid, suggesting that β-cholanic acid is a more potent inhibitor than 
probenecid in the presented model.  
While bile acids appear to be specific for inhibition of ABCC1 over ABCB1, it should be 
noted that we did not examine the possible effects of bile acids on other ABC transporter 
proteins. Since the MCF-7TXT10 cell line used was previously shown to express both ABCB1 and 
ABCC2  (33), we cannot rule out the ability of β-cholanic acid to inhibit ABCC2 transporter 
activity. The restoration of doxorubicin uptake and cytotoxicity in cells overexpressing 
exogenous ABCC1 (HEK293MRP-1 cells) further suggests that the effect of bile acids in 
sensitizing cells to chemotherapy is primarily due to their ability to affect ABCC1 transport and 
not through potential additional effects on other proteins implicated in doxorubicin resistance.  
 The selectivity of bile acids for inhibition of ABCC1 transport activity (with little effect 
on ABCB1-mediated drug efflux) is noteworthy, since current ABCC1 inhibitors do not exhibit 
strong selectivity for drug transporters. For example, cyclosporine A inhibits a wide variety of 
ABC transporters  (8, 9, 13) and, as demonstrated in this and another study (17), MK571 also 
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inhibits ABCB1-mediated drug efflux. In contrast, our current study suggests that β-cholanic 
acid may have greater specificity, with no effect on doxorubicin accumulation in ABCB1-
expressing cells. It thus warrants further examination. This would include assessing the efficacy 
of bile acids to augment efflux of a variety of chemotherapy drugs in chemoresistant cells, 
including cell lines genetically engineered to overexpress a specific ABC transporters. In 
particular, expression vectors should include ABC transporters previously implicated in 
chemotherapy resistance and drug disposition, including additional ABCC isoforms  (38) and 
ABCG2  (39). 
Our study also showed that bile acids have no effect on doxorubicin accumulation into 
drug-sensitive tumour cells that do not express ABC drug transporters. This is important, since 
bile acids are known to affect lipid solubility  (19) and this could increase plasma membrane 
permeability towards doxorubicin and other chemotherapy agents tumour. 
While in some cases, cells treated with very low doses of doxorubicin did exhibit high 
survival fractions than their untreated counterparts, this is likely an artifact of the clonogenic 
process. While care is taken to ensure equal plating of cells between samples, in some cases 
cells may get spread to the periphery of the plate where colonies cannot be distinguished 
clearly, or in some cases, platting efficiency can vary within an experiment. For this reason, 
only representative clonogenic experiments were presented, while IC50 values were calculated 
as an average of 3 or more independent clonogenic studies. 
  Hembruff et al  (33) demonstrated that a majority of MCF-7 cells selected for resistance 
to anthracyclines and taxanes expressed ABCB1, including cells selected for resistance to 
docetaxel, paclitaxel or epirubicin. Docetaxel-selected cell lines also expressed ABCC2 at low 
selection doses (Cells exposed up to an intermediate selection dose were used in our study 
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(MCF-7TXT10 cells)). In contrast, the doxorubicin-resistant cells used in our study predominantly 
expressed the ABCC1 transporter, with no elevated expression of ABCB1  (33). Since only our 
MCF-7DOX2-12 cell line showed reductions in doxorubicin accumulation in the presence of bile 
acids, we therefore chose to focus on ABCC1 rather than ABCB1, which is not expressed in 
MCF-7DOX2-12 cells. In addition, the docetaxel-resistant cell line used in our study overexpresses 
both ABCB1 and ABCC2 (MCF-7TXT10 cells) and did not show any changes in doxorubicin-
uptake when treated with β-cholanic acid. This suggests that β-cholanic acid also has no effect 
on ABCC2-mediated drug transport and/or that ABCC2 does not contribute sufficiently to the 
doxorubicin-resistant phenotype.   
  We proceeded to further test our hypothesis using two other ABCC1 expressing cell 
lines, the doxorubicin-resistant H69AR lung cancer cell line, and an ABCC1-transfected cell line 
(HEK293MRP1). For both cell lines, high concentrations of bile acids reduced the IC50 values for 
doxorubicin by 3-4 fold compared to their respective parental controls. Similar to what was 
observed in parental MCF-7 cells, bile acids had no effect on doxorubicin sensitivity in parental 
H69 and HEK293 cells. We do note that complete restoration of sensitivity is not achieved in the 
MCF-7 cells as compared to the other cell lines, despite the lower expression leve of ABCC1 in 
the MCF-7 cells as compared to the H69 or HEK cells.  We suggest that this may be due to other, 
yet undefined, resistance factors which would contribute to the MCF-7 resistance phenotype. 
One of the major obstacles in studying the regulation and function of ABC transporters 
and their contribution to drug resistance in tumour cells is that they cannot be studied in 
complete isolation of the cell. The transport activity of these molecules, however, can be studied 
by creating micelles derived from cells engineered to express specific transporters. These micelle 
models have the benefit of isolating a specific transporter and measuring its ability to actively 
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transport fluorescent substrates into micelles. While such approaches can accurately measure 
transport kinetics, a full tumour cell line model is preferred when studying the contribution of 
drug transporters to drug resistance in cells and the ability of ABC transporter inhibitors (such as 
bile acids) to augment drug sensitivity. This is because a variety of molecules, proteins, and 
cellular organelles impact on tumour cell sensitivity to chemotherapy. 
Previous studies have shown that bile acids can inhibit ABCC1 transport activity in 
erythrocytes in the low micromolar range (28, 40). These studies demonstrated that various bile 
acids can inhibit ABCC1 transporter activity in a cellular system. In these studies, the researchers 
monitored the efflux of a pre-loaded fluorescent molecule from erythrocytes. These studies do 
provide insight into the effects of bile acids on ABCC1 transporter activity, since erythrocytes 
are known to express appreciable levels of ABCC1. However, it is not the only ABC transporter 
present in erythrocytes  (29, 40–42). In addition to ABCC1, erythrocytes also express ABCC4 
and ABCG2  (41, 42).  
As we have demonstrated here, the potency of the bile acids appears to be lower in terms 
of their ability to affect ABCC1-mediated doxorubicin efflux. Where prior studies in 
erythrocytes have suggested that deoxycholic acid has an IC50 of 16 μM for inhibition of 
fluorescent substrate efflux, we have observed IC50’s ~10-fold higher for inhibition of ABCC1-
mediated doxorubicin efflux from tumour cells. Unlike the previous studies in erythrocytes, our 
study focussed on nucleated cancer cells which, as seen in many tumour cell lines, are poyploid. 
Chromosomal duplications could contribute to substantially higher levels of ABC transporter 
expression in drug-resistant cells, well above those observed in normal erythrocytes. Indeed, a 
chromosomal region harbouring the ABCC1 gene (16p13.1) is amplified almost 100-fold in a 
multidrug-resistant lung cancer cell line  (16). Also, we focussed our study on the effect of bile 
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acids on the ABCC1-mediated transport of doxorubicin, a clinically relevant chemotherapy agent  
(43–45). Moreover, we chose to study highly chemoresistant tumour cells, rather than 
erythrocytes. Nevertheless, the studies in erythrocytes underscore additional effects that bile 
acids can be expected to exert on normal cell populations in the host. Moreover, our study does 
not represent the first study on the effects of bile acids on tumour cells. Several groups have 
attempted to use bile acids and their derivatives as carrier agents for chemotherapy delivery, or 
even to induce apoptosis  (46–48). However, our observations clearly show that the bile acids in 
this case are not simply acting as carriers for doxorubicin, since no increase in doxorubicin 
accumulation was observed in tumour cells not expressing ABCC1 transporters. 
 Our findings related to bile acids provide significant insight into the development of new 
chemo-sensitizing agents. Furthermore, β-cholanic acid is a known inhibitor of several members 
of the aldo-keto reductase family, most notably AKR1C3 and AKR1B10, which are known to 
promote drug resistance through the hydroxylation of doxorubicin to the considerably less 
cytotoxic doxorubicinol  (30).  
Clinically, high levels of bile acids are well tolerated in patients (19), suggesting minimal 
negative systemic effects on host liver and brain tissues. The blood brain barrier is rich in its 
expression of ABCB1  (8), but unlike MK571, β-cholanic acid would not be expected to inhibit 
this drug transporter. By inhibiting ABCC1 specifically, β-cholanic acid would be expected to 
augment accumulation of doxorubicin in ABCC1-expressing tumours, while retaining ABCB1’s 
ability to protect sensitive brain tissues to the damaging effects of doxorubicin.  
 Despite these possible positive outcome from using bile acids to inhibit ABCC1 activity 
in chemoresistant cells, the concentrations required to inhibit ABCC1 activity are 10-fold higher 
than that required for erythrocytes. While normal circulating levels of bile acids in humans are 
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typically very low (3-8 μM), it is unclear what effect high concentrations of bile acids would 
have on the host  (21). Higher levels of intracellular bile acids can be detected in certain disease 
states. However, these conditions usually result in apoptosis occurring in affected cells. In 
contrast, high doses of another bile acid (ursodeoxycholic acid, derived from bear gallbladders) 
are usually well tolerated in patients  (19). 
While we observed no appreciable loss of cell viability in the presence of high levels of 
bile acids, Mrowczynska et al. showed that erythrocytes could tolerate very high levels of bile 
acids, much higher than those used in our study. Nevertheless, much work remains to be 
conducted to better understand the systemic effects and clinical toxicities associated with bile 
acid treatment. Our study also indicates that the concentration required to inhibit ABCC1 
transport is highly dependent on the model used for study and possibly the level of expression of 
ABCC1. Further experimentation in animal models would be required to examine the therapeutic 
efficacy and systemic toxicities of doxorubicin in the presence of various bile acids. 
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Chapter 8  
Overarching Discussion and Future Directions 
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8.1: Discussion 
 The phenomenon of chemotherapy resistance is a complex problem that faces physicians 
in the treatment of cancer  (1). As a model for studying chemotherapy resistance, cancer cell 
lines have proven to be very useful tool. Thanks to the diligent work of a variety of researchers, 
we have learned about the various mechanisms associated with chemotherapy resistance  (2–6). 
These resistance mechanisms can be observed at several different levels. The first is the entry of 
the chemotherapy agent into the cells. This can be modulated by a variety of mechanisms, from 
various solute carriers which can bind to and transport the agents into the cell, to ABC 
transporters which will actively remove the chemotherapy agents from the cell  (6, 7). 
Mechanisms of resistance can also act in the cytosol of the cells by either metabolizing the 
chemotherapy agents, sequestering the compounds in lysosomes, or modifying the target to 
reduce their affinity for the chemotherapy agent  (7). A complicating factor of studying these 
mechanisms is that in most cases, selection of cells for resistance to chemotherapy, as done in 
laboratory settings, results in activation of several different mechanisms of resistance. While 
some of these mechanisms appear to develop regularly across many cancer types, others are 
more difficult to detect. Here we illustrate how the effects of one chemotherapy resistance 
mechanism can overshadow the role of another. Additionally we demonstrate that a single 
compound can have effects on two distinct chemotherapy resistance mechanisms. 
 We began our investigation of resistance mechanisms by examining the role of Aldo-keto 
reductases. While the cell model we used did express increased levels of a drug transporter, 
ABCC1, we were interested in examining alternate mechanism of resistance as early studies on 
the MCF-7DOX2-12 cell line did not respond to the then suspected pan-ABC transport inhibitor 
cyclosporine A. Following microarray analysis of the cell MCF-7 cell line, it was discovered that 
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members of the AKR superfamily of enzymes showed significant increases of expression. These 
enzymes, specifically AKR1C3 and AKR1B10, are known to metabolize anthracyclines into less 
toxic forms  (8, 9). An additional characteristic of these enzymes is their role in steroid 
metabolism, specifically estrogen metabolism. The MCF-7 cell line as a model is characterized 
as an ER positive breast cancer and as such could be impacted by increases in estrogen synthesis. 
Given the fact that each of these enzymes is capable of metabolizing doxorubicin to the less toxic 
doxorubicinol as well as contribute to pro-growth/pro-survival estrogen signalling  (10, 11), the 
observation of increased expression of AKR enzymes would be expected to contribute to 
chemotherapy resistance. Upon investigation we were able to confirm that the increased 
expression of AKR1C3 was related to increased levels of estrogen synthesis. This increase in 
estrogen synthesis was observed and did correlate with increased resistance. However further 
investigation into the estrogen signalling pathway revealed that estrogen receptor α levels were 
downregulated in resistant cells which correlated with reduced estrogen signalling. Further 
studies on the estrogen signalling pathway was the focus of a previous thesis (Chewchuk, 2010). 
Briefly, estrogen signalling was seen to be impaired in MCF-7DOX2-12 cells and shows an inverse 
relationship to AKR1C3 expression. We propose that the role of reduced estrogen signalling 
would result in reduced growth rate of cells which would allow for cellular repair following 
insult by chemotherapy agents. Indeed reduced growth rates are observed in these doxorubicin 
resistant cells. 
 The role of AKR1C3 was further solidified by use of a chemical inhibitor, β-cholanic 
acid. This bile acid binds the active site of the enzyme competitively and prevents the conversion 
of estrone into estradiol, the final step in estrogen synthesis. Similarly, β-cholanic acid interferes 
with the binding of doxorubicin to the active site preventing its metabolism to doxorubicinol. 
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Initial experiments showed that treating MCF-7DOX2-12 cells with the inhibitor resulted in a 
significant restoration of sensitivity to doxorubicin. The effects of the inhibitor were verified by 
measuring the cells’ ability to convert estrone to estradiol. However, follow-up experiments in 
which AKR1C3 was either over-expressed in wild type MCF-7 cells or knocked down by siRNA 
in MCF-7DOX2-12 cells showed no change in chemo-sensitivity. This finding is in direct contrast 
to other studies in which AKR1C3 overexpression resulted in increased resistance to doxorubicin  
(2). We answer this by recognizing that our system was limited in the degree to which we could 
over express AKR1C3. In the competing models, overexpression of 200 fold were achieved 
while we were only able to overexpress AKR1C3 to a maximum of 7 fold above wild type 
levels.  
As for the lack of change in cells where we knock down AKR1C3, we observed that the 
resistant cells also overexpressed AKR1B10 which is also known to metabolize doxorubicin, and 
would also be sensitive to inhibition by β-cholanic acid. We therefore attempted to knock down 
both AKR proteins simultaneously in the MCF-7DOX2-12 cells. This also resulted in no change in 
chemotherapy resistance. As a consequence we concluded that while the AKR proteins can 
contribute to the resistance phenotype, they were not primarily or solely responsible for 
doxorubicin resistance. We hypothesized, then, that an alternate mechanism had to be 
responsible for the cells’ ability to survive doxorubicin. Upon re-examination of the micro-array 
data, as well as previous studies on the MCF-7DOX2-12 cell line, we noted the overexpression of 
ABCC1, a transporter protein known to export anthracyclines from the cell to the extracellular 
space or sequester them in lysosomes. Additionally, experiments designed to measure the 
amount of doxorubicin retained within cells illustrated that upon treatment with β-cholanic acid, 
MCF-7DOX2-12 cells retained increased levels of doxorubicin relative to their untreated controls. 
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This lead to the hypothesis that β-cholanic acid could be having an impact on resistance 
mechanisms other than AKR1C3. 
As discussed in chapter 7 of this thesis, we tested the possibility that β-cholanic acid had 
the ability to block the function of the ABCC1 transporter. We found that β-cholanic acid had 
profound effects on doxorubicin sensitivity in cell lines which expressed ABCC1. At this point 
in the study, a question remained as to the mechanism of inhibition. One possible way that bile 
acids could impact on ABCC1 function would be to serve in their most basic role by solubilizing 
lipids and cholesterol molecules in the cell membrane and altering the fluidity of the membrane 
which could disrupt the 3D structure of the ABC transporter. While membrane fluidity is a factor 
that should be considered when studying trans-membrane proteins, it is an unlikely factor in this 
situation, as we would expect to see the same effect in cells expressing ABCB1 as a transporter. 
However, upon testing β-cholanic acid on MCF-7TXT and A2780ADR cells, we saw no effects on 
restoring doxorubicin retention. This is an important finding since the MCF-7TXT cell line was 
selected for resistance to paclitaxel and is known to express high levels of ABCB1  (3). While 
this cell line shared a common history with the MCF-7DOX2-12 cell line, it was selected for 
resistance to an alternate chemotherapy agent, and as such may not be sufficiently analogous for 
comparison. To verify that the effect we observed was not dependent on the drug used for 
selection for resistance we also tested the A2780ADR cell line, an ovarian cancer cell line which 
was selected for resistance to doxorubicin and known to express ABCB1 as a mechanism of 
chemotherapy resistance  (12). Once again, no effect on drug retention was observed. We 
suspected that the effect of β-cholanic acid on chemotherapy retention within the cell was 
specific to the ABCC1 transporter as we confirmed that and ABCB1 inhibitor was able to resort 
doxorubicin retention in these cells.  
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One of the characteristics of ABCC1 is that it possesses 3 distinct substrate binding sites, 
each of which is capable of recognizing different substrates  (13,14). β-cholanic acid has a 
similar structure to doxorubicin and may bind to the same substrate binding site as doxorubicin, 
as it does in the AKR enzymes. This would prevent doxorubicin binding the site and 
subsequently prevent its efflux from the cell. An alternate possibility is that β-cholanic acid is 
interacting with one of the other substrate binding sites preventing the normal function of the 
transporter. In either case, an ideal system to test these possibilities would be to first use in silico 
analysis and attempt to map the structure of β-cholanic acid onto the substrate binding sites of 
ABCC1. This would require a 3D crystal structure of the protein, which unfortunately does not 
exist due to the complex nature of ABCC1.  
The data collected thus far suggests that in addition to the effects of β-cholanic acid by 
inhibiting AKR enzymes, it is also capable of interfering with the activity of ABCC1. The exact 
mechanism by which β-cholanic acid interferes with ABCC1 is yet to be elucidated, however 
preliminary findings suggest a possibility of non-competitive inhibition (see appendix Figure 
9-1). It should be noted that the data pertaining to the exact mechanism of inhibition was 
acquired from a whole cell system. This method of observing kinetics of membrane transport 
present several problems. First is the issue of membrane composition. The plasma membrane is 
comprised of many different lipid compounds each contributing to different structures of the 
membrane. These include but are not limited to lipid rafts, which may play a role in protein 
transporter structure/function, cholesterol and other derivatives, which play a role in membrane 
fluidity and can affect the rate at which solutes cross the plasma membrane. Any of these 
membrane structures can be disrupted by bile acids which could account for variance in the 
changes in drug uptake in the cells. We also note that the changes in Km and Vmax, while 
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statistically different, are much smaller than we expected based on the total drug uptake 
measured by fluorescence.  
The benefit of using whole cells in a kinetic assay is that the membrane will contain other 
proteins and sugars which would support the cellular structure and allow the system to better 
tolerate the bile acids being tested. However this system does add complications to measuring 
the function of a single resistance factor. Knowing that β-cholanic acid can impact on enzymatic 
processes within the cells, namely the AKR metabolic enzymes, attempting to study the effects 
on ABCC1 transport is difficult. To minimize the variables associated with whole cell systems 
we used a stable transfected cell model to study the effects of β-cholanic acid on ABCC1 
transport.  
Due to the nature of ABC transporters, it is impossible to study their function in the 
absence of a plasma membrane. In addition, bile acids are commonly used to dissolve simple 
lipids. Deoxycholic acid, for instance, is a common additive in cell lysis reagents to facilitate 
emulsification of the phospholipid bilayer of the cells. Note that this is at higher concentrations 
than were used in our experiments. Due to the possible complications associated with use of bile 
acids we opted to use a whole cell system to analyze the kinetics of transport inhibition. The 
alternative, and more commonly used method, involves the use of specially designed micelles 
which contain the transporter along their surface. These micelles would then be treated with ATP 
and the necessary substrates. For study of ABCC1 transport the typical substrates would be 
methotrexate and glutathione. One could then add the inhibitors to the liposomal mix and 
measure the amount of methotrexate which enters the liposome. The concern using such a 
system is that the bile acids may completely disrupt the micelles preventing any usable data from 
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being gathered. Nevertheless this system could be employed for future experimentation and 
attempt to better elucidate the nature of inhibition on ABCC1 by β-cholanic acid. 
While β-cholanic acid is commonly used to treat liver disease, this is typically 
accomplished by oral ingestion. As noted previously, β-cholanic acid as a treatment for liver 
disease promotes the secretion of secondary bile acids from the liver which are normally toxic in 
high quantities. Additionally, β-cholanic acid is not typically absorbed in the digestive tract the 
way cholic or chenodeoxycholic acids are. As a result, we postulate that oral administration of β-
cholanic acid would not be effective at treating most cancers. Furthermore since bile acids are 
known to promote cell growth and survival through activation of the farnasoid x receptor, β-
cholanic acid is not likely to be a good candidate in treating cancers of the digestive tract such as 
colon cancer. We would propose that β-cholanic acid would rather be a useful tool for treating 
cancers which are shown to express ABCC1 and/or AKR1C3 or 1B10 as primary mechanisms of 
chemotherapy resistance. Additionally, for the treatment to be effective it would have to be 
administered intravenously in parallel with traditional chemotherapy to allow the drugs to better 
access the cancers.  
This brings us to one of the major limitations of β-cholanic acid as a supplemental 
treatment for chemotherapy resistant cancer, and that is the relatively high concentration needed 
to inhibit each AKR1C3 and ABCC1 (100-200uM). We note that these concentrations are very 
close to the maximum levels of β-cholanic acid which can be dissolved in aqueous solutions. 
This could present problems in administering β-cholanic acid intravenously as it could 
potentially precipitate in the blood stream during treatment. This could lead to damaging emboli 
which could be lethal to the patient. In addition, we noted in an earlier chapter that while low 
dose of circulating bile acids could have beneficial effects on cell survival, high concentrations 
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of bile acids are associated with tissue damage (liver fibrosis as an example). Additionally, while 
β-cholanic acid is useful at removing bile acids in liver disease, it could have a detrimental effect 
when administered intravenously by promoting the secretion of cholic acid and 
chenodeoxycholic acid into the circulatory system. For these reasons we propose that, rather than 
use β-cholanic acid directly for co-treating chemotherapy resistant cancers, artificial derivatives 
would be more useful for patient care. 
8.2: Future Directions 
As we see in a variety of systems in vitro, chemotherapy resistance is not restricted to any 
one mechanism, although one mechanism will tend to dominate over others. Typically, as cells 
develop resistance to chemotherapy they will adopt multiple mechanisms to promote their 
survival, and these mechanisms may change during their selection for resistance as the selective 
pressures change. As we discussed earlier, cells can alter many aspects of their physiology to 
combat the damaging effects of chemotherapy. Here we studied the roles of 2 major contributors 
to anthracycline resistance, ABCC1 transporters and AKR1C3 (doxorubicin metabolizing 
enzyme). While these two modes of resistance are distinct, they can each function to protect 
cancer cells from the damaging effects of doxorubicin. As we have demonstrated however a 
single compound, β-cholanic acid, is capable of inhibiting each of these mechanisms of 
resistance. By simultaneously blocking chemotherapy export and metabolism, we could prevent 
the cancer cells from detoxifying themselves. The added benefits of this are that, by blocking 
AKR metabolism of doxorubicin, many of the toxic side effects caused by doxorubicin 
metabolites could be avoided.  
As we have noted, since the optimum method of deliver of β-cholanic acid for the 
treatment of resistant cancer would be intravenous injection, and normal circulating levels of bile 
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acids are typically very low, there is a concern that high doses of β-cholanic acid added to the 
circulation could have toxic side effects. It is difficult to say for certain if this would be the 
outcome, as bile acids have never been administered in this manner before. It is known that low 
doses of β-cholanic acid administered orally can have regenerative effects on liver tissue, 
however it is not known what effects these doses would have if applied directly to the 
circulation. Injecting β-cholanic acid intravenously could have protective effects on various 
tissues of the body or detrimental ones. An important step in developing β-cholanic acid as a 
treatment for doxorubicin resistant cancers would be to test the tolerances of escalating doses of 
β-cholanic acid in animal models. Following this, we could use various doses of β-cholanic acid 
in conjunction with doxorubicin to treat animals with xenografted ABCC1 expressing tumours to 
determine if this method could be successfully applied to in vivo systems.  
While β-cholanic acid is a promising lead in the treatment of ABCC1 and AKR 
expressing chemotherapy resistant cancers, we have outlined some of the possible complications 
due to the high concentrations needed. We would therefore propose that the chemical structure of 
β-cholanic acid could serve as a template for design of new compounds which would target 
ABCC1 and AKR1C3 as a future direction. The goal of this would be to produce a compound 
which would be effective at blocking both resistance mechanisms while minimizing potential 
side effects. This strategic design would present a major challenge. With β-cholanic acid 
exhibiting a high level of specificity for interfering with ABCC1 and not ABCB1, β-cholanic 
acid treatment would likely not have the same negative side effects as other ABCC1 inhibitors 
like MK571 which can have off-target effects on ABCB1 at higher concentrations. Among these 
are neurological effects suffered by patients when ABCB1 is inhibited due to the loss of 
protection at the blood-brain barrier  (15). We propose therefore that β-cholanic acid would fill 
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the role of a more targeted agent against ABCC1 as a resistance mechanism could therefore 
avoid some of the side-effects of less specific agents. These new agents would first be tested for 
their efficacy in vitro against both modes of resistance, as well as specificity to ABCC1 and 
AKR1C3. Following this, as with β-cholanic acid, tolerance and efficacy in animal models 
would have to be tested before any attempt can be made clinically. If successful, development of 
a specific and potent inhibitor of ABCC1 and AKR1C3 could prove extremely useful in patient 
care by providing new treatment options for difficult cancer cases.  
8.3: Concluding Remarks 
 While chemotherapy resistance continues to be a growing issue with treatment of various 
cancers. We present here a new tool that can potentially be used to combat some of these 
resistant cancers. The use of bile acids in medical treatment is not without precedent, admittedly 
not for cancer treatment. While much work would need to be performed to validate the 
observation here as well as optimize the treatment condition for in vivo systems, we believe that 
the use of bile acids (specifically β-cholanic acid) or their chemical derivatives would greatly 
improve survival outcomes as well as improve quality of life. This would be achieved in a two-
fold process by sensitizing cancers to conventional therapies and minimizing toxic side effects 
from chemotherapy metabolites. Furthermore by specifically targeting only AKR1C3 and 
ABCC1, we could avoid off target effects commonly seen in current anti-resistance treatments. 
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9.1: Expanded Materials/Methods 
9.1.1: Cell Culture 
 
 The MCF-7 (breast cancer) cell line was purchased from ATCC (Manassas, VA), 
maintained in high glucose DMEM supplemented with 10% FBS and 100 μg/ml streptomycin 
and 100 units/ml penicillin (all from Hyclone, Mississauga, Ontario). Cells were subcultured 
once every 7-8 days, or once cells had reached 90% confluence, and routinely supplemented with 
fresh media every 4 days. Cells were maintained at 37˚ C in 5% CO2. For sub-culturing, cells 
were washed once with sterile PBS followed by the addition of 3 ml (for T75 flasks (Sarstedt)) 
of sterile Trypsin 0.25% EDTA solution (Gibco). Once the cells were lifted from the growth 
surface, the cell suspension was then added to 1 ml of growth medium to inactivate the trypsin, 
and the flask was washed again with sterile PBS to collect any residual cells. The cell suspension 
was subjected to centrifugation at 233 x g for 10 min at 20˚ C in a Beckman Coulter Allegra X-
12R centrifuge. Cell pellets were resuspended in media and re-plated. Cells were previously 
selected for resistance to either Doxorubicin (dox) or Epirubicin (epi) by treating cells with an 
initial concentration of drug at 1,000-fold bellow the IC50. Drug concentrations were gradually 
increased in either 3 fold or 1.5 fold increments depending on the cells’ ability to tolerate the 
new drug concentration. A co-culture control cell line was selected in parallel which had no drug 
added. Drug resistant cells were maintained in media supplemented with either dox or epi. Drug 
concentrations were as follows: Dox1 – 3x10
-7
 M, Dox2 Dose 7 – 6.48x10
-9
 M, Dose 8 – 1.94x10-
8 
M, Dose 9 – 2.91x10-8 M, Dose 10 – 4.36x10-8 M, Dose 11- 6.54x10-8 M, Dose 12 – 9.81x10-8 
M, Epi Dose 12 – 8.52x10-7 M. Resistant cells were removed from drug-containing media 3-4 
days prior to being subjected to experimentation. For experiments involving estrogen signalling 
and/or metabolism, Dextran/Charcoal (DC) filtered media was used. 
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9.1.2: Dextran Charcoal Filtering 
 
 DMEM medium supplemented with 10% FBS and antibiotics was treated with 0.5% 
(w/v) dextran coated charcoal (Sigma, St. Louis, MO), and heated to 50 ˚C with constant shaking 
for 30 min. The charcoal stripped media was then sterile filtered (Sarstedt 0.22 μm, 500 ml). 
DMEM media was supplemented with 10
-7
 M estradiol for ER signalling experiments, or 10
-7
 M 
etsrone (both from Sigma, St. Louis, MO) for metabolic testing.  
9.1.3: Trypan Blue Exclusion Assay 
 
 Cells were grown in the absence of chemotherapy agent for 1 week prior to plating. Cells 
were washed, lifted and counted, plated in 10 cm plates (1,000,000 cells/plate), and left to 
incubate for 9 days. Individual plates were harvested every 2 days beginning with 24 h post 
plating. Cells were counted on a hemocytometer using the Trypan Blue Exclusion stain (Fisher). 
Briefly, cells were suspended in 1-10 ml of media, and a 15 μl aliquot of each cell suspension 
was stained with an equal volume of 1% Trypan Blue. Total cell number was determined by 
counting the sum of Trypan-excluding cells and Trypan-stained cells. This protocol was 
modified to a 6 well format by plating 100,000 cells/well and resuspending the cells in 100 to 
1,000 μl of media. Growth rate was calculated from a Boltzmann Sigmoidal Curve (Graphpad 
Prizm V 5.0).  
9.1.4: Estrone Metabolism Assay 
 
 5x10
5
 cells/well were plated in 6 well plates (Sarstedt), in DMEM medium supplemented 
with 10% FBS and antibiotics and allowed to adhere overnight. The next day, cells were washed 
and 5 ml of DC-DMEM was added to each well. Cells were either treated with vehicle control 
(5% DMSO), 10
-7
 M estrone, 10
-7
 M estrone with 5 nM letrozole, or 10
-7
M estrone with 0.2 mM 
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β-cholanic acid. Cells were treated for 24 h at which point aliquots of media were collected and 
stored at -20 ˚C. Samples were diluted 10-fold prior to being tested for estradiol levels. Estradiol 
levels were assayed using E2 ELISA kits (US Biological) as per the manufacturer’s protocol. 
Briefly, 50 μl of standards and unknown samples were added to individual wells, coated with an 
antibody specific for E2, in duplicate. In addition a competitive HRP conjugated estradiol 
molecule was added to each sample well. This substrate competes with the unconjugated E2 
substrate in the samples and will result in a signal developed that correlated to the E2 
concentration in each well. Samples were incubated at room temperature for 1 h on a Stoval 
Belly Dancer plate shaker with mild shaking to facilitate even dispersal of the binding substrates. 
After the incubation period, the samples were decanted and were washed 3 times with provided 
wash buffer. Colorimetric reagent was next added to each well and incubated for 1 h at room 
temperature. The plates were read on a Spectramax 340 PC spectrophotometer at a wavelength 
of 650 nm. Concentrations were extrapolated from a standard curve based on percent absorbance 
from the negative control. All data was analyzed using Graphpad Prism software (version 5.0 
Graphpad Prism Software Inc.). 
9.1.5: Clonogenic Assay 
 
 Cell survival was measured using a clonogenic assay. Cells were first collected by 
trypsinization, stained with Trypan blue, and counted as previously described (section 2.3). Cells 
were then diluted to a concentration of 4,000 cells/ml, and 5 ml of this cell suspension was added 
to T25 flasks (i.e., 200,000 cells/flask) (Sarstedt). 18-24 h post plating, the culture medium was 
removed and replaced with 5 ml of medium supplemented with a 3 fold increasing concentration 
of drug. The drug concentration ranged from 3x10
-11
 M to a maximum concentration of 3x10
-6
 
M, with one flask left untreated as a negative standard. The cells were incubated as described 
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previously, for 24 h. Following the 24 hour incubation period, cells were lifted as previously 
described and centrifuged with collected media and wash buffers to ensure that all viable cells 
were retained. The solutions were decanted and then the cell pellets were resuspended in 300 μl 
of full media and then transferred to 13 ml tubes containing 2.6% methylcellulose (Shin Etsu, 
Biddle Sawyer, NY.) supplemented with 30% FBS (Gibco). Methylcellulose/cell suspensions 
were thoroughly vortexed to ensure even cell distribution, and then aliquoted into 6 well 
clustered dished (Corning). Colonies were counted 13-14 days post-plating. 
9.1.6: Plasmid DNA Transfection and Cloning 
 
 Plasmids containing the open reading frame for AKR1C3 used for overexpression, were 
ordered from Invitrogen. ORF pENTR211 plasmids (see appendix) were received transformed 
into bacterial vectors (DH5-α). Bacteria were cultured on LB-Agar plates containing 50 μg/ml of 
kanamycin as a selective agent. The ORF was cloned from the host plasmid by linearizing the 
plasmid with EcoRI restriction enzyme followed by a PCR reaction to amplify the ORF only. 
PCR mix contained 0.2 mM dNTP mix, 1.5 mM MgCl2, 0.2 μM each of forward and reverse 
primers (F: 5’-GCTAAGATCTTCATGGATTCCAAACACCAGTGTG-3’, R: 5’-
TCGACTCGAGGTACAAGAAAGCTGGGTTCTAATATTCATC-3’), 2.5 units of Qiagen 
HotstarTaq, and 14.7 ng of template DNA. The ORF underwent 25 cycles in a Techne TC 312 
thermocycler.  
The PCR products were run on a 0.9 % agarose electrophesis gel to isolate the ORF 
product. Using a transilluminating UV table, the single band was removed from the gel and the 
Gel/ORF was mixed with 3 volumes of QG buffer (Qiagen) and incubated at 50 ˚C for 10 min 
(until gel completely dissolved) according to the manufacturer’s protocol. One volume of 
isopropanol was added to the tube and mixed. The solution was added to a QIAquick column and 
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subjected to centrifugation for 1 min at 17,000 x g. The column was washed with PE buffer and 
once again spun for 1 min at 17,000 x g. The ORF DNA was eluted using 50 μl of buffer EB and 
once again subjecting the column to centrifugation for 1 min at 170 00 x g. 
The AKR1C3 cDNA was next ligated into a pCMV-Tag plasmid such that the FLAG-
Tag was incorporated into the c-terminal domain. The ligated plasmid was next cultured on 
kanamycin-containing plates to select for AKR-Tag plasmid expression. The bacterial DNA was 
purified using Qiagen QIAprep miniprep plasmid extraction kits and QIAprep maxiprep kits 
(Qiagen). Plasmid concentration and purity were determined using an A260/280 ratio measured 
on a Beckman Coulter U530 spectrophotometer. The AKR-Tag insert was confirmed by 
sequencing (MOBIX) and by restriction endonuclease analysis. 
Stable clones were next generated by transfecting MCF-7CC cells grown to 90% 
confluence in10 cm plate with 24 μg of plasmid DNA complexed to 24 μl of Lipofectamine 2000 
(Invitrogen). Complexes were prepared by incubating 24 μg of plasmid DNA and 24 μl of 
Lipofectamine, each, in 1.5 ml of Optimem medium (Invitrogen) for 5 min. Following this 
incubation period, the two volumes of optimum were combined to generate the DNA-
Lipofectamine complexes. These complexes were allowed to form for 25 min prior to being 
added to 10 cm plates containing 15 ml of antibiotic free DMEM supplemented with 10% FBS. 
Cells were transfected overnight, and then subjected to selective screening using 2.0 mg/ml 
G418 (Sigma, St. Louis, MO). Selective concentration was determined by generating a kill curve 
by treating untransfected cells with increasing concentrations of G418 (0-2.5 mg/ml). The 
concentration was chosen based on the lowest concentration to kill over 80% of the cell 
population after 1 week of treatment (see appendix). Selective pressure was maintained for 72 h 
post-transfection. A population of cells were subcultured and frozen for storage in liquid 
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nitrogen, while individual cell colonies were also selected, grown, and frozen for later use. 
Empty vector clones were generated as a negative control using the same protocol described 
above. A total of 46 AKR-Tag clones and 24 empty vector clones were collected and stored. 
 Transient AKR1C3 over expressing cells were also generated in the same manner as the 
stable clones with the following exceptions: 24 μg of plasmid DNA was used complexed to 60 μl 
of Lipofectamine 2000. The cells were transfected for 18 h and were then replated for subsequent 
experiments. The amount of overexpression was verified via Western Blot for each transiently 
transfected experiment. 
9.1.7: Protein Extraction 
 
 MCF-7 co-culture control or drug resistant cells were grown to 70-80% confluence on 10 
cm plates (Sarstedt) in DMEM medium supplemented with 10% FBS for basal protein 
extraction, or switched to DC-DMEM 24 h prior to testing for estrogen signalling treatments. For 
estrogen-treated cells, the cells were treated with either a 5% DMSO vehicle control or 10
-7
 M 
Estradiol for 30 min for optimum phosphorylation of estrogen receptor. The culture medium was 
removed and the cells were washed 2-3 times with PBS (0.15 M NaCl, 2.7 mM KCl, 1.0 mM 
KH2PO4, 10 mM Na2HPO4). Cells were lysed using 500 μl of RIPA buffer (1% (v/v) NP-40, 
0.5% (w/v) deoxycholic acid, 0.1% (w/v) SDS, dissolved in PBS) supplemented with 1x 
Complete Inhibitor Cocktail (Roche), 10 μM NaF, 2 mM Na3VO4 and 1 μM PMSF (all from 
Sigma, St. Louis, MO). Cells were lifted from plates using plate scrapers, and the crude lysates 
were left on ice for no more than 5 min before being sheared by being passed through a 21-gauge 
needle 5-10 times. Crude lysates were then subjected to centrifugation at 17,000 x g for 10 min. 
at 4 ˚C. The supernatants were collected and stored at -80 ˚C. 40 μl aliquots were taken for total 
protein quantification using BCA assay, and quantified according to the manufacturer’s protocol 
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(Pierce). Briefly, extracts and standards were added into the bottom of 96 well assay plates. BCA 
reagent was added, and plates were incubated at 37 ˚C for 30 min. The protein samples were read 
on a Spectramax 340 PC spectrophotometer at a wavelength of 540 nm. The data were analyzed 
and concentrations were extrapolated using Graphpad Prism software (version 5.0, Graphpad 
Inc.). Protein samples were then aliquoted into 1.5 ml tubes containing 1x Laemmli sample 
buffer (0.05 M Tris (pH 6.8), 8% (v/v) glycerol, 0.03 M DTT, 0.08% (w/v) bromophenol blue) 
and boiled for 5 min prior to being resolved on gels by electrophoresis. 
9.1.8: Western Blot 
9.1.8.1: SDS PAGE Gel Electrophoresis 
 
 Protein extracts were run on 10% or 12% (for resolving smaller proteins) poly-
acrylamide gels using the Tetra-gel system (Bio-Rad) in a 1x running buffer (25mM Tris, 192 
mM Glycine, 3.5 mM SDS). Precession Pro Standard ladder (Bio-Rad) was used for protein size 
comparison. Samples and ladder were subjected to an initial charge of 90 V for the duration of 
10-15 min, followed by a charge of 130 V for 30-45 minutes depending on resolution of band 
sizes. Proteins were next transferred to nitrocellulose membranes using a Bio-Rad semi-dry 
transfer apparatus in transfer buffer (48 mM Tris, 39 mM Glycine, 0.037% (w/v) SDS, 20% (v/v) 
Methanol). Proteins were using 12 V for 45 min. Successful transfer of the proteins was 
confirmed through staining with 1% (w/v) PonceauS stain (Sigma, St. Louis, MO). Membranes 
were blocked using either a 5% (w/v) skim milk solution or a 5% (w/v) BSA solution suspended 
in 0.1% TBST (20 mM Tris pH 8.0, 137 mM NaCl, 0.1% (v/v) Tween 20) (in the case of probing 
for phosphorylated proteins) for 1 h at room temperature.  
9.1.8.2: Blotting 
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Membranes were incubated overnight at 4 ˚C while being probed with primary antibodies 
(concentrations varied based on probe of interest, averaged dilution was 1:1,000 from 
commercial stock). Primary antibody was diluted in either 5% (w/v) skim milk solution or 5% 
(w/v) BSA solution and membranes were incubated on a shaker at 4 ˚C, overnight. After the 
incubation period, the membranes were washed 3 times in 5 min intervals with TBST (20 mM 
Tris pH 8.0, 137 mM NaCl, 0.1% v/v tween-20). Secondary antibodies were applied, in a 
1:10,000 dilution from commercial stock suspended in a 5% skim milk solution, for 1 h at room 
temperature with gentle shaking. Membranes were next washed 3 times with TBST and once 
with TBS (20 mM Tris pH 8.0, 137 mM NaCl) in 5 min intervals. Chemiluminescent reagent 
(West Pico, Pierce) was added next and the membranes were incubated for 5 min. Visualization 
of the chemiluminescent reactions were observed by either exposure to film followed by 
development, or via gel doc camera system (FluorChem™, Α Innotech) depending on intensity 
of signal. Integrated density values were acquired using ΑEase FC software and analyzed using 
Microsoft Excel (Microsoft Office 2007, Microsoft). 
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Table 9-1 Antibody Dilutions 
Material Source Titre 
Used/Application 
Company 
Anti-Rabbit-HRP 
conjugate 
Goat polyclonal 1:10 000 WB Santa Cruz 
Anti-Mouse-HRP 
conjugate 
Goat polyclonal 1:10 000 WB Santa Cruz 
Anti-GAPDH Mouse monoclonal 1:10 000 WB Santa Cruz 
Anti-ERα-P-Ser118 Mouse monoclonal 1:1 000 WB Cell Signal 
Anti-ERα Mouse monoclonal 1:1 000 WB Cell Signal 
Anti-AKR1C3  Mouse monoclonal 1:1 000 WB Sigma 
Anti-ERK-P-
T202/Y204  
Rabbit monoclonal 1:1 000 WB Cell Signal 
Anti-BCL-2 Mouse monoclonal 1:200 WB Santa Cruz 
Anti-FLAG Mouse monoclonal 1:1 000 WB Strategene 
Anti-Cyclin D1 Mouse monoclonal 1:1 000 WB Upstate 
Anti-γ-Tubulin Monoclonal mouse 1:20 000 WB Sigma 
Anti-γ-Tubulin  Polyclonal rabbit 1:10 000 WB Sigma 
Anti-ERK  Rabbit monoclonal 1:1 000 WB Cell Signal 
Anti-ERβ  Rabbit polyclonal 1:1 000 WB Santa Cruz 
Anti-ABCC1 Mouse monoclonal 1:1000 WB Cell Signal 
 
9.1.8.3: Stripping and Re-Probing 
 
 When probing for phosphorylated proteins, it was necessary to strip the phospho-specific 
antibodies and re-probe the blots with a non-phospho-specific antibody. Membranes were 
incubated for 1 h at 50 ˚C in stripping buffer (6.24 mM Tris pH 6.7, 2% (w/v) SDS, 100 mM β-
mercaptoethanol). The membranes were washed twice in TBST for 5 min, each followed by a 
brief wash in TBS. A test exposure was conducted by adding ECL to the membranes and 
exposing the membranes to fresh film for 10 min to confirm the antibodies had been stripped. 
Membranes were then re-blocked using 5% (w/v) skim milk in TBST for 1 hour. Following 
blocking, membranes were probed for proteins as, described above. 
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9.1.9: Q-PCR 
9.1.9.1: RNA extraction 
 Cells were grown in 10 cm plates with DMEM supplemented with 10% FBS and grown 
to 80% confluence. Qiagen RNeasy kits were used to extract total RNA from the cells. Briefly, 
the cells were washed twice with PBS, and 600 μl of buffer RLT (supplemented with 10 μl of β-
mercaptoethanol per ml) was added to each plate. Cells were then scraped and homogenized by 
shearing through a 20 gauge needle (5 times) and added to an equal volume of 70% ethanol. 
Samples were applied to an RNeasy spin column and subjected to centrifugation at >8,000 x g 
for 15 sec. Columns were washed and the RNA was eluted in water. All RNA samples were 
frozen and stored at -80 ˚C, in addition 5 μl aliquots were taken for RNA analysis. 
9.1.9.2: RNA analysis 
 All RNA samples were analyzed using RNA 6,000 Nano Assay Lab Chip kit (Agilent) as 
per manufacturer’s directions using an Agilent 2100 Bioanalyzer. Briefly, all assay reagents were 
warmed to room temperature prior to use, RNA samples were denatured by boiling at 70 ˚C for 2 
min. and 1 μl samples were analyzed for quality as well as quantity. In addition to quantifying 
the RNA, the Bioanalyzer also provides information regarding the 28S/18S ratio. 
9.1.9.3: RT-PCR 
 RNA (1 μg) was treated with DNase (Invitrogen) prior to reverse transcription to remove 
any residual DNA. RNA was reverse transcribed by first adding a 1x first strand buffer 
(Invitrogen), DTT, 10 mM dNTPs, 20 ng/μl T20 primers, and 200 units of M-MLV reverse 
transcriptase. This mixture was incubated at 37 ˚C for 2 h and then incubated at 95 ˚C for 5 min 
to inactivate the M-MLV. Samples were stored at -80 ˚C. 
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9.1.9.4: Q-PCR 
 cDNA derived from co-culture control dose 12 cells was used to generate a standard 
curve (0.25-0.004 x dilution). Samples were diluted 0.062 fold from stock in RNase/DNase free 
water. 5 μl of each standard and unknown sample was loaded in triplicate on a 96 well PCR plate 
(Corning). Gene specific primers were diluted to 200 μM in RNase/DNase free water and further 
diluted to a working concentration of 300 nM. 7.5 μl of working primer solution was added to 
each well containing template cDNA. Finally 12.5 μl of SYBR Green mix (Bio-Rad) is added to 
each well. The plate was sealed with clear heat resistant adhesive film to prevent evaporation and 
the plates were subjected to centrifugation at 100 x g for 5 min. Plates were placed in a Q-PCR 
machine (Applied Biosystems) and run for 40 cycles followed by a dissociation curve analysis. 
Cycling began with an initial heating of the samples to 95 ˚C for duration of 10 min to activate 
the TAQ polymerase. This was immediately followed by further heating the sample at 95 ˚C for 
15 sec followed by cooling and annealing of the primers at 55 ˚C for 15 sec then elongation of 
the primers at 72 ˚C for 30 sec. This pattern was repeated for 40 cycles. Upon completion of the 
40 cycles, the samples underwent dissociation analysis which involved heating the samples to 95 
˚C and gradually cooling them to 60 ˚C then gradually heating the samples again to 95 ˚C. 
Fluorescence measurements were taken every cycle as well as at every degree change for the 
dissociation analysis. Data was captured using a 7900HT Sequence Data System (Applied 
Biosystems) using Sequence Data System acquisition software (V. 2.1, Applied Biosystems). 
Gene expression was standardized to S28 expression. 
9.1.10: ER-α TRANS-AM Analysis 
 Active nuclear ER-α levels were assayed using TRANS-AM kits purchased from Active 
Motif. These kits function as an ELISA analogue to the gel mobility shift assay. Briefly, nuclear 
262 
 
extracts were prepared by growing cells in 10 cm plates to confluence. The high confluence is 
required to collect sufficient amounts of nuclear protein for the assay. Nuclear extracts were 
prepared as per manufacturer’s instructions. Protein concentrations were determined using 
Bradford Assay as the Lysis Buffer (Active Motif) contained DTT which would interfere with 
the BCA assay. 
 ER-α transcription factor assay was performed as per manufacturer’s directions. Briefly, 
nuclear protein samples were loaded onto 96 well assay plates coated with Oligonucleotides 
corresponding to the estrogen response element. These were allowed to incubate at room 
temperature for 1 hour with mild agitation to facilitate binding of the transcription factors. 
Following the incubation period, the samples were washed 3 times with 1x Wash Buffer (Active 
Motif) and the plates were tapped dry using absorbent paper. Primary antibody (anti-ER-α, 
1:2000) (Active Motif) was added to each sample well and allowed to incubate at room 
temperature for 1 hour without agitation. Samples were then washed 3 times with 1x Wash 
Buffer as previously described. Secondary anti-rabbit-HRP conjugated antibody was then added 
(1:2000) (Active Motif) to each sample well. Plate was allowed to incubate for 1 hour at room 
temperature without agitation. Samples were then washed 4 times as previously described. 
Colorimetric substrate was added to each well and allowed to develop for 5 min at room 
temperature. Immediately after the developing period, stop solution was added to each well to 
halt the developing process. Samples were read on a Spectramax 340 PC spectrophotometer at a 
wavelength of 450 nm. Plates were blanked to sample wells that had no protein added as a 
negative control. All data was analysed using Graphpad Prizm software (V. 5.0, Graphpad 
Software Inc.) 
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9.1.11: ER-α Knockdown 
 ER-α levels were artificially knocked down using Artemisinin. Artemisinin interferes 
with transcription of the ESR1 gene by blocking transcription factor binding to the promoter 
region of the gene. Cells were plated at roughly 30% confluence in 10 cm plates containing 
DMEM supplemented with 10% FBS and antibiotics. 24 h post plating, the media was removed 
and replaced with DMEM supplemented with 10% FBS and either 300 μM Artemisinin or 0.1% 
v/v DMSO as a vehicle control. Cells were allowed to grow at 37 ˚C, 5% CO2 for 72 h. 
Following the treatment period, proteins were extracted from the cells as previously described. 
Protein samples were assayed via western blot technique for ER-α, BCL-2, and Cyclin D1 levels. 
9.1.12: Chemotherapy uptake analysis 
9.1.12.1: Fluorescent based uptake analysis 
 Steady-state doxorubicin retention was measure via flow cytometry. Cells were seeded 
onto 6 well plates at a density of 200,000 cells per well and allowed to set. Cells were treated 
with 2 μM doxorubicin, various concentrations of β-cholanic acid, deoxycholic acid, MK571, 
probenecid or a combination of one of these with doxorubicin for a period of 6 h. Cells were 
collected and suspended in 1 ml PBS. Suspended cells were run on an FC500 flow cytometer 
(Beckman-Coulter) using an FL2 (575 nm) filter to detect doxorubicin fluorescence. Data shown 
represents the mean of results obtained in 3 independent experiments and 10,000 events were 
measured in each individual experiment. 
9.1.12.2: Radiolabeled uptake analysis 
 Steady state docetaxel uptake was measured using 
3
H tagged docetaxel. Briefly, cells 
were plated at 200,000 cells per well in a 6 well plate. 18-24 h post plating cells were treated 
with 
3
H-docetaxel for 6 h. Cells were washed 3 times with PBS and lifted from the plates using 
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200 μL trypsin/EDTA. Lifted cells were added to scintillation tubes. Scintillation fluid was 
added to each tube and placed into a Beckmann coulter scintillation counter. Scintillation 
counting was performed to measure the amount of radio labeled docetaxel in each sample. 
9.1.12.3: Kinetic uptake analysis 
To determine the nature of inhibition of ABCC1 transport activity by β-cholanic acid, 
(
14
C)-doxorubicin accumulation was measured in MCF-7DOX2-12 cells at different doxorubicin 
concentrations in the presence and absence of cholanic acid for 4 hours and Lineweaver-Burke 
plots of 1/uptake velocity versus 1/doxorubicin concentration were generated. Cells were then 
collected and cellular doxorubicin levels quantified by liquid scintillation counting.  
9.1.13: Glutathione retention analysis 
Glutathione levels in MCF-7DOX2-12 whole cell extracts were measured using a 
glutathione detection kit from ENZO. Cells were plated in 10 cm plates at a density of 2 x 10
6
 
cells per plate. Cells were pre-treated with buthionine sulphoximine (50 μM for 1h) Cell lysates 
were collected and glutathione assayed as per kit instructions. Data shown are mean of 3 
independent trials ± SEM. 
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9.2: Supplemental Data 
Figure 9-1 Analysis of doxorubicin uptake kinetics. 
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Figure 9-1. Lineweaver-Burk plot of ABCC1 inhibition by β-cholanic acid. Panel 1 shows the 
optimization experiment to determine the time point at which uptake could be measured within 
the linear range. Panel 2 shows optimization data to determine the minimal range of accurately 
detectable levels of radio labeled doxorubicin. Panel 3 data shows lineweaver Burk analysis 
exhibiting convergence of two lines on the same x-intercept indicating a non-competitive 
inhibition on ABCC1 by β-cholanic acid. 4 highest concentration points are average of 3 trial, 6 
lowest concentrations of dox are average of 5 trials. Linear regression analysis revealed that β-
cholanic acid caused a small increase in the Vmax of drug uptake from 5.5x10
-9
 mMoles/h to 
7.7x10
-9
 mMoles/h and a small decrease in Km from 1.1x10
-6
 mM to 9.2x10
-7
 mM. These 
differences were further compared by using graphpad prims for lineweaver-Burk analysis as well 
as michaelis-menton kinetics with an n of 5 in each experiment and were found to be significant 
at P<0.05. 
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Figure 9-2 Optimization of drug uptake measures for fluorescence assay 
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Figure 9-2 Optimization for measure of uptake of doxorubicin. Cells were treated with 2 μM 
doxorubicin for varied times as indicated. Cells were then washed and lifter with trypsin as 
described in the methods section. Fluorescence intensities were recorded to determine the time at 
which optimal differences in uptake could be accurately measured. 
